Protocol J2W- MC-PYAB (m) 
 
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants with Mild to Moderate COVID- 19 Illness  
 [STUDY_ID_REMOVED]  Approval Date: 02- Mar-2021 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the cli nical 
investigation of LY3819253 and LY3832479 , unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries. 
Note to Regulatory Authorities:   This document may contain protected personal data and/or commerc ially confidential 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release.  In the United States, this document is subject to Freedom of Information Act (FOIA) Exempti on 4 and may not be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title:
A Rando mized, Doubl e-blind, Placebo -Controlled, Phase 2/3Study  to Eval uate the Efficacy and 
Safety of LY3819253 and LY 3832479 in Participants withMild to Moderate COVID -
19Illness
Protocol Number: J2W- MC-PYAB
Amendment Number: m
Compound (s):LY3819253 , LY3832479
Study Phase: 2/3
Short Title: A rando mized, double -blind, placebo -controlled, Phase 2/3study  to evaluate 
LY3819253 and LY 3832479 in part icipants withmild to m oderate COVID -
19
illness
Sponsor Name: Eli Lilly  and Com pany
Legal Registered Address: Indianapo lis, Indiana USA 46285
Regulatory Agency Identifier Number(s)
IND: 150440
Approval Date: Protocol amendment ( m)Electronically Signed and Approved by Lilly ondate 
provi ded below.
Approval Date: 02-Mar-2021 GMT
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
2Medical Monitor Name and Contact Information will be provided separately 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment (l) 03-February-2021
Amendment ( k) 20-January -2021
Amendment (j) 07-January -2021
Amendment (i) 30-November -2020
Amendment (h) Not applicable .  Not app roved orsubmitted to 
regulato ry agencies or independent review boards .
Amendment (g) 17-November -2020
Amendment (f) 20-October -2020
Amendment (e) 13-October -2020
Amendment (d) 18-September -2020
Amendment (c) 31-August -2020
Amendment (b) 31-July-2020
Amendment (a) 19-June -2020
Original Protocol 30-May -2020
Amendment m
Overall Rationale for the Amendment:
This amendment addresses the removal o f treatm ent arms 16 and 17.  Treatment arms 16 and 17 
were planned to eval uate shorter administration times .  Th isevaluat ion will now take pl acein 
PYAB add endum 3.0with treatm entarms 20 and 21 .  As a result, references to treatment arms 
16 and 17 in the main protocol were rem oved and the object ives and endpo intsfor treatm ent 
arms 13- 14 and 18- 19 were separated.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
4Section # and Name Description of Change Brief Rationale
1.1 Synopsis
1.2 Schema 
1.3.2 Sche dule of Activities (SoA)
3.0 Objectives and Endpoints
4.1.1 Design Outline
4.2 Scientific Rationale for Study 
Design
5.1 Inclusion Criteria 
6.1.2 Temporary Stopping Criteria 
8.2.2 Vital Signs
9.1 Statistical Hypotheses 
9.2 Sampl e Size Determination
9.4 Statistical Analyses
9.4.2 Primary Endpoints 
9.4.3.1 Key Secondary Endpoints
9.4.3.2 Safety
9.4.3.3 Additional Secondary 
Endpoints 
9.4.6 Subgroup Analyses 
9.5 Interim Analyses 
9.6 Data Monitoring Committee Treatment arms 16 and 17 
and related text were 
removed .The evaluation of shorter administration 
tim
es will now take place in the PYAB 3.0 
addendum with treatment arms 20 and 21.
1.1Synopsis
3.0 Objectives and EndpointsTreatment arms 13- 14 and 
18-19 objectives and 
endpoint s were separated
and updated .The treatment arms 13
-14 and 18 -19 will be 
analy zed separately.   Endpoints updated for 
the removal of treatment arms 16-17 and 
also for clarity .
1.1 Synopsis 
1.2 Schema
4.1.1 Design OutlineUpdated note to indicate 
that the protocol addenda 
include treatment arms for 
this study .Generalized the statement to avoid future 
amendments if changes were made in the 
protocol addenda .
4.3 Justification for Dose Added new subheadings and 
specify the subcutaneous 
doseFor clarification
5.1 Inclusion Criteria Criterio n #5 Replaced 
“agreements and guidance” 
with “requirementsSection 10.4 contains reproductive and 
contraceptive requirements.
9.1 Statistical Hypotheses Updated hypothesis for 
treatment arms 13- 14 and 
added hy pothesis for 18-19.Separated objectives and endpoints
9.2 Sample Size Determination Updated text for treatment 
arms 13-14 and 18 -19New objectives and endpoints
9.4 Statistical Analyses Key secondary  endpoints of 
overall clinical status will 
use data from “multiple” 
treatment arms instead of 
“all”.Updated analysis.
9.4.2 Primary Endpoints Updated text for treatment 
arms 13-14 and 18 -19New objectives and endpoints
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
5Section # and Name Description of Change Brief Rationale
9.4.3.1 Key Secondary Endpoints Updated text for treatment 
arms 13-14 and 18 -19Updated objectives and endpoints
9.4.3.3 Additional Secondary 
EndpointsUpdated text for treatment 
arms 13-14 and 18 -19Updated objectives and endpoints
Throughout the protocol Minor editorial and 
formatting changesMinor, therefore not described
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
6Table of Contents
1. Protocol Summary ...................................................................................................... 9
1.1. Synopsis ....................................................................................................................... 9
1.2. Schema ....................................................................................................................... 17
1.3. Schedule of Act ivities (SoA) ...................................................................................... 18
1.3.1. Treatment Arms 1 -4 and 6 .......................................................................................... 19
1.3.2. Treatment Arms 7 -9, 13 -14, 18-19 .............................................................................. 27
2. Introduction .............................................................................................................. 35
2.1. Study  Rati onale .......................................................................................................... 35
2.2. Background ................................................................................................................ 35
2.3. Benefit/Risk Assessment ............................................................................................ 36
3.
Objectives and Endpoints ......................................................................................... 39
3.1. Treatment arms 1 -4 and 6 ........................................................................................... 39
3.2. Treatment arms 7 -9..................................................................................................... 41
3.3. Treatment arms 13 -14.................................................................................................43
3.4. Treatment arms 18 -19.................................................................................................45
4. Study Design ............................................................................................................. 47
4.1. Overall Design ............................................................................................................ 47
4.1.1. Design Outline ............................................................................................................ 47
4.2. Scientific Rationale for Study  Design ......................................................................... 49
4.3. Justification for Dose .................................................................................................. 51
4.4. End of Study  Definit ion.............................................................................................. 52
5. Study Population ...................................................................................................... 53
5.1. Inclusio n Cri teria........................................................................................................ 53
5.2. Exclu sion Criteria....................................................................................................... 54
5.3. Lifest yle Considerat ions............................................................................................. 55
5.4. Screen Failures ........................................................................................................... 55
6. Study Intervention .................................................................................................... 56
6.1. Study  Intervent ion(s) Administered ............................................................................ 56
6.1.1. Speci al Treatm ent Consi derat ions............................................................................... 57
6.1.2. Temporary  Stopping Cri teria...................................................................................... 58
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 59
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 60
6.4. Study  Intervent ion Compliance ................................................................................... 60
6.5. Concomitant Therapy .................................................................................................61
6.6. Dose Modificat ion...................................................................................................... 62
6.7. Intervention after the End of the Study ........................................................................ 62
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 63
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 63
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 63
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 63
7.3. Lost to Follow up ....................................................................................................... 64
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
78. Study Assessments and Procedures ......................................................................... 65
8.1. Efficacy Assessments .................................................................................................65
8.1.1. Symptom s and Overall Clinical Status Participant Quest ionnaire ................................ 65
8.2. Safety Assessments .................................................................................................... 66
8.2.1. Physical Examinat ions................................................................................................ 66
8.2.2. Vital Signs.................................................................................................................. 66
8.2.3. Clinical Laboratory  Assessments ................................................................................ 67
8.2.4. Hospitalization events .................................................................................................68
8.2.5. Procedures of Special Interest ..................................................................................... 68
8.2.6. Respiratory  Support .................................................................................................... 69
8.3. Adverse Events and Serious Adverse Events .............................................................. 69
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 69
8.3.2. Method of Detecting A Es and SAEs ........................................................................... 69
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 70
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 70
8.3.5. Pregnancy ................................................................................................................... 70
8.3.6. Hypersensi tivity Reacti ons......................................................................................... 70
8.3.7. Infusio n-related Reacti ons .......................................................................................... 71
8.3.8. Inject ion Site Reacti ons .............................................................................................. 71
8.3.9. Product Complaint s.................................................................................................... 71
8.4. Treatment of Overdose ............................................................................................... 72
8.5. Pharmacokinet ics........................................................................................................ 72
8.5.1. Bioanaly tical.............................................................................................................. 73
8.6. Pharmacodynamics ..................................................................................................... 73
8.7. Genet ics..................................................................................................................... 73
8.8. Biomarkers ................................................................................................................. 73
8.9. Immunogenicit y Assessments ..................................................................................... 74
8.10. Health Economics ....................................................................................................... 74
9. Statist ical Considerations ......................................................................................... 75
9.1. Statistical Hypotheses .................................................................................................75
9.2. Sample Si ze Determinat ion......................................................................................... 75
9.3. Popul ations for Analyses ............................................................................................ 77
9.4. Statistical Analyses ..................................................................................................... 78
9.4.1. General Considerations ............................................................................................... 78
9.4.2. Primary Endpo ints...................................................................................................... 79
9.4.3. Secondary  Endpo ints.................................................................................................. 79
9.4.4. Exploratory  Analyses .................................................................................................. 82
9.4.5. Immunogenicit y Analyses ........................................................................................... 82
9.4.6. Subgroup Analyses ..................................................................................................... 83
9.5. Interim Analyses ......................................................................................................... 83
9.6. Data Monitoring Committee (DMC) ........................................................................... 85
10. Supporting Documentation and Operational Considerations ................................ 86
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 86
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 86
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
810.1.2. Financial Disclo sure................................................................................................... 86
10.1.3. Inform ed Consent Process .......................................................................................... 87
10.1.4. Data Protection ........................................................................................................... 87
10.1.5. Committees Structure .................................................................................................88
10.1.6. Disseminat ion of Clinical Study  Data ......................................................................... 88
10.1.7. Data Qualit y Assurance .............................................................................................. 88
10.1.8. Source Documents ...................................................................................................... 90
10.1.9. Study  and Si te Start and Cl osure ................................................................................. 90
10.1.10. Publicat ion Policy ....................................................................................................... 91
10.1.11. Invest igator Informat ion............................................................................................. 91
10.1.12. Long -Term  Sample Retent ion..................................................................................... 91
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 92
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 95
10.3.1. Definit ion of AE......................................................................................................... 95
10.3.2. Definit ion of SAE ....................................................................................................... 96
10.3.3. Recording and Fo llow-Up of AE and/or SAE ............................................................. 97
10.3.4. Reporting of SAEs ...................................................................................................... 99
10.4. Appendix 4: Contraceptive Guidance and Collect ion of 
Pregnancy Information ............................................................................................. 100
10.5. Appendix 5: Genetics ............................................................................................... 103
10.6. Appendix 6: Reco mmended Laboratory Test ing for 
Hypersensi tivity Events. ........................................................................................... 104
10.7. Appendix 7: Liver Safet y: Suggested Actions and Follow -up 
Assessments ............................................................................................................. 106
10.8. Appendix 8: Abbreviat ions....................................................................................... 110
10.9. Appendix 9: Protocol Amendment History ............................................................... 112
11. References ............................................................................................................... 137
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
91. Protocol Summary
1.1. Synopsis
Protocol Title: A Rando mized, Doubl e-blind, Placebo -Controlled, Phase 2/3Study  to Evaluate 
the Efficacy and Safetyof LY3819253 and LY 3832479 in Participants with Mild to Moderate 
COVID -19Illness
Rationale :
The severe acute respiratory  syndrome corona virus 2 (SARS -CoV -2) has resulted in the 
pandemic spread of coronavi rus disease 2019 ( COVID -
19), which in criticalcases results in 
progressive pulmo nary failure , com plicati ons wi th acute respi ratory  distress syndrome (ARDS), 
and death.  There is an urgent need for effect ive therapeutics to modify disease outcomes.
LY3819253 and LY 3832479 areneutralizing IgG1 monoclonal ant ibodies(mAb) to the spike 
protein of SARS -CoV -2.  They  aredesigned to block vi ral attachm ent and entry  into hum an 
cells,and to neutraliz e the virus , potenti ally treating even established COVID -19 by  provi ding a 
combinat ion of specific ,potent, neutralizing ant ibodiestoSARS -CoV -
2.
This study  aims to eval uate the impact of LY3819253 and LY 3832479 on vi ral clearance and 
clinical outcomes in pa rticipants with COVID -
19illness.  The data fro m this study  will inform 
decisio ns for the clinical development of LY3819253 and LY 3832479 . 
Objectives and Endpoint s:
Treatment arms 1-4 and 6
Objectives Endpoints
Primary
Characterize the effect of LY3819253, and LY3819253 
in combination with LY3832479 ,compared to placebo 
on SARS -CoV -2 viral load and viral clearanceChange f rom baseline to Day 11 (± 4 days) in SARS -
CoV-2 viral load 
Secondary
The secondary objectives are to c haracterize the effect 
of LY3819253 ,and LY3819253 in combination with 
LY3832479 ,compared to placebo on…
safety Safety assessment ssuch as AEs and SAEs
SARS -CoV -2 viral load among participants with 
≤8days since symptom onsetChange f rom baseline to Day 11 (± 4 days) in 
SARS -CoV-2 viral load among participants 
enrolled with ≤ 8 days of symptoms prior to 
randomization 
symptom resolution Time to symptom resolution 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
10Proportio n of participants demonstrat ing symptom 
resolution via the symptom questionnaire on Days
7, 11, 15 and 22
Change in symptom score (total of ratings) from 
baseline to Days 7, 11, 15 and 22 
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating sympt om 
improvement via the symptom questionnaire on 
Days 7, 11, 15 and 22
SARS -CoV -2 viral load and viral clearance Proportio n of participants that achieve SARS -
CoV-2 clearance (Days 7, 11, 15 and 22)
Time to SARS -CoV -2 clearance 
SARS -CoV-2 viral load area under the response -
time curve (AUC ) assessed through Day 29
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day s 29, 60 and 85
oCOVID -19 related hospitalization
(defined as ≥24 hours of acute care)
oa COVID -19 related emergency room 
visit, o r 
odeath
Additional Secondary
Characterize the pharmacokinetics of LY3819253 and 
LY3819253 in combination with LY3832479Mean concentration of LY3819253 and 
LY3819253 in the presence of LY3832479 on
Day 29
Mean concentration of LY3832479 in the presence 
of LY3819253 on Day 29
Abbreviations:  AE = adverse event; SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory syndrome coronavirus 2. 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
11Treatment arms 7-9
Objectives Endpoints
Primary
Characterize the effect of LY3819253 in combination 
with LY3832479 compared to placebo on overall 
participant clinical statusProportio n (percentage) of participants who experience 
COVID -19 related hospitalization ( defined as ≥24 
hours of acute care) or death from any cause by Day 
29.
Key Secondary
The key secondary  objectives are to c haracterize the 
effect of LY3819253 in combination with LY3832479, 
compared to placebo on…
the reduction of SARS -CoV -2 viral load Change f rom baseline to Day 7 (±2 day s)
Persistently high SARS -CoV -2 viral loadProportio n of participants with SARS -CoV -2 viral 
load greater than 5.27 on Day 7 (+2 days)
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 2 9
oCOVID -19 related hospitalization
(defined as ≥24 hours of acute care) , or
oa COVID -19 related emergency room 
visit, o r 
odeath from any  cause
sustained symptom resolution time to sustained symptom resolution
Additional Secondary
SARS -CoV -2 viral load reduction Change f rom baseline to 
oDay 3 (+ 1day)
oDay 5 (±2 day s)
SARS -CoV-2 viral load area under the response -
time curve (AUC ) assessed through Day 7
SARS -CoV -2 viral clearanceTime to SARS -CoV -2 clearance 
symptom resolution Time to symptom resolution 
Time to complete symptom resolution
Time to sustained complete symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days
2-11
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 2-11
safety Safety assessments such as AEs and SAEs
Abbreviations:  AE = adverse event; SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory syndrome coronavirus 2. 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
12Treatment arms 13-14
Objectives Endpoints
Primary
Persistently high SARS -CoV -2 viral load for treatment 
arm 14 compared to treatment arm 13.Proportio n of participants with SARS -CoV -2 viral load 
greater than 5.27 on Day 7 (+2 days)
Key Secondary
Reduction of SARS -CoV -2 viral load for treatment 
arm 14 compared to treatment arm 13.Change f rom baseline to Day 7 (± 2 day s)
Clinical status for treatment arm 14 compared to all 
high-risk placebo participants in treatment arms 8 and 
13.Proportio n (percentage) of participants who experience 
COVID -
19 related hospitalization ( defined as ≥24 
hours of acute care) or death from any cause by Day 
29.
Additional Secondary
Clinical status for treatment arm 14 compared to all 
high-risk placebo participants in treatment arms 8 and 
13.Proportio n (percentage) of participants who experience 
these events by Day 29
COVID -19 related hospitalization (
defined as ≥24 
hours of acute care) , or
a COVID -19 related emergency room visit, or 
death f rom any  cause
Treatment arm 13 compared to treatment arm 14 on…
sustained symptom resolution time to sustained symptom resolution
SARS -CoV -2 viral load reduction Change f rom baseline to 
oDay 3 (+1 day )
oDay 5 (±2 day s)
SARS -CoV-2 viral load area under the response -
time curve (AUC ) assessed through Day 7 
SARS -CoV -2 viral clearance Time to SARS -CoV -2 clearance 
symptom resolution Time to symptom resolution 
Time to complete symptom resolution
Time to sustained complete symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days
2-11
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 2 -11
safety Safety assessments such as AEs and SAEs, 
including date and time of events
Abbreviations:  AE = adverse event; SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory syndrome coronavirus 2. 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
13Treatment arms 18-19 
Objectives Endpoints
Primary
Persistently high SARS -CoV -2 viral load for treatment 
arm 19 compared to treatment arm 18Proportio n of participants with SARS -CoV -2 viral load 
greater than 5.27 on Day 7 (+2 days)
Key Secondary
Reduction of SARS -CoV -2 viral load for treatment 
arm 19 compared to treatment arm 18Change f rom baseline to Day 7 (± 2 day s)
Overall p articipant clinical status for treatment arm 19 
compared to all high -risk placebo participants in 
treatment arms 8 and 13Proportio n (percentage) of participants who experience 
COVID -19 related hospitalization ( defined as ≥24 
hours of acute care) or death from any cause by Day 
29.
Additional Secondary
Clinical status for treatment arm 19 compared to all 
high-risk placebo participants in treatment arms 8 and 
13Propo rtion (percentage) of participants who experience 
these events by Day 29
COVID -19 related hospitalization (
defined a s ≥24 
hours of acute care) , or
a COVID -19 related emergency room visit, or 
death f rom any  cause
Treatment arm 19 compared to treatment arm 18 on…
sustained symptom resolution time to sustained symptom resolution
SARS -CoV -2 viral load reduction Change f rom baseline to 
oDay 3 (+1 day )
oDay 5 (±2 day s)
SARS -CoV-2 viral load area under the response -
time curve (AUC ) assessed through Day 7 
SARS -CoV -2 viral clearance Time to SARS -CoV -2 clearance 
symptom resolution Time to symptom resolution 
Time to complete symptom resolution
Time to sustained complete symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days
2-11
symptom improvement Time to symptom improvement
Proportio n of participants d emonstrating symptom 
improvement via the symptom questionnaire on 
Days 2 -11
safety Safety assessments such as AEs and SAEs, 
including date and time of events
Abbreviations:  AE = adverse event; SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory syndrome coronavirus 2. 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
14Overall Design :
This is a Phase 2/3 , randomized, doubl e-blind, placebo -controlled, single- dose study  in 
participants wi th mild to moderate COVID -19illness. 
Design Outline
Screening
Interested participants or their legally  authori zed representative will sign the appropriate 
inform ed consent and child/adolescent assent document(s), as appropriate, prior to completion of 
any procedures.
The invest igator will review symptom s, risk factors and other non -invasive inclusio n and 
exclusio n criteria pri or to any  invasive procedures.  If the participant is eligible after this review, 
then the site will perform the invasive procedures to confirm eligibilit y.
Treatment and As sessment Period
This is the general sequence of events during the treatment and assessment period:
Com plete baseline procedures and sample collect ion
Parti cipants are randomized to an intervent ion group
Parti cipants receive study  intervent ion, and
Com plete all safet y monitoring and post -dose sample co llection.
This table describes the visit t ypes for treatm ent arms 1 -4and 6 .
Study Day Visit Type
1  Site  
2, 4, 5 and 6 Telepho nevisits
3, 7, 11, 15,18, 22, 25and 29 May be conducted as outpatient clinic or home visits
Early  discontinuation and follow -up May be conducted as outpatient clinic or home visits
This table describes the visit t ypes for treatm ent arms 7 -9, 13 - 14, 18-19.
Study Day Activity Visit Type
1  Follow SoA Site  
2, 4, 6 and 22 Follow SoA Telepho nevisits
3, 5, 7, 11, and 29 Follow SoA May be conducted as outpatient 
clinic or home visits
8, 9, and 10 Collect participant questionnaire 
symptom and overall clinical 
status assessmentsTelephone visits
Early  discontinuation and follow -up Follow SoA May be conducted as outpatient 
clinic or home visits
If a participant is hospitalized, procedures and assessments will cont inue per the SoA. 
This table describes d ischarge fro m hospi talscenarios if an outpatient is subsequent ly 
hospi talized.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
15Discharge from hospital (Outpatients Subsequently Hospitalized)
If hospital discharge … Then…
Occurs prior to Day 29 participants will be asked to complete the remaining 
study assessments at the timepoints indicated in the 
SoA.  
NOTE: Strategies to manage infection risks and reduce 
the burden of return visits should be used by sites, such 
as home visits .
Occurs on the same day as a study assessment visit assessments do not need to be repeated if the study 
assessments occurred within 8 hours of discharge and 
there has been no change in clinical status and the 
information is available to the site .
Does not occur at or prior to Day 29 assessments will continue to occur weekly up to Day 
60 or until hospital discharge, whichever is sooner.
Post- treatment follow -up
Post-treatm ent follow-up assessments will be conducted at Day  60 and Day  85 to assess clinical 
status and for adverse events. Strategies to manage infection risks and reduce the burden of 
return visits may be used by sites, such as ho me visits.
Disclosure Statement : This is a treatm ent study .  Treatment arms 1-9and 13 - 14 areparticipant 
and invest igator blinded .Treatment arms 1 8-19 are open lab el.
Number of Participant s:
Treatment arms 1
-4 and 6
Approximately  500 participants allo cated across five treatment arms (treatm ent arms 1 -4 and 6) .  
Addit ional placebo participants may be enro lled to ensure up to 50 concurrent placebo controls 
for treatm ent arm  6.  
Up to 100 additional particip ants may be introduced for optional treatment arm 5.  See Section 9.5
for interim analysis details.
Treatment arms 7 -9, 13- 14, and 1 8-19
Parti cipants in treatm ent arm s 7-9, 13 -14, and 18-19are adults and ado lescents with at least 1 
risk factor for developing severe COVID
-19 illness.  There i s no set sam ple size for the 
adolescent parti cipants. 
The pl anned sam ple size for the primary  com parison of treatment arm s 7 and 8 isapproximately  
1000 participants equally rando mized to placebo or the combinat ion of LY3819253 and 
LY3832479.   
The pl anned sam ple size for treatm ent arm  9 is approximately  500 participants. Since treatment 
arm 9 begins enrollment after treatment arm 7, addit ionalparticipants will  be enrolled in 
treatm ent arm  8 to ensure at least a 33% increase inplacebo participants andadequate pl acebo 
control  for the primary  com parison of treatm ent arm s8 and 9.
The pl anned sam ple size for treatm ent arms 13 and 14 is approximately  
400 parti cipants 
rando mized 2:3, placebo :combinat ion of LY3819253 and LY3832479.  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
16The pl anned sam ple size for treatm ent arm s 18 and 19 is approximately 460 participants per 
treatm ent arm . 
Intervention Groups and Duration :
This table describes the planned treatment arms.  
Treatment arms Dose Intervention Route of Administration
1 --- Placebo
Intravenous2 700 mg LY3819253
3 2800 mg LY3819253
4 7000 mg LY3819253
Optional 5 To Be Determined LY3819253
6 2800 mg + 2800 mg LY3819253+LY3832479
7 2800 mg + 2800 mg LY3819253+LY3832479
8 --- Placebo
9 700 mg + 1400 mg LY3819253+LY3832479
13 --- Placebo
14 350 mg + 700 mg LY3819253+LY3832479
18 700 mg + 1400 mg LY3819253+LY3832479
19 250 mg + 500 mg LY3819253+LY3832479 Subcutaneous
NOTE: PYAB protocol addenda also include treatment arms for this study .
Theoptional LY3819253 treatment arm 5 may be added based on interim analysis result s.  
Parti cipants will receive intervent ion on Day  1, assessmen ts occur to Day  29 and follow-up to 
Day 85.
Treatment arm 1 is the corresponding placebo control for treatment arms 2 -4 and 6.  
Treatment arm 8 is the corresponding placebo control for treatment arm s 7and 9 .  
Treatment arm 13 is the concurrent placebo control for treatment arm 14.  
Treatment arms 1 8-19 are open -label.  
Data Monitoring Committee: Yes.
A
n assessment committee will analyze the interim study  data for treatm ent arms 1 -4 and 6.
An external data monitoring co mmit tee (DMC) willanalyze unblinded safet y data for treatm ent 
arms 7-9, 13-14 , and 1 8-19.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
171.2. Schema
Abbreviations:  LY = Lilly study intervention; PYAA = J2W -MC-PYAA; PYAB = J2W -MC-PYAB ; TBD = to be 
determined .
NOTE:  Treatment arms 1-9 , 13
-14, and 18are administered as an intravenous infusion.  
Treatment arm 19 is administered as subcutaneous injection. 
PYAB protocol addenda also include treatment arms for this study .
Figure 1. S tudy J2W -MC-PYA Bschema

CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
181.3. Schedule of Activities (SoA)
Assessments obtained previously  as part of routine clinical care may  be used as the baseline assessment ifthey were done no more 
than 48 hours before rando mizat ion.  Visits may be conducted as a telephone c all, outpatient clinic or home visit , as long as the 
protocol  SoA isfollowed. Refer to the study day and visit type table in Sect ion 4.1.1 for addi tional clarificati on.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
191.3.1. Treatment Arms 1 -4 and 6
This SoA is for parti cipants in treatment arms 1 -4 and 6.
Schedule of Activities for Treatment Arms 1 -4 and 6
Study 
J2W -MC -PYA B Screen Double -blind treatment and assessmentsE
DFollow -up 
if hospital 
inpatient 
on Day 29Post-
treatment
follow -upComments
Study Day1 2
*3 4
*5
*6
*7 11 15 18 22 25 29E
DEvery 7 
days until 
discharge 
or Day 6060 85Screening and Day 1 procedures 
may occur on the same day.
* = telephone visit(s)
Visit window 
(± number of days)-- -- +1 +1 2 2 2 2 2 2 2 2 4 4Visits may not be combined.
Procedures
Informed Consent X
Inclusion and 
exclusion criteria 
reviewX
DemographicsXIncluding age, gender, race, 
ethnicity
Preexisting 
conditio ns and 
medical history
XObtained from interview or 
available information .
Includes:  timing of exposure and 
onset of symptoms suggestive of 
SARS -CoV -2 infection, and risk 
factors and comorbidities 
associated with severe COVID -19 
illness, such as living in a nursing 
home or long -term care facil ity. 
Height X
Weight X
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
20Schedule of Activities for Treatment Arms 1 -4 and 6
Study 
J2W -MC -PYA B Screen Double -blind treatment and assessmentsE
DFollow -up 
if hospital 
inpatient 
on Day 29Post-
treatment
follow -upComments
Study Day1 2
*3 4
*5
*6
*7 11 15 18 22 25 29E
DEvery 7 
days until 
discharge 
or Day 6060 85Screening and Day 1 procedures 
may occur on the same day.
* = telephone visit(s)
Visit window 
(± number of days)-- -- +1 +1 2 2 2 2 2 2 2 2 4 4Visits may not be combined.
Prior treatments 
of special interest 
within the last 30 
daysXNSAIDs, antivirals, antibiotics, 
anti-malarials, corticosteroids, 
immunomodulators or other 
investigational treatments.
Tobacco use X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X
Adverse events 
(AEs)X X X X X X X X X X X X X X X X X XAny events that occur after signing 
the informed consent are 
considered AEs as defined in 
Section 10.3.
Physical Evaluation or Clinical Assessments
Physical 
examinationX
Symptom -directed 
physical examX X XAs indicated based on participant 
status and standard of care.  May 
be performed by qualified 
personnel per local regulations.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
21Schedule of Activities for Treatment Arms 1 -4 and 6
Study 
J2W -MC -PYA B Screen Double -blind treatment and assessmentsE
DFollow -up 
if hospital 
inpatient 
on Day 29Post-
treatment
follow -upComments
Study Day1 2
*3 4
*5
*6
*7 11 15 18 22 25 29E
DEvery 7 
days until 
discharge 
or Day 6060 85Screening and Day 1 procedures 
may occur on the same day.
* = telephone visit(s)
Visit window 
(± number of days)-- -- +1 +1 2 2 2 2 2 2 2 2 4 4Visits may not be combined.
Vital signs
X X X X X X X X X X X X X XDocumentation of hospital -based 
exam is acceptable.
Includes: body temperature, pulse 
rate, BP, respiratory rate, SpO2, 
and supplemental oxygen flow 
rate, FiO2 if known, and method of 
delivery, if applicable. 
Record SpO2 while participant is 
at rest.
Screening visit only : SpO2 while 
breathing room air. Data not 
collected on CRF.
Day 1 timing: 
 immediately before the 
infusion 
 every 15minutes during the 
infusion , as possible, and
 every 30 minutes for 2 hours 
after the infusio n.  
During infusion, only record pulse 
rate, BP and SpO2 . Automation 
may be used.  See Section 8.2.2 for 
data collected on CRF.
All other study days :once daily.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
22Schedule of Activities for Treatment Arms 1 -4 and 6
Study 
J2W -MC -PYA B Screen Double -blind treatment and assessmentsE
DFollow -up 
if hospital 
inpatient 
on Day 29Post-
treatment
follow -upComments
Study Day1 2
*3 4
*5
*6
*7 11 15 18 22 25 29E
DEvery 7 
days until 
discharge 
or Day 6060 85Screening and Day 1 procedures 
may occur on the same day.
* = telephone visit(s)
Visit window 
(± number of days)-- -- +1 +1 2 2 2 2 2 2 2 2 4 4Visits may not be combined.
Hospitalization 
events
Daily X X X XRecord if the following events 
occur:
 Emergency room visits
 hospitalized
 ICU admittance, 
 Extended care facility 
admittance, and 
 discharge
Clinical status and 
concomitant 
procedures if 
participant is 
hospitalized
Daily  if hospitalized X XDocumentation from hospital 
records is acceptable.
Includes: 
consciousness status (ACVPU),
limitation on activities due to 
COVID -19, and requirements for
 Ongoing hospital medical 
care
 Supplemental oxygen
 Non-invasive ventilation or 
high flow oxygen device
 Mechanical ventilation
 ECMO , or
 Additional organ support (e.g. 
pressors, renal replacement). 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
23Schedule of Activities for Treatment Arms 1 -4 and 6
Study 
J2W -MC -PYA B Screen Double -blind treatment and assessmentsE
DFollow -up 
if hospital 
inpatient 
on Day 29Post-
treatment
follow -upComments
Study Day1 2
*3 4
*5
*6
*7 11 15 18 22 25 29E
DEvery 7 
days until 
discharge 
or Day 6060 85Screening and Day 1 procedures 
may occur on the same day.
* = telephone visit(s)
Visit window 
(± number of days)-- -- +1 +1 2 2 2 2 2 2 2 2 4 4Visits may not be combined.
Laboratory Tests and Sample Collection
Hematology
X X X X XDay 1: before IV infusion
All other days: sample may occur 
at any  time during the day
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Clinical 
Chemistry
X X X X XDay 1: before IV infusion
All other days: sample may occur 
at any  time during the day
No samples needed if participant is 
hospitalized 
Lilly -designated central laboratory
 C-reactive 
protein (CRP); 
high -
sensitivity
 Ferritin
 D-dimer
 Procalcitonin
 TroponinX X X X XDay 1: before IV infusion
All other days: sample may occur 
at any  time during the day 
No sample needed if participant is 
hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
24Schedule of Activities for Treatment Arms 1 -4 and 6
Study 
J2W -MC -PYA B Screen Double -blind treatment and assessmentsE
DFollow -up 
if hospital 
inpatient 
on Day 29Post-
treatment
follow -upComments
Study Day1 2
*3 4
*5
*6
*7 11 15 18 22 25 29E
DEvery 7 
days until 
discharge 
or Day 6060 85Screening and Day 1 procedures 
may occur on the same day.
* = telephone visit(s)
Visit window 
(± number of days)-- -- +1 +1 2 2 2 2 2 2 2 2 4 4Visits may not be combined.
Documentation of 
positive SARS -
CoV-2 viral 
infection XSample for first positive test must 
be collected within 3 days prior to 
start of infusion.
Local laboratory and/or Point -of-
Care testing.
Urine or serum 
pregnancy X X XOnly for WOCBP (Section 10.4
Appendix 4) 
Local laboratory
Pharmacokinetic 
(PK) sample
X X X X X XDay 1: before IV infusion and 
anytime just prior to the end of 
infusion .
All other scheduled samples may 
occur at any time during the day.
No samples needed if participant is 
hospitalized.
Lilly -designated central laboratory
Immunogenicity 
(ADA) sample
X X X X X XDay 1:  collect before IV infusion. 
All other scheduled and 
unscheduled immunogenicity 
samples should be collected with a 
time-matched PK sample.
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
25Schedule of Activities for Treatment Arms 1 -4 and 6
Study 
J2W -MC -PYA B Screen Double -blind treatment and assessmentsE
DFollow -up 
if hospital 
inpatient 
on Day 29Post-
treatment
follow -upComments
Study Day1 2
*3 4
*5
*6
*7 11 15 18 22 25 29E
DEvery 7 
days until 
discharge 
or Day 6060 85Screening and Day 1 procedures 
may occur on the same day.
* = telephone visit(s)
Visit window 
(± number of days)-- -- +1 +1 2 2 2 2 2 2 2 2 4 4Visits may not be combined.
Pharmacodynamic 
(PD) NP swab 
X X X X X X X X X XSwab is taken from both nostrils . 
Day1: swab before IV infusion.
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Explo ratory  
biomarker 
samplesX X X X XDay 1: before IV infusion.
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Pharmacogenetics 
sample XLilly -designated central laboratory
Randomization and Dosing
Randomization X
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
26Schedule of Activities for Treatment Arms 1 -4 and 6
Study 
J2W -MC -PYA B Screen Double -blind treatment and assessmentsE
DFollow -up 
if hospital 
inpatient 
on Day 29Post-
treatment
follow -upComments
Study Day1 2
*3 4
*5
*6
*7 11 15 18 22 25 29E
DEvery 7 
days until 
discharge 
or Day 6060 85Screening and Day 1 procedures 
may occur on the same day.
* = telephone visit(s)
Visit window 
(± number of days)-- -- +1 +1 2 2 2 2 2 2 2 2 4 4Visits may not be combined.
Administer study 
interventio n (IV 
infusion)
XStudy  intervention must be 
administered within 3 days from 
the time of first positive SARS -
CoV-2 test sample collection.
For participants that receive 
dialy sis on the same day as the IV 
infusion, complete dialysis first 
followed by the IV infusion.
Participants will be monitored for 
at least 2 hours after completion of 
the infusion.
Participant Questionnaire
Symptoms and 
overall clinical 
statusDaily on Day s 1-29 for outpatients only X X XDay1: assess prior to dosing
Abbreviations:  ACVPU = alert, consciousness, verbal, pain, unresponsive scale; ADA = anti -drug antibody; BP = blood pressure; ECMO = extracorporeal membrane 
oxygenation; ED = early discontinuation visit; FiO2 = fraction of inspired oxygen in the air; ICU = intensive care unit ; IV = intravenous; NP = nasopharyngeal; NSAIDS = non -
steroidal anti -inflammatory drugs; SpO2 = saturation of peripheral oxygen; WOCBP = women of child -bearing potential.  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
271.3.2. Treatment Arms 7 -9, 13 - 14 , 18-19
This SoA i s for parti cipants in treatment arms 7 through 9, and 13 and 14 , 18and19.  
Schedule of Activities for Treatment Arms 7 -9, 13-14, 18-19
Study 
J2W-MC - PYA B Screen Double -blind treatment and assessments EDFollow -up if 
hospital inpatient 
on Day 29Post-
treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 1122
*29 EDEvery 7 days 
until discharge or 
Day 6060 85Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) 
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Informed Consent X
Informed Assent
for adolescent 
participantsXParent or legal guardian signs informed 
consent form and participant signs 
assent form, as appropriate per local 
requirements.
Inclusion and 
exclusion criteria 
reviewX
Demographics X Including age, gender, race, ethnicity
Preexisting 
conditio ns and 
medical historyXObtained from interview or available 
information .
Includes:  risk factors and comorbidities 
associated with severe COVID -19 
illness, such as living in a nursing home 
or long -term care facility. 
Prespecified 
medical history for 
COVID -19XIncludes COVID -19 diagnosis date and 
onset of COVID -19 sy mptoms.
Height X
Weight X
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
28Schedule of Activities for Treatment Arms 7 -9, 13-14, 18-19
Study 
J2W-MC - PYA B Screen Double -blind treatment and assessments EDFollow -up if 
hospital inpatient 
on Day 29Post-
treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 1122
*29 EDEvery 7 days 
until discharge or 
Day 6060 85Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) 
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Prior treatments of 
special interest XWithin the last 30 days:  NSAIDs, 
antivirals, antibiotics, anti -malarials, 
corticosteroids, immunomodulators or 
other investigational treatments.
At any time:  SARS -CoV-2vaccine.
Prior non-SARS -
CoV-2vaccine 
treatments within 
the last 90 daysXFor adolescents only
Substance use 
(Tobacco)XIncludes use of e -cigarettes, such as 
vaping
Concomitant 
medicationsX X X X X X X X X X X X X X X
Adverse events 
(AEs)X X X X X X X X X X X X X X XAny events that occur after signing the 
informed consent are considered AEs as 
defined in Section 10.3.
Additional details regarding reporting 
frequency and method of detecting AEs 
and SAEs can be found in Section 8.3.
Physical Evaluation or Clinical Assessments
Physical 
examinationX
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
29Schedule of Activities for Treatment Arms 7 -9, 13-14, 18-19
Study 
J2W-MC - PYA B Screen Double -blind treatment and assessments EDFollow -up if 
hospital inpatient 
on Day 29Post-
treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 1122
*29 EDEvery 7 days 
until discharge or 
Day 6060 85Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) 
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Symptom -directed 
physical examX X XAs indicated based on participant status 
and standard of care.  May be 
performed by qualified personnel per 
local regulations.
Vital Signs and 
Oxygen Support
Includes: body 
temperature, pulse 
rate, BP, respiratory 
rate, SpO2, and 
supplemental oxygen 
flow rate, FiO2 if 
known, method of 
delivery, if 
applicable, and 
oxygen support 
procedures.X X X X X X X X X X XDocumentation of hospital -based exam is 
acceptable.
Record SpO2 while participant is at rest.
Screening visit only : SpO2 while breathing 
room air. Data not collected on CRF.
IV dose Day 1 timing:
 immediately before administration
 every 15 minutes during the infusion, 
as possible and applicable
 if infusion is <15 minutes, immediately 
following completion of infusion
 every 30 minutes for 1 hour after the 
administration.  
During infusion, only record pulse rate, BP 
and SpO2. Automation may be used.  
SQ dose Day 1 timing:   
 immediately b efore injection , and
 every 30 minutes for 1 hour after the 
administration.  
All other study days: once daily. 
See Section 8.2.2 for data collected on CRF.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
30Schedule of Activities for Treatment Arms 7 -9, 13-14, 18-19
Study 
J2W-MC - PYA B Screen Double -blind treatment and assessments EDFollow -up if 
hospital inpatient 
on Day 29Post-
treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 1122
*29 EDEvery 7 days 
until discharge or 
Day 6060 85Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) 
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Hospitalization 
eventsDaily X X X X X XRecord if the following events occur or 
occurred since prior visit:
 Emergency room visits
 hospitalized
 ICU admittance, 
 Extended care facility admittance, 
and
 Discharge
Clinical status and 
concomitant 
procedures if 
participant is 
hospitalizedDaily  if hospitalized X X X XDocumentation from hospital records is 
acceptable if hospitalized at any time.
Includes:
 NEWS 2 Consciousness (ACVPU)
 Limitation on activities due to 
COVID -19 using the Patient 
Global Assessment for Daily 
Activities of Physical Function
 Concomitant procedures of interest 
for organ support (e.g., proning, 
renal support)
 Additional organ support (e.g. 
pressors, renal replacement).  
Oxygen support and vital signs data 
should be collected while participant is 
hospitalized.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
31Schedule of Activities for Treatment Arms 7 -9, 13-14, 18-19
Study 
J2W-MC - PYA B Screen Double -blind treatment and assessments EDFollow -up if 
hospital inpatient 
on Day 29Post-
treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 1122
*29 EDEvery 7 days 
until discharge or 
Day 6060 85Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) 
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Laboratory Tests and Sample Collection
Hematology X X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Clinical Chemistry X X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day
No samples needed if participant is 
hospitalized 
Lilly -designated central laboratory
C-reactive 
protein (CRP); 
high -
sensitivity
Ferritin
D-dimer
Procalcitonin
TroponinX X X X XFor adults only
Day 1: before treatment administration
All other days: sample may occur at any 
time during the day 
No sample needed if participant is 
hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
32Schedule of Activities for Treatment Arms 7 -9, 13-14, 18-19
Study 
J2W-MC - PYA B Screen Double -blind treatment and assessments EDFollow -up if 
hospital inpatient 
on Day 29Post-
treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 1122
*29 EDEvery 7 days 
until discharge or 
Day 6060 85Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) 
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Documentation of 
positive SARS -
CoV-2 viral 
infection XSample for first positive test must be 
collected within 3 days prior to start of 
administration .
Local laboratory and/or Point -of-Care 
testing.
Urine or serum 
pregnancy X X XOnly for WOCBP (Section 10.4
Appendix 4) .  Not applicable for 
females pregnant at screening.  
Local laboratory
Pharmacokinetic 
(PK) sampleX X X X X X XDay 1
IV infusion: before IV infusion (adults 
only) and within 30 minutes after the 
end of infusion .
SQ injection: anytime after dosing , 
preferably as close to the end of the 
visit as possible.
Day 3 sample for SQ dose , treatment 
arm 19 ,only.
All other scheduled samples may occur 
at any  time during the day.
No samples needed if participant is 
hospitalized.
Lilly -designated central laboratory
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
33Schedule of Activities for Treatment Arms 7 -9, 13-14, 18-19
Study 
J2W-MC - PYA B Screen Double -blind treatment and assessments EDFollow -up if 
hospital inpatient 
on Day 29Post-
treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 1122
*29 EDEvery 7 days 
until discharge or 
Day 6060 85Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) 
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Immunogenicity 
(ADA) sampleX X X X X XDay 1:  collect before treatment 
administration . 
All other scheduled and unscheduled 
immunogenicity samples should be 
collected with a time -matched PK 
sample.
No sample needed for Day 3 SQ dose.
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Pharmacodynamic 
(PD) NP swab X X X X X X XSwab is taken from both nostrils . 
Day 1: swab before treatment 
administration.
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Explo ratory  
biomarker samplesX X X X X X X XDay 1: before treatment administration.
Day 60 and 85: serum sample only
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Pharmacogenetics 
sampleXFor adults only
Lilly -designated central laboratory
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
34Schedule of Activities for Treatment Arms 7 -9, 13-14, 18-19
Study 
J2W-MC - PYA B Screen Double -blind treatment and assessments EDFollow -up if 
hospital inpatient 
on Day 29Post-
treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 1122
*29 EDEvery 7 days 
until discharge or 
Day 6060 85Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) 
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Randomization and Dosing
Randomization X
Administer study 
interventio nXStudy  intervention must be 
administered within 3 days from the 
time of first positive SARS -CoV-2 test 
sample collection.
For participants that receive dialysis on 
the same day as administration of study 
intervention, complete dialy sis first 
followed by the study treatment.
Participants will be monitored for at 
least 1 hour after completion of 
treatment administration .
Participant Questionnaire
Symptoms and 
overall clinical 
statusDaily on Day s 1-11 for outpatients only X X X X X Day 1: assess prior to dosing
Abbreviations:  ACVPU = alert, consciousness, verbal, pain, unresponsive scale; ADA = anti -drug antibody; AEs = adverse events; BP = blood pressure; CRF = case report form; 
ED = early discontinuation visit; FiO2 = fraction of inspired oxygen in the air; ICU = intensive care unit; IV = intravenous; NP = nasopharyngeal; NSAIDS = non -steroidal anti -
inflammatory drugs; SAEs = serious adverse events; SARS -CoV-2 = severe acute respiratory syndrome coronavirus 2; SpO2 = saturation of peripheral oxygen; SQ = 
subcutaneous; WOCBP = women of child -bearing potential.  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
352. Introduction
The efficient communit y spread of SARS -CoV -2has resulted in the current pandemic of 
COVID -19, whi ch in severe and crit ical cases results in progressive pulmo nary infect ion, 
complicated by  respi ratory  failure, wi th a high prevalence of acute respiratory  distress syndro me.  
Although several therapies have been explored in severe COVID -19, none have improved
survival, including a ntivirals, glucocortico ids, and immunoglobulins (Liu et al .2020). 
The SARS -CoV -2gains entry  to cells through binding of the spike (S) protein to ACE2 receptors 
on cells (Hoffmann 2020).  Eli Lilly and Co mpany has a partnership wit h AbCellera Bio logics 
Inc. (AbCellera; Vancouver, Canada) to develop neutralizing IgG1 monoclonal ant ibodies 
(mAbs) to the Spike (S) protein of SARS -CoV -2 as a potential treatment for COVID-19.  
Candi date antibody  gene sequences have been selected from a recent ly recovered COVID -19 
United States patient’s serum using AbCellera’s core plat form screening technol ogies. 
LY3819253 and LY3832479 areneutralizing IgG1 monoclonal ant ibodies(mAb) to the spike 
protein of SARS -CoV -2.  They  aredesigned to block viral attachment and entry  into hum an 
cells,and to neutraliz e the virus , potenti ally treating even established COVID -19 by  provi ding a 
combinat ion of specific ,potent, neutralizing ant ibodiestoSARS -CoV -
2.  The blocking o f viral 
entry  into respi ratory  cells an d viral  replicat ion, and viral neutralization is expected to mit igate 
the severit y of disease in pat ients in who m ongoing viral spread and replicat ion is the primary 
driver of COVID -19 pathophysio logy.  The decrease in vi ral replicati on may  also shorten a 
patient’s extent and duration of viral shedding and transmissio n, posit ively impacting public 
healt h. 
2.1. Study Rationale
This study  aims to eval uate the impact of LY3819253 and LY3819253 in co
mbinat ion with 
LY3832479 on vi ral clearance and clinical outcomes in pa rticipants with mild to m oderate 
COVID -19illness.  The data from this study  will inform decisi ons f or the clinical development 
of these neutralizing IgG1mAbs . 
2.2. Background
Nonclinical informat ion for LY3819253 and LY3832479 aredescribed in each respect ive 
Invest igator’s Brochure (IB) .  
Lilly is evaluat ing the safet y, tolerabili ty, pharm acokinet ics (PK), and pharmacodynamics (PD) 
of LY3819253 in participants hospitalized for COVID -19, in a rando mized, placebo -controlled, 
doubl e-blind, singl e ascending dose, Phase 1, first in human study  (Study  J2W -MC-PYAA
[PYAA]). Study  PYAA start edprior to thi s study  and inform edthe dose l evels administered in 
Study  PYAB.
Lilly is evaluat ing the safet y, tolerabili ty, PK, and immunogenicit yof LY38 32479 in healt hy 
participants, in a rando mized, placebo -controlled, single dose, Phase 1 study  (Study  J2Z
-MC-
PGAA [P GAA]) under IND 150707.  Concurrent with Study  PGAA, LY38 32479 is also under 
develop ment in China in an ongoing Phase 1 clinical study in healt hy participants, Study  JS016 -
001-I.  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
362.3. Benefit/Risk Assessment
Inform ation on the safet y and tol erabilit y of LY 3819253 in humans will come fromStudy  
PYAA . All available study  data will be reviewed before that dose is administered in Study  
PYAB . 
Risk of Neutralizing Antibodies
Anticipated risk is considered low and is based on the known mechanism o f action for hum an 
derived neutralizing ant ibodies in acute viral disease states.  LY3819253 and LY3832479 consist 
ofhighly  specific mAb sdirected at forei gn (non-human) epi tope(s).  The com plementari ty 
determining regions (CDRs) of the mAb swere derived fro m B lymphocy tes of  a convalescent 
naturally  SARS -CoV -2-infected patient and, thus, have undergone natural posit ive and negative 
select ion pressures in vivo , 
unlike humanized ant ibodies generated in mice.  No clinically 
relevant off -target binding has been observed in t issue cross reactivit y studi es of  membrane 
targets in human tissues. Therefore, off -target binding and ti ssue cross -reactivit y are considered 
unlikely .  
A theoretical risk is that these intervent ions may cause antibody -dependent enhancement (ADE) 
of viral  replicat ion.  Thi s is based on responses observed to some mo noclonal  antibody  therapies 
used in o ther unrelated viral diseases.  To address this risk, LY38192 53and LY3832479 have 
been assessed wit h in vitro cell culture models and, for LY 3819253, an in vivo nonhuman 
primate model.
The risk of clinical ADE for either intervention or in combinat ion is considered low due to
the structural features of LY 3832479, which is engineered to suppress its binding to Fc 
receptors and C1qm
the absence of ADE fromin 
vitrostudies , and
the absence of ADE fromin vivo nonhuman primate studies for LY 3819253.
LY3819253 will also be administered to pa rticipants at sufficient ly high dose levels to neutralize 
SARS -CoV -2 and avo id sub -neutralizing concentrations i n the presence of virus that are 
typically  associ ated wi th ADE.  
Risk of Infusion -related Reactions and Injection Site Reactions
Addit ional manageable risks associated with most therapeutic monoclo nal ant ibodies are 
infusio n
-related hypersensit ivity and cytokine rel ease reacti ons.  The infusio nsin this study  will 
be administered at a controlled rate, the study  partici pants will  be m onitored closely, and 
adjustm ents in the infusio n rate will be made and/or the infusio n stopped, if indicated.  
Additional information regarding infusio n reaction management options is in Section 6.1.1 .and 
Secti on6.1.2.
There i s also potenti al for inject ion site reactions (ISRs) with subcutaneous dosing
.  
LY3819253
As of 2 Octo ber 2020, 727 participants received blinded treatment ofLY3819253 700 mg, 
2800 mg, or 7000 mg, or placebo.   Seri ous infusio n-related reactions, including events consistent 
with anaphylaxis, were reported in these ongoing studies with LY3819253 (FDA EUA fact sheet 
2020).  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
37Clinical worsening of COVID -19 after administratio n of LY3819253 has been reported and may 
include symptoms of pyrexia, hypoxia or increased respiratory  difficul ty, rapi d heart rate (e.g. 
atrial fibrillat ion, sinus tachycardia), fat igue, and altered mental status. Some of these events 
requi red hospi talizati on.  It i s unkno wn if these events were related to LY3819253 use or were 
due to progression of COVID -19. 
Combination of LY3819253 and LY3832479
As of 04 November 2020, 542 participants in Study PYAB received blinded treatment ofeither 
placebo or the combinat ion of 2800 m g LY3819253 and2800 m g LY3832479 .Three
participants reported single im mediate non-serious events of prurit is(2events )and dyspnea (1
event ).  
Benefit/Risk in the Adolescent Population
With respect to adolescents, t here are no approved vaccines for the prevent ion of COVID- 19 or 
approved drugs to treat COVID -19.  T he SARS -CoV -2 infect ionsin the adol escent populat ion 
generally are less severe than adul ts and may  even be asymptomat ic(Hoan g et al . 2020) .  
However , the risks of serious illness requi ring hospi talizat ion and sometimes result ing indeath, 
is higher in pediatric pat ients with a number of risk factors that generally correspond to those in 
adults, such as obesit y, diabetes, chronic lung disease , and immunocompro mised status , as well 
as some condit ions that are unique to pediatrics, such as congenital heart disease (Kim et al.
2020; Shekerdemian et al . 2020 ).  
Adolescents wi th risk factors for severe disease and hospitalizat ionmay benefit from early  
administration of experimental anti-viral therapies such as the combinat ion of LY3819253 and 
LY383 2479, especially given the current safet y profile .Based on FDA guidance documents, the 
data from  even a small number of adolescents isuseful inmaking regulatory science decisio ns
(FDA May 2020 and FDA June 2020).
Benefit/Risk in the Pregnant Population
In vitro t issue cross -reactivit y assays wit h LY 3819253 and LY3832479 determined that there is 
no binding to human fetal t issues. 
Interim analysis fro m this study  suggest treatm ent wi th LY3819253 may  decrease the ri sk of
hospi talizati on in mild to m oderate COVID -19 patients (Chen et al. 2020).  Pregnant females and 
pregnant females with addit ional risk factors for severe disease and hospitalization may benefit 
from early  administrati on of  experimental  anti
-viral therapies such as the combinat ion of 
LY3819253 and LY3832479, especially given the current safety  profile . Based on the FDA 
guidance docum ent, the data from  this popul ation may be useful  in making regulatory  science 
decisio ns and enro llment is encouraged in clinical trials (FDA May 2020). 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
38Over all Benefit /Risk Assessment
Given the data on LY 3819253 and LY3832479, the well described safet y profile o f other 
therapeuti c mAbs ,and the lackof disease di rected therapeutic options for patients with COVID -
19illness, the overall benefit -risk assessment for this study  is considered favorable.
More detailed informat ion about the known and expected benefits and risks a nd reasonably 
expected adverse events of LY3819253 and LY3832479 may be found in each respect iveIB. 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
393. Objectives and Endpoints
3.1. Treatment arms 1 -4 and 6
Objectives Endpoints
Primary
Characterize the effect of LY3819253, and LY3819253
in combination with LY3832479 ,compared to placebo 
on SARS -CoV -2 viral load and viral clearanceChange f rom baseline to Day 11 (± 4 days) in SARS -
CoV-2 viral load 
Secondary
The secondary objectives are to c haracterize the effect 
of LY3819253 ,and LY3819253 in combination with 
LY3832479 ,compared to placebo on…
safety Safety assessment ssuch as AEs and SAEs
SARS -CoV -2 viral load among pa rticipan ts with 
≤8days since symptom onsetChange f rom baseline to Day 11 (± 4 days) in 
SARS -CoV-2 viral load among participants 
enrolled with ≤ 8days of symptoms prior to 
randomization
symptom resolution Time to symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days
7,11, 15 and 22
C
hange in symptom score (total of ratings) from 
baseline to Days 7, 11, 15 and 22 
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 7, 11, 15 and 22
SARS -CoV -2 viral load and viral clearance Proportio nof participants that achieve SARS -
CoV-2 clearance (Day s 7, 11, 15 and 22)
Time to SARS -CoV -2 clearance 
SARS -CoV-2 viral load area under the response -
time curve (AUC )assessed through Day 29
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day s 29, 60 and 85
oCOVID -19 related hospitalization
(defined as ≥24 hours of acute care)
oa COVID -19 related emergency room 
visit, o r 
odeath
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
40Objectives Endpoints
Additional Secondary
Characterize the pharmacokinetics of LY3819253 and 
LY3819253 in combination with LY3832479Mean concentration of LY3819253 and 
LY3819253 in the presence of LY3832479 on Day 
29
Mean concentration of LY38 32479 in presence of 
LY3819253 on Day 29
Explorator y
The exploratory objectives are to characterize the 
effect of LY3819253 and LY3819253 in combination 
with LY3832479 compared to placebo on…
SpO2 over time SpO2 AUC assessed through Day 29
symptom severity Symptom severity as assessed by mean AUC 
through Day 29 of sy mptom questionnaire
overall improvement using the NIAID ordinal 
scaleComparison of the mean worst daily NIAID 
ordinal eight -point scale values at Days 7, 11, 15
and 22
Additional Exploratory
Characterize emergence of viral resistance to 
LY3819253 and LY3819253 in combination with 
LY3832479Comparison from baseline to the last evaluable time 
point up to Day 29
Abbreviations:  AE = adverse event; NIAID = National Institute of Allergy and Infectious Diseases; SAE =serious 
adverse event; SAR S-CoV -2 = severe acute respiratory syndrome coronavirus 2 ; SpO2 = saturation of peripheral 
oxygen .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
413.2. Treatment arms 7 -9
Objectives Endpoints
Primary
Characterize the effect of LY3819253 in combination 
with LY3832479 compared to placebo on overall 
participant clinical statusProportio n (percentage) of participants who experience 
COVID -19 related hospitalization ( defined as ≥24 
hours of acute care) or death from any cause by Day 
29.
Key Secondary
The secondary objectives are to c haracterize the effect 
of LY3819253 in combination with LY3832479, 
compared to placebo on…
the reduction of SARS -CoV -2 viral load Change f rom baseline to Day 7 (± 2 day s)
persistently high SARS -CoV -2 viral loadProportio n of participants with SARS -CoV -2 viral 
load greater than 5.27 on Day 7 (+2 days)
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 2 9
oCOVID -19 related hospitalization
(defined as ≥24 hours of acute care) , or
oa COVID -19 related emergency room 
visit, o r 
odeath from any  cause
sustained symptom resolution time to sustained symptom resolution
Additional Secondary
SARS -CoV -2 viral load reduction Change f rom baseline to 
oDay 3 (+1 day)
oDay 5(±2days)
SARS -CoV-2 viral load area under the response -
time curve (AUC ) assessed through Day 7
SARS -CoV -2 viral clearance Time to SARS -CoV -2 clearance 
symptom resolution Time to symptom resolution 
Time to complete symptom resolution
Time to sustained complete symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days
2-11
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 2-11
safety Safety assessments such as AEs and SAEs
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
42Objectives Endpoints
Exploratory
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Days 22,60 and 85
oCOVID -19 related hospitalization
(defined as ≥24 hours of acute care) , or
odeath from any  cause
Characterize the pharmacokinetics of LY3819253 in 
combinatio n with LY3832479Mean concentration of LY3832479 in presence of 
LY3819253 on Day 29
Abbreviations:  AE = adverse event; SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory 
syndrome coronavirus 2 . 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
433.3. Treatment arms 13-14
Objectives Endpoints
Primary
Persistently  high SARS -CoV -2 viral load for treatment 
arm 14 compared to treatment arm 13Proportio n of participants with SARS -CoV -2 viral load 
greater than 5.27 on Day 7 (+2 days)
Key Secondary
Reduction of SARS -CoV -2 viral load for t reatment 
arm 14 compared to treatment arm 1 3Change f rom baseline to Day 7 (± 2 day s)
Clinical status for t reatment arm 14 compared to all 
high-risk placebo participants in treatment arms 8 and 
13Proportio n (percentage) of participants who experience 
COVID -19 related hospitalization (defined as ≥24 
hours of acute care) or death from any cause by Day 
29.
Additional Secondary
Clinical status for treatment arm 14 compared to all 
high-risk placebo participants in treatment arms 8 and 
13Propo rtion (percentage) of participants who experience 
these events by Day 29
COVID -19 related hospitalization (
defined as ≥24 
hours of acute care) , or
a COVID -19 related emergency room visit, or 
death f rom any  cause
Treatment arm 13 compared to treatment arm 14 on…
sustained symptom resolution time to sustained symptom resolution
SARS -CoV -2 viral load reduction Change f rom baseline to 
oDay 3 (+1 day )
oDay 5 (±2 day s)
SARS -CoV-2 viral load area under the response -
time curve (AUC ) assessed through Day 7 
SARS -CoV -2 viral clearance Time to SARS -CoV -2 clearance 
symptom resolution Time to symptom resolution 
Time to complete symptom resolution
Time to sustained complete symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days
2-11
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 2 -11
safety Safety assessments such as AEs and SAEs , 
including date and time of events
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
44Objectives Endpoints
Exploratory
Treatment arm 14 compared to treatment arm s8 and 
13onoverall participant clinical statusProportio n (percentage) of participants who 
experience these events by Days 22, 60 and 85
oCOVID -19 related hospitalization
(defined as ≥24 hours of acute care) , or
odeath from any  cause
Characterize the pharmacokinetics of LY3819253 in 
combinatio n with LY3832479Mean concentration of LY3832479 in presence of 
LY3819253 on Day 29
Abbreviations:  AE = adverse event; SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory 
syndrome coronavirus 2 . 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
453.4. Treatment arms 18-19
Objectives Endpoints
Primary
Persistently high SARS -CoV -2 viral load for treatment 
arm 1 9compared to treatment arm 1 8Proportio n of participants with SARS -CoV -2 viral load 
greater than 5.27 on Day 7 (+2 days)
Key Secondary
Reduction of SARS -CoV -2 viral load for treatment 
arm 19 compared to treatment arm 18Change f rom baseline to Day 7 (± 2 day s)
Overall p articipant clinical status for treatment arm 19 
compared to all high -risk placebo participants in 
treatment arms 8 and 13Proportio n (percentage) of participants who experience 
COVID -19 related hospitalization ( defined as ≥24 
hours of acute care) or death from any cause by Day 
29.
Additional Secondary
Clinical status for treatment arm 19 compared to all 
high-risk placebo participants in treatment arms 8 and 
13Propo rtion (percentage) of participants who experience 
these events by Day 29
COVID -19 related hospitalization (
defined as ≥24 
hours of acute care) , or
a COVID -19 related emergency room visit, or 
death f rom any  cause
Treatment arm 19 compared to treatment arm 18 on…
sustained symptom resolution time to sustained symptom resolution
SARS -CoV -2 viral load reduction Change f rom baseline to 
oDay 3 (+1 day )
oDay 5 (±2 day s)
SARS -CoV-2 viral load area under the response -
time curve (AUC ) assessed through Day 7 
SARS -CoV -2 viral clearance Time to SARS -CoV -2 clearance 
symptom resolution Time to symptom resolution 
Time to complete symptom resolution
Time to sustained complete symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days
2-11
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 2 -11
safety Safety assessments such as AEs and SAEs, 
including date and time of events
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
46Objectives Endpoints
Exploratory
Treatment arm 19 compared to treatment arm s 8 and 
13onoverall participant clinical statusProportio n (percentage) of participants who 
experience these events by Days 22, 60 and 85
oCOVID -19 related hospitalization
(defined as ≥24 hours of acute care) , or
odeath from any  cause
Characterize the pharmacokinetics of LY3819253 in 
combinatio n with LY3832479Mean concentration of LY3832479 in presence of 
LY3819253 on Day 29
Abbreviations:  AE = adverse event; SAE =serious adverse event; SARS -CoV -2 = severe acute respiratory 
syndrome coronavirus 2 . 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
474. Study Design
4.1. Overall Design
This is a Phase 2 /3, placebo -controlled ,doubl e-blind, rando mized single -dose study  in 
participant s with 
mild to moderate COVID- 19illness .
4.1.1. Design Outline
Abbreviations :  PD = pharmacodynamic; PYAB = Study J2W -MC-PYAB.
Figure 2. Overview of participant flow from time of SARS -CoV- 2 symptoms to IV 
infusion.
Screening
Interested participants or thei r legally  authori zed representative 
will sign the appropriate 
informed consent and child/ado lescent assent document(s) , as appropriate, prior to com pletion of  
any procedures. The participant may enter the study  with a previ ous posi tive SARS -CoV -2 viral 
test result fro m an external test ing facilit y.  This test result must be the first time the patient has 
tested posit ive for SARS -CoV -2.
The invest igator will review symptoms, risk factors and other non -invasive inclusio n and 
exclusio n criteria pri or to any  invasive procedures.  If the participant is eligible after thi s review , 
then the site will perform the invasive procedures to confirm eligibilit y.
Treatment and Assessment Period
This is the general sequence of events during the treatment and assessment period :
Complete baseline procedures and sample co llection
Participants are randomized to an intervent ion group
Parti cipants receive study intervent ion, and
Complete all  safety  monitoring and post -dose sample co llection.

CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
48Treatment Arms
This table describes the planned treatment arms.  
Treatment arms Dose Intervention Route of Administration
1 --- Placebo
Intravenous2 700 mg LY3819253
3 2800 mg LY3819253
4 7000 mg LY3819253
Optional 5 To Be Determined LY3819253
6 2800 mg + 2800 mg LY3819253+LY3832479
7 2800 mg + 2800 mg LY3819253+LY3832479
8 --- Placebo
9 700 mg + 1400 mg LY3819253+LY3832479
13 --- Placebo
14 350 mg + 700 mg LY3819253+LY3832479
18 700 mg + 1400 mg LY3819253+LY3832479
19 250 mg + 500 mg LY3819253+LY3832479 Subcutaneous
NOTE: PYAB protocol addenda also include treatment arms for this study .    
As LY3819253 dose levels in Study J2W-MC-PYAA ( PYAA ) are determined to be safe, 
treatm ent arm s 2-4 may be introduced i n Study  PYAB .    
An optional LY3819253 -only treatment arm 5 may be added based on interim analysis results.  
Treatment arm 1 is the corresponding placebo control for treatment arms 2- 4 and 6.  
Treatment arm 8 is the corresponding placebo control for treatment arm s
7and 9 .  
Treatment arm 13 is the co ncurrent placebo control for treatment arm 14.
Treatment arms 1 8-19 are open -label.  
For treatm ent arm  19, a safety  review will occur after approximately 20 part icipants are dosed
and have at least 24 hours of safet y data,before cont inuing dosing subsequent participants.  The 
investigator and the Lilly sponsor team are responsible for determining if safet y is acceptable to 
continue dosi ng subsequent participants. 
Visit Types during the Treatment and Assessment Period
This table describes the visit t ypes for treatm ent arms 1 -4 and 6
.
Study Day Visit Type
1  Site  
2, 4, 5 and 6 Telepho nevisits
3, 7, 11, 15, 18, 22, 25and 29 May be conducted as outpatient clinic or home visits .
Early  discontinuation and follow -up May be conducted as outpatient clinic or home visits
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
49This table describes the visit t ypes for treatm ent arms 7 -9, 13-14, 18-19.
Study Day Activity Visit Type
1  Follow SoA Site  
2, 4, 6 and 22 Follow SoA Telepho nevisits
3, 5, 7, 11, and 29 Follow SoA May be conducted as outpatient 
clinic or home visits
8, 9, and 10 Collect participant questionnaire 
symptom and overall clinica l
status assessmentsTelepho ne visits
Early  discontinuation and follow -up Follow SoA May be conducted as outpatient 
clinic or home visits
Guidelines if a Participant is Hospitalized
If a participant is hospitalized, procedures and assessments will cont inue per the SoA. 
This table describes d ischarge fro m hospi talscenarios if an outpatient is s ubsequent ly 
hospitalized .
If hospital discharge … Then…
Occurs prior to Day 29 participants will be asked to complete the remaining 
study assessments at the timepoints indicated in the 
SoA.  
NOTE: Strategies to manage infection risks and reduce 
the burden of return visits should be used by sites, such 
as home visits .
Occurs on the same day as a study assessment visit assessments do not need to be repeated if the study 
assessments occurred within 8 hours of discharge and 
there has been no change in clinical status and the 
information is available to the site .
Does not occur at or prior to Day 29 assessments will continue to occur weekly up to Day 
60 or until hospital discharge, whichever is sooner.
Post-treatment follow -up
Post-treatm ent follow-up assessments will be conducted at Day  60 and Day 85 to assess clinical 
status and for adverse events. Strategies to manage infection risks and reduce the burden of 
return visits may be used by sites, such as ho me visits.
4.2. Scientific Rationale for Study Design
Overall Design
This study  is designed to evaluate the efficacy of LY3819253 in a range of doses that will inform 
the clinical drug development plan for LY3819253 , and to evaluate the effica cy of the 
combinat ion of LY3819253 and LY3832479.
The fo llow-up at Day  85 adequately covers the duration for immune response.
Due to emerging data , participants will no longer receive placebo and new potential participants 
will have the opportunit yto receive act ive interventi on.  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
50Treatment arms 18- 19 are open -labelbecause of the change in primary endpo int to a more 
objective evaluat ion of change in viral load.  This also removes the need for a double -dummy 
design requiring every  parti cipant to re ceive an infusion and subcutaneous injections .  
Safety review sareincluded for treatment arm 19to minimize the risk o f any unant icipated safet y 
concerns in participants before fully  enrolling the treatment arm. 
Participant Characteristics
The participant population are those infected with SARS -CoV -2 that ha vedevel oped symptom s 
consistent with COVID -19.  There is historical evidence that patients infected with upper 
respi ratory  viruses who are treated early  in thei r disease course have better r esponses to anti -viral 
therapi es(Aoki et.al ., 2003) .  Thi s hypothesis will be tested with a focused subgroup analysis on 
participants who received intervent ion within 8 days of symptom onset and a viro logy endpo int 
(see Section 3).
The populat ion of participants with mild to moderate COVID -
19illness was chosen to evaluate 
if effect ive antiviral antibody therapy may preven t progressi on to the severe form of COVID -19 
illness by treati ng this popul ation early in their disease course and prior to respiratory  
compromise and failure.   
The populat ion of participants in treatm ent arm s 7-9 arerequired to have at least 1 risk fact or for 
developing sever eCOVID -19 illness .The risk factors were based on the Centers for Disease 
Control guidance (CDC resource page , available at: https://www .cdc.gov/coronavirus/2019 -
ncov/need -extra -precauti ons/peopl e-at-increased -
risk.ht ml?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019 -
ncov%2Fneed -extra -precautions%2Fpeople -at-higher -risk.ht ml).  Participants with these risk 
factors areat highe r risk for m ore severe disease and hospitalizat ion. This popul ation was 
chosen to evaluate if effective ant iviral ant ibody  therapy  may prevent hospi talizat ion or death .
Adolescent Participants
There are no approved treatments for adolescent sinfected with SARS -CoV -2 or to prevent 
infect ion in adolescent s with co morbidities that place them  at increased ri sk shoul d they  become 
exposed to SARS -CoV -2.  Per FDA request, adolescents at higher risk for severe disease and 
hospi talizati on are included in this study.
To minimize invasive procedures and blood volume collect ionconcerns in ado lescents , certain 
laboratory  tests and sample collect ions are excluded for this populat ion .
Pregnant Participants
Interim analysis fro m this study  suggest treatm ent wi th LY3819253 may  decrease the ri sk of 
hospi talizati on in mild to m oderate COVID -19 patients (Chen et al. 2020).  Pregnant females and 
pregnant females with addit ional risk factors for severe disease and hospi talizati on may  benefi t 
from early  administrati on of  experimental  anti
-viral therapies such as the combinat ion of 
LY3819253 and LY3832479, especially given the current safety  profile . Per FDA guidance , 
pregnant individuals may be included in this stud y(FDA, May  2020) .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
51Participants who have received a SARS -CoV-2vaccination
SARS -CoV -2 vaccines are now available to the public .  Those who received a SARS -CoV -2
vaccine are now allowed in the study  to assess the safet y of LY3819253 and LY3832479 after a 
person received thevaccine .
Interim Reviews
The interim safety  and efficacy  review swill inform the clinical drug development plan for
LY3819253 and the combinat ion of LY3819253 and LY3832479.
4.3. Justification for Dose
LY3819253
The dose levels of LY3819253 administered in this study  areinformed by Study  PYAA . Asdose
inform ationfrom Study  PYAA are determined to be safe , thesedose levels may be added to the 
study . 
The starting dose of 700 mg LY3819253 in Study  PYAA is selected based on PK and PK/PD of 
viral dynamics modeling tohave a sustained concentration above the in vitro IC90 of viral cell-
entry  neutralizat ion in the lung t issue for at least 28 day sin 90% of the pa rticipant populat ion.  
The m aximum  dose of 7000 m g is selected due to uncertaint y in model predicted PK 
concentrations, viral load reduction and consideratio n of infusion vo lume in participants.  The 
dose will not exceed 7000 mginthis study . 
The proj ected human half -life is expected to be in the 2 -4 weeks range.  
LY3819253 + LY3832479
To provi de coverage of the different but overlapping epitopes on SARS -CoV-2 receptor binding 
domainsites, the dose sel ection rati onale for each single mAb intervent ion in the combinat ion is
the sam e as for the dose rationale for asingle mAb intervent ion.  
2800 mg LY3819253 and 2800 mg LY3832479
Thedose sel ection of2800 m g LY3819253 and 2800 mg LY3832479 is based on PK and PK/PD 
modeling to have a sustained lung concentration above the in vitro IC90 of viral cell -entry  
neutralizat ion (95thpercentile o f the estimates) in the lung tissue for at least 28 day sin greater 
than 90% of the pa rticipant popul ation.  The PK included addit ional variabil ity to cover 
transl ational uncertainty .  The 95thpercent ile was chosen asaconservative measure.
The dose levels are fixed, not body  weight based.  Given the planned dose l evels , the predi cted 
impact of body  weight on therapeuti c response will be minimal. 
Addition of adolescents
In treatm ent arms 7 and 8, adult pa rticipa nts are currently randomized 1:1 to receive placebo or a 
combinat ion of 2800m g LY3819253 and2800mg LY3832479 . Based on PK extrapolation 
(exposure -matching) , adol escent s≥ 40 kg dosedwith2800 m g areexpected to reach the sam e 
exposure (C maxand AUC) as adults for both LY3819253 and LY3832479.  Exclusio n criterion 
#29 was added to ensure all participants have a body  weight ≥ 40 kg .  Thus ,adolescen t 
participants will receive the same dose l evel as the adul t parti cipants .  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
52700mg LY3819253 and 1400 mg LY3832479
In treatm ent arm s 9and 18 , participants will receive a combinat ion of 700 mg LY3819253 and
1400 mg LY3832479 .  To provi de coverage of the different but overlapping epitopes on SARS-
CoV -2 receptor binding domain sites for the combinat ion of LY3819253 and LY3832479, the 
dose sel ection rati onale for each single mAb in the combination is the same as for the dose 
rationale for a single mAb. 
The dose of 700 mg LY3819253 wasconfirmed as the maximum therapeut ic dose in the PYAB 
interim analysis based on viral load, symptoms and clinical outcomes.  T he dose of 1400 mg 
LY3832479 isselected asthe maxim um therapeut ic dose based on an approximate 2-fold higher 
IC50 to LY3819253 .  At these dose levels , 
thecombinat ionis expected to reduce viral load 
based on viral dynamic PK/PD modeling (updated with reduced transl ational uncertaint y)and 
have a sustained concentration above the respect ive IC90 of viral neutralizat ion for at least 28 
days in 90% of the participant popul ation.
350 mg LY3819253 and 700 mg LY3832479
Treatment arm 1 4participants will receive a combinat ion of 350 m g LY3819253 and 700 m g 
LY3832479.  The doses were selected based on PK/PD modeling, in addit ion to interim PK, viral 
load, symptoms, clinical outcome and safet y data from  Study  J2X-MC-PYAH (BLAZE -
4).
250 mg LY3819253 and 500 mg LY3832479
Treatment arm 1 9participants will receive a comb ination of 250 m g LY3819253 and 500 m g 
LY3832479.  The subcutaneous doses were selected based on PK/PD modeling as described 
above, in addit ion to interim PK, viral load, symptoms, clinical outcome and safet y data from  
Study PYAH.   
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if they have completed all requi red 
phases of the study  including the last scheduled procedure shown in the S o
A.
The end o f the study  is defined as the date of last scheduled procedure shown in the So Afor the 
last parti cipant in the tri al globally.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
535. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.   
Due to the crit icality of part icipant health, verbal interview of the potential participant, or their
legal representative or family member, may  be the source for disease characterist ics and medical 
history , unless otherwise specified within the eligibilit y criteria.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1. A re ≥12years of age at the time of screening
Disease Characteristics
2.
Are current ly not hospi talized
3. H ave one or m ore mild ormoderate COVID -19 symptom s (FDA May 2020, Available at: 
https://www .fda.gov/regul atory -inform ation/search -fda-guidance -docum ents/covid -19-
developing -drugs -and-biological -products -treatm ent-
or-prevent ion)
i.Fever
ii.Cough
iii.Sore throat
iv.Malaise
v.Headache
vi.Muscle pain
vii. Gastrointestinal symptoms , or
viii. Shortness o f breath with exert ion
4.Must have sample collection for first posit iveSARS- CoV-2 viral infect iondeterminat ion
≤3 days prior to start of the infusio n
Sex
5.Are m alesor females , including pregnant females
Reproductive and Contraceptive requi rements areprovi ded in Sect ion 10.4,Appendix 4.   
Contraceptive use by m alesor females shoul d be consistent with local regulat ions for 
those parti cipat ing in clinical studies. 
Study Procedures
6.Understand and agree to comply  with planned study  procedures
7.Agree to the collect ion of nasopharyngeal swabs and venous blood
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
54Informed Cons ent
8.The parti cipant or l egally  authori zed representative givesigned inform ed consent and/or 
assent as described in Section10.1.3 which includes compliance with the requirements 
and restrictions listed in the informed consent form (ICF) and in this protocol . 
Treatment arm s 7-9, 13 - 14, 18-19
27.Are ≥18 years of age and s atisfy at least one of the fo llowing at the time of screening
Are pregnant
Are ≥ 65 years of age
Have a BMI ≥ 35
Have chronic ki dney disease
Have type 1 or ty pe 2 diabetes
Have immunosuppressive disease
Are current ly receiving immunosuppressive treatment , or
Are ≥ 55 y ears of age AND have
ocardi ovascular di sease , OR
ohypertensio n, OR 
ochronic obstructive pulmo nary disease or other chroni c respi ratory  disease
Note: BMI i s rounded tothe nearest whole number , for exam ple,34.5 i s rounded to 35.
28.Are 12 -17 years of age (inclusive) AND sat isfy at least one of the fo llowing at the time of 
screening
Are pregnant
Have a BMI ≥85thpercentile for their age and gender based on CDC growth 
charts, https://www .cdc.gov/growthcharts/clinical_charts.ht m
Have sickle cell disease 
Have congenital or acquired heart disease 
Have neurodevelopmental disorders , for example , cerebral palsy  
Have a medical -related techno logical dependence, for example , tracheostomy , 
gastrostomy , or posit ive pressure ventilat ion (not rel ated to COVID -19)
Have asthma or reactive airway or other chronic respiratory  disease that requires 
daily  medicat ion for control
Have type 1 or ty pe 2 diabetes
Have chronic kidney disease
Have immunosuppressive disease , or
Are current ly receiving immunosuppressive treatment .
5.2. Exclusion Criteria 
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
9.Have SpO2 ≤ 93% on room  airat sea l evel or PaO2/FiO2 < 300
, respiratory  rate ≥30 per 
minute, heart rate ≥125 per minute (FDA May 2020 )
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
5510.Requi re mechanical vent ilation or anticipate dimpending need for m echanical  ventilation 
11.Have known allergies to any  of the com ponents used in the formulat ion of the 
intervent ions
12.Have hemodynamic instabilit y requiring use of pr essors within 24 hours of 
rando mizat ion
13.Suspected or proven serious, active bacterial, fungal, viral, or other infect ion (besides 
COVID -19) that i n the opinio n of the invest igator could const itute a ri sk when taking 
intervent ion
14.Have any co -morbidity requiring surgery  within <7 day s, or that i s considered life -
threatening within 29 days
15.Have any serious conco mitant sy stemic disease, condit ion or disorder that, in the opinio n 
of the invest igator, should precl ude parti cipat ion in thisstudy .
Other Exclus ions
16.Have a history  of a posi tive SARS -CoV -2 serology test
17.Have a history  of a posi tive SARS -CoV -2 test prior to the one serving as eligibilit y for 
this study
18.Have received an invest igational intervent ion for SARS -CoV -2 prophylaxis wit hin 30 
days before dosing
19.Have received treatment with a SARS -CoV -2 specific mo noclonal ant ibody
20.Have received convalescent COVID -19 pl asma treatm ent 
21.Exclusio n criterion [21] removed in amendment (k)
22.Have part icipated, within the last 30 days, in a clinical study  involving an invest igational 
intervent ion.  If the previous investigational intervent ion has a long half -life, 5 half -lives 
or 30 day s, whichever i s longer, shoul d have passed.
23. A reconcurrent ly enrolled in any other type of medical research judged not to be
scientif ically or m edically  com patible wit h this study
24.Are breast feeding
25. A re invest igator site personnel directly affiliated wit h this study , and   
29.Have body  weight <40 kg .
5.3. Lifestyle Considerations
Reproductive and Contraceptive guidance is provided in Section 10.4, Appendix 4.
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequen tly enrolled in the study .A minimal set of screen failure informat ion is required to 
ensure transparent reporting of screen failure partici pants to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries fro m regulatory  
authori ties. Minimal informat ion includes demography, screen failure details, eligibilit y criteria, 
and any  serious adverse event (SAE) .
Individuals who do not meet the criteria f or parti cipati on in this study  (screen failure ) may not be 
rescreened. 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
566. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to /used by a study  parti cipant 
according to the study  protocol .  
6.1. Study Intervention(s) Administered
Each participant will receive either placebo ,LY3819253 , or a combinat ion of LY3819253 and 
LY383 2479.   
Theoptional treatm ent arm  5LY3819253 dose l evel may be tested based on interim analysis 
resul ts.  The dose l evels for thi s opti onal treatm ent arm  will not exceed 7000 mg and may 
include 175 mg.   
Study  intervent ion must be administered within 3 days of the first posit ive SARS -CoV -2 test 
samp le collect ion
.
Intervention 
NamePlacebo LY3819253 LY3832479
Dose 
Formulation0.9% sodium chloride 
solutionSolution
Dosage Level(s) 
(mg)Not applicable 250 350 700 2800 7000 500 700 1400 2800
Use placebo experimental
IMP and NIMP IMP IMP
Sourcing Commercially available 
0.9% sodium chloride 
solutionFrom Lilly
Packaging and 
LabelingCommercially available 
0.9% sodium chloride 
solutionStudy Intervention will be provided in glass vials and will be 
labeled appropriately
Abbreviations:  IMP = investigational medicinal product.
Infusio n and subcutaneous dose preparation informat ion may be found in the pharmacy  
preparati on instructi ons.
The infusio n rate m ay be reduced as deemed necessary  if an infusio n react ion is observed
(Secti on 6.1.1.2 ).  Participants will be monitored for at least 1 hour after com pletion of  the 
infusio n. 
Subcutaneous inject ions will be administered in the abdo men.  Thedose will be a dministered as 
3injections of 2-mL each.  Different quadrant sof the abdo menshoul dbe used for each inject ion.  
Record t he package number and locationof administrati on.
The site must have age-appropri ate resuscitat ion equipment, emergency drugs and appropriately 
training staff available during the infusio n and for at least 1 hour after the complet ion of the 
infusio n. 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
576.1.1. Special Treatment Considerations
6.1.1.1. Premedication for Infusions
Prem edicat ion for infusio nsis not pl anned.  However, if an infusion react ion occurs during 
administration or if the participant has a medical history  suggesting a potential benefit from 
prem edicat ion, the study  invest igator (s) should determine the appropriate premedicat ion.  T he 
investi gator sand sponsor may decide to usepremedicat ion if the frequency o f infusion react ions 
among parti cipants warrants i t.
If minor infusio n reactions are observed ,administration of acetaminophen, 500 mg to 1000 mg, 
antihistamines and/or other appropr iately indicated medicat ions may be given prior to the start of 
infusio ns for subsequent participants. 
The decisio n to implement premedicat ion for infusio ns in subsequent participants will be made 
by the investigator and sponsor and recorded in the study  documentati on.  
Any premedicat ions given will be documented as a concomitant therapy .
6.1.1.2. Management of Infusion Reactions
All participants shoul d be m onitored cl osely , asthere is a risk of infusio n reaction and 
hypersensit ivity (incl uding anaphylaxis) with any bi ological  agent.  
Symptoms and Signs
Symptom s and si gns that m ay occur as part of an infusio n reaction include, but are not limited to 
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash
including urt icaria, pruri tus, myalgia, and dizziness.  
Infusio n-related reacti onsseveri tywill be assessed and reported using the Divisio n of Allergy 
and Infect ious Diseases ( DAIDS )Table for Grading the Severit y of Adult and Pediatric Adverse 
Events, version 2.1 (J uly 2017) . 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
58This table describes the severit y of react ions according to DAIDS. 
Parameter Mild Moderate Severe Severe and 
Potentially 
Life-threatening
Acute Allergic 
ReactionLocalized urticaria 
(wheals) with no 
medical intervention 
indicatedLocalized urticaria 
with intervention 
indicated 
OR 
Mild angioedema 
with no intervention 
indicatedGeneralized Urticaria 
OR
Angioedema with 
interventio n indicated 
OR
Symptoms of mild 
bronchospasmAcute anaphylaxis 
OR 
Life-threatening 
bronchospasm 
OR
Laryngeal edema
Cytokine 
Release 
SyndromeaMild signs and 
symptoms 
AND
Therapy , that is, 
antibody infusion 
interruption not 
indicatedTherapy  (that is, 
antibody infusion) 
interruption 
indicated
AND
Responds promptly 
to sy mptomatic 
treatment
OR
Prophy lactic 
medications 
indicated for ≤24 
hoursProlonged severe 
signs and symptoms 
OR
Recurrence of 
symptoms following 
initial improvementLife-threatening 
consequences 
(for example, 
requiring pressor or 
ventilator support)
a= A disorder characterized by nausea, headache, tachycardia, hypotension, rash, and/or shortness of breath.
Source:  Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 
2.1 (July 2017).
6.1.2. Temporary Stopping Criteria
Changes to the planned dosing schedule must be appropriately documented and communicated 
with the study  personnel and the IRB/IEC before dosing cont inues.   
Treatment arms 1-9, 13 - 14
The Assessment Committee (AC) members individually will review unblinded safet y data for 
treatm ent arm s 1-4 and 6, and meet as described in the AC Charter. The Assessment Committee 
(AC) will conduct a full safet y review before determining if enrollment shoul d be stopped and/or 
other study  param eters shoul d be m odified. (see Se ction 9.6).
The Data Monitoring Co mmit tee (DMC) maystop enrollment or change other study  parameters
based on their review for treatm ent arms 7 -9, 13- 14, and 18 .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
59Treatment arm 19
For the first 20 -30 participants administered intervent ion, dosing will be re-evaluated if these 
circumstances occur 
3or more parti cipants develop AEs that are considered to be related to study  treatm ent
OR
1 or m ore pa rticipants develop AEs that are considered to be related to study  treatm ent 
and are serious (SAEs) or graded as severe.
The invest igator and the Lilly sponsor team are responsible for determining if safet y is 
acceptable to continue dosing. 
Adverse Event -related Information
This table describes the location of AE -related info rmation in this protocol.
Topic Location
DAIDS table describing severity of reactions Section 6.1.1.2
Definitio n of AE s Section 10.3.1
Assessment of Intensity/Severity Section 10.3.3
6.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate storage conditions have been maintained 
during transit for all study  intervent ion received a nd any  discrepancies are reported and resolved 
before use of the study  interventi on.
To protect blinding, where applicable, the interventions must be prepared by  unblinded si te 
personnel qualified to prepare study  intervent ionwho arenot invo lved in any o ther study -related 
procedures.   Instructi ons for preparation will be provided by  the sponsor.
Only participants enro lled in the study  may receive study  intervent ion and only authorized site 
staff may supply or administer study  intervent ion. 
All study  intervent ion must be stored in a secure, environmentally controlled, and monitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access limited 
to the invest igator and authorized site staff.
The invest igator or designee is responsible for study intervent ion accountabilit y, reconciliat ion, 
and record maintenance (i .e., recei pt, reconciliation, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons are 
provi ded i n the pharmacy manual .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
606.3. Measures to Minimize Bias: Randomization and Blinding
Randomization
All participants will be centrally rando mized to study  intervent ion using an Interactive Web 
Response Sy stem  (IWRS). Before the study is init iated, the l og in informat ion anddirections f or 
the IWRS will be provided to each site.
Participantswill be stratified by durat ion since symptom onset to randomization (≤8days v ersus 
>8 days)and age at the time of screening (<18 years of age versus ≥18 years of age).   
All eligible partici pants will be randomized, init ially following an equal all ocati on to treatm ent 
arms.  Given the staggered start of the treatment arms, periodic adjust ments to the allocat ion 
ratio, informed by planned interim analyses, may be m ade in an effort to achieve an equal 
allocat ion across the treatment arms at the end of enro llment. If addit ional placebo participants 
are enrolled, then the allo cation rati o may change accordingly .  See Secti on 9.5for details.
Blinding
For the blinded treatment arms, neither parti cipants, nor i nvest igators, nor the sponsor study team 
will be aware of treatment assi gnments pri or to the final data base locks at the conclusion o f the 
study .  
This table describes general procedures for unblinding.
Unblinding (IWRS) Emergency unblinding for adverse events may be performed through the 
IWRS.  All actions resulting in an u nblinding event are recorded and 
reported by the IWRS
In case of an emergency, the investigator has the sole responsibility for 
determining if unblinding of a participants’ intervention assignment 
iswarranted
Participant safety must always be the first co nsideratio n in making such a 
determination. However, the investigator should make all attempts to 
contact the Medical Monitor in advance of unblinding
If a participant’s intervention
assignment is unblinded, the sponsor must be 
notified immediately after breaking the blind even if consultation occurred 
in advance
The date and reason that the blind was broken must be recorded in the 
source documentation .
Abbreviations:  IWRS =interactive web -response sy stem.
If an invest igator , site personnel performing assessments, or participant is unblinded while the 
infusio n is ongoing, the participant must be discontinued fro m the study  intervent ion and the 
infusio n stopped.  If any amount of study  interventio n was administered, fo llow pro cedures 
according to the SoA.
6.4. Study Intervention Compliance
Participants will receive study  intervent ion directly fro m the invest igator or designee, under 
medical supervisio n.  The date and time of dosing will be recorded in the source documents and 
recorded in the CRF.  The dose of study intervent ion and study  parti cipant i dentificat ion will be 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
61confirmed at the time of dosing by a member of the study  site staff other than the person 
administering the study  interventi on.  
6.5. Concomitant Therapy
Prior Treatm ent 
Any pri or therapy , such as antivirals, antibiot ics, vaccines, or anti -malarials used as treatment 
prior to si gning informed consent should be recorded.
Therapy  prior to enrol lment with ant ivirals including lopinavir/ritonavir , rem desivir, or other 
therapeuti c agents (e.g. corticosteroids) are permitted. 
Convalescent COVID -19 pl asma treatm ent is not allowed prior to enrollment.
For adol escent parti cipants, record any  non- SARS-CoV -2 vaccines received 90 days prior to 
signing informed consent.
Concomitan t Therapy
Parti cipants shoul d be treated according to standard of care, even as it evo lves, and medicat ions 
may be part of the treatment paradigm. Therefore, remdesivir may be init iated as standard of 
care for participants hospitalized with severe disease (if available through the FDA Emergency 
Use Authorizat ions) outsi de of l ocal standard of care per written policies or guidelines.
If the local standard of care per wr itten policies or guidelines (that is, not just an individual 
clinician decisio n) includes lopinavir/ritonavir, chloroquine, hydroxychloroquine or other 
investigat ional agents, then init iating these during the study is permitted, but may require 
additional safet y monitoring by  the si te.
Convalescent COVID -19 pl asma treatm ent is not allowed. 
Any medicat ion, invest igational agent, or vaccine, including over the counter or prescript ion 
medicines, vitamins, and/or herbal supplements , or other specific categori es of interest thatthe 
participant is receiving at the time of enro llment or receives during the study  must be recorded 
along wi th
Reason for use
Dates of administration including start and end dates , and
Dosage information including dose and frequency for concomitant therapy  of special  
interest .
Acetaminophen and corticosteroid use are permitted at any t ime during the study .  
Other concomitant medicat ion may be considered on a case -by-case basis by the invest igator in 
consultation wit h the sponsor if requi red.
The sponsor should be contacted if there are any questions regarding conco mitant or pri or 
therapy .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
626.6. Dose Modification
This protocol allo ws so me alteration fro m the current ly outlined dosing schedule, but the 
maximum dose of LY3819253 will not exce ed7000 mg or the maximum tolerated dose from 
PYAA .  
6.7. Intervention after the End of the Study
No continued access is planned after completion of this study ,as addit ional efficacy would be 
needed to demonstrate continued access criteria.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
637. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Discontinuati on of  specific sites or of the trial as a who le are handled as part of regulatory, 
ethical, and trial oversight considerat ions in Section10.1.9 .,Appendix 1 .
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a participant to perm anent ly discont inue (definit ive 
discontinuat ion) study  intervent ion. If the IV infusio nis definit ively discontinued, the 
participant willremain in the study  forthe rem ainder of the assessment visits through Day  29 
and also for the post -treatm ent follow-up visit s on Days 60 and 85 as described in the SoA.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study  
at any  time at his/her own request 
at the request of his/her designee (for example, parents or legal guardian)
at the discretion of the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons , or
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
If the participant, for any  reason, requi res treatm ent wi th another therapeuti c agent that has been 
demonstrated to be effect ive for treatm ent of the study  indicati on, discont inuat ion from the study  
occurs pri or to introducti on of  the new agent.
Discontinuati on is expected to be unco mmo n.
At the time of discont inuation, if possible, an early discont inuat ion visit should be conducted as 
described in the SoA.  The participant should also return for the post -treatm ent follow-up visit s.  
If the participant discont inues on the same day as a normally scheduled visit, only one set of 
laboratory  tests, sam ple collect ion and assessments arecollected.
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent .  If a participant
withdraws fro m the study , theymay request destruction of any  samples taken and not tested ,and 
the invest igator must document this in the site study records .
7.2.1. Discontinuation o f Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  intervent ionunless 
there are extenuating circumstances that make it medically necessary for the participant to 
continue study  intervent ion.  
If the invest igator and the sponsor CRP agree it is medically appropriate to continue, the 
investigator must obtain documente d approval from the sponsor CRP to allow the inadvertently 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
64enrolled participant to continue in the study with or without treatment with investigational 
product. 
Safety follow up i s as outlined in 
Secti on 1.3(Schedule of Act ivities) 
Secti on 8.2(Safet y Assessments), and 
Secti on 8.3(Adverse Events and Serious Adverse Events).
7.3. Lost to Follow up
A participant will be considered lost to follow -up if theyrepeatedly  fail to return for scheduled 
visits and is unable to be con tacted by  the study  site.Site personnel are expected to make 
diligent attempts to contact participants who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
Site personnel, or an independent third party , will  attem pt to collect the vital status of the 
participant wi thin legal  and ethical boundaries for all participants that received study  
intervent ion.Public sources may be searched for vita l status inform ation.If vital status is 
determined to be deceased , this will be docum ented and the participant will not be considered 
lost to foll ow-up. Sponsor personnel will not be invo lved in any attempts to collect vital status 
inform ation.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
658. Study As sessments and Procedures
Study  procedures and their timing are summarized in the SoA.
Protocol waiver s or exem ptions are not allowed.
Monitoring of blinded safet y data will continue throughout the study and will be conducted by  
blinded study  team members.  Details of the blinded safet y reviews, including the frequency  and 
approximate timing, are specified in the trial level  safety review pl an.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant should cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participant s screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
8.1. Efficacy Assessments
Hospitalization events (Secti on 8.2.4 ), procedures of special interest (Section 8.2.5 ),vital signs 
(Secti on 8.2.2 )and symptomo logy (Secti on 8.1.1 ) will be used to characterize the effect of 
LY3819253 and LY3819253 in co mbinat ion with LY3832479 compared to pl acebo on clinical 
status .
8.1.1. Symptoms and Overall Clinical Status Participant Questionnaire
Participants willrate the ir overall clinical status and severit y of sym ptom s associ ated wi th 
COVID -19by a daily questionnaire .  This quest ionnaire is for outpatients only .
Participants will com plete three questions about their overall clinical status daily, including 
severit y of symptom s 
general physical healt h, and 
chang e in overall healt h.
The quest ionnaire contains these s ymptom s
cough 
shortness of breath 
feeling feverish 
fatigue 
body  aches and pain 
sore throat 
chills 
headache
loss of appet ite, and
changes in taste and smell .  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
66Each symptom  will be scored daily by the participant as experienced during the past 24 hours .
Rating Score
None or absent 0
Mild 1
Moderate 2
Severe 3
Parti cipants will rate changes in taste and smell with a y es/no response.
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
8.2.1. Physical Examinations
A complete physical examinat ionwill be performed at the screening visit. This examinat ion 
excludes pelvic, rectal, and breast examinat ionsunless clinically indicated.
A symptom -directed physical  examinat ion will be performed at other visits, as specified in the 
SoA and as clinically indicated.
Invest igators should pay special attention to clinical signs related to COVID -19, to ongoing 
medical condit ions and to previous serious illnesses.
8.2.2. Vital Signs
Vital signs will  be measured as specified in the SoA and as clinically indicated.  Vital signs 
include
Body  temperature
Blood pressure
Pulse rate
Respiration rate
Saturati on of  peripheral  oxygen, and
Suppl emental  oxygen fl ow rate , FiO2 if known, and method of delivery, if applicable.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
67Treatments 1 -4 and 6
This table outlines Day 1 vital signs data collect ion on the CRF in relat ion to the infusio nfor 
treatm ent arm s 1-4 and 6.   Infusio ntimesmay vary depending on the parti cipant .
Timepoint (minutes) Collect data on CRF
Immediately before infusion Yes
During Infusion , as possible --
   15 No
   30 Yes
   45 No
   60 Yes
After Infusion –every 30 minutes for 2 hours after the end of the infusion --
   90 Yes
   120 No
   150 No
   180 No
Treatment arms 7-9, 13 -14, 18
This table outlines Day 1 vital signs data collect ion on the CRF in relat ion to the infusio nfor 
treatm ent arm s 7-9, 13 -14, and 18 .  Infusio n times may vary  depending on the participant. 
Timepoint (minutes) Collect data on CRF
Immediately before infusion Yes
If infusion is <15 minutes ,immediately following completion of infusion Yes
During Infusion s >15 minutes , as possible --
   15 No
   30 Yes
   45 No
   60 Yes
After Infusion –every 30 minutes for 1 hour after the end of the infusion --
   end of infusion +30 minutes Yes
   end of infusion +60 minutes No
Addit ional vital signs may be m easured during the study  if warranted, as determined by the 
investigator.
Treatment arm 19
Vital signs data collect ion on the CRF will occur immediately before the subcutaneous inject ion, 
and at 30 minutes after the inject ion.
8.2.3. Clinical Laboratory Assessments
See Secti on 10.2,Appendix 2 for the list of clinical laboratory tests to be performed and the SoA 
for the timing and frequency .  All protocol -requi red laboratory  assessments, as defined in 
Appendix 2, must be conducted in accordance wit h the l aboratory  manual and the SoA.
Clinically significant abnormal laboratory  findings are those which are not associated with the 
underlying disea se, unless judged by the invest igator to be more severe than expected for the 
participant's condit ion.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
68All laboratory  tests wi th values considered clinically  significantly abnorm al during parti cipat ion 
in the study  or wi thin 28 days after the dose of study intervent ion shoul d be repeated until the 
values return to normal or baseline or are no longer considered clinically significant by the 
investigator or sponsor .
If such values do not return to normal/baseline wit hin a peri od of  time judged reasonable by  the 
investigator, the etiology  shoul d be i dentified and the sponsor notified.
The invest igator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study  in the AE section of the CRF. 
The laboratory  reports m ust be filed wit h the source documents. 
All protocol -requi red laboratory  assessments, as defined in Appendix 2, must be conducted in 
accordance with the laboratory  manual and the SoA.
If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are considered 
clinically significant by  the investi gator (e .g., SAE or AE or dose modificat ion), report in the AE 
section of the CRF.
Pregn ancy Testing
Women of childbearing potential (WOCBP) m ust undergo p regnancy testing according to the 
SoA.  
8.2.4. Hospitalization events
If a participant is admitted to the hospital ,the parti cipant will remain in the study  and f ollow the 
procedures outlined in the SoA.  Hospitalizat ion is defined as ≥24 hours of acute care.
The date of hospitalization events will be recorded in the CRF and include s
hospitalization
emergency room  visit 
ICU admitt ance
Extended care facilit y admi ttance, and 
Discharge .
8.2.5. Procedures of Special Interest
The parti cipants’ clinical status and concurrent procedures of special interest will be recorded in 
the CRF and include consci ousness status using the alert, consci ousness, verbal, pain, 
unresponsive scale (ACVPU), limitat ion on activi ties due to COVID -19using the patient global 
assessment for daily activities o f physical f unc tion, and requirements for 
ongoing hospital medical care
supplemental  oxygen
non-invasive vent ilation or a high flow oxygen device
mechanical  ventilation
ECMO, or
additional organ support ( e.g. pressors, renal replacement) .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
698.2.6. Respiratory Support
Once enro lled in the study , parti cipants m ay be managed wit h high -flow nasal  cannula, 
noninvasive posit ive pressure vent ilation or any  other form  respi ratory  support as nee ded per 
investigator discret ion. 
8.3. Adverse Events and Serious Adverse Events
AEswill be reported by  the parti cipant , or, when appropriate, by  a caregiver, surrogate, or the 
participant's legally  authori zed representative.
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the parti cipant to di scont inue the study  intervent ionor study .
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All AEs and SAEs will be collected from the time of signing of  the informed consent form (ICF)
until participation in study  has ended .
Adverse events that begin before the start of study  intervent ion but after signing of the ICF will 
berecorded on the Adverse Event CRF.
Although all AEs after signing the ICF are recorded by the site in the CRF/electronic data entry, 
SAE report ing to sponsor begins after the pa rticipan t has signed the ICF and has received study  
intervent ion.  Ho wever, if an SAE occurs after signing the ICF, but prior to receiving study  
intervent ion, it needs to be reported within the SAE reporting t imeframe if it is considered 
reasonably  possibly  related to study  procedures .
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Secti on 10.3,Appendix 3. The 
investigator will submit any updated SAE data to the sponsor within 24 hours of i t being 
available.   
Invest igators are not obligated to actively seek AE sor SAE safter concl usion of the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the event to be reasonably 
related to the study  intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Section10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the participant is the preferred method to inquire about AE
occurrences .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
708.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/conta cts. All SAEs will be followed until reso lution, stabilizat ion, the event 
is otherwi se explained, or the participant is lost to fo llow-up (as defined in Sect ion7.3). Further 
inform ation on fo llow-up procedures is provi dedin Secti on10.3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the sa fety of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB)/Independent Ethics Committees 
(IEC) , and invest igators.
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informa tion (e.g., summary or list ing of SAEs) from the sponsor will review and then file 
it with the IB and will notify the IRB/IEC, if appropriate according to local requi rements.
8.3.5. Pregnancy
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Section 10.4, Appendix 4.
Abnorm al pregnancy outcom es, for example , spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, and ectopi c pregnancy ,are considered SAEs.
8.3.6. Hypersensitivity Reactions
If a hypersensit ivity reacti on occurs, a dditional details describing each symptom should be 
provi de
d to the sponsor in the infusio n-related reaction/hypersensit ivity CRF . 
If symptoms and/or signs occur during or within 6 hours after infusio n and are believed to be 
hypersensit ivity or due to cy tokine release, then investigators are encouraged to report th e event 
as infusio n-related immediate hypersensit ivity reacti onor cy tokine rel ease-associ ated infusio n 
reacti on, respectively.
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are re ceiving intervent ion. It is recommended that participants
who experience a systemic hypersensit ivityreact ion be treated per the local standard of care .  
In the case of generalized urticaria or anaphylaxis, addit ional blood and urine samples should be 
collected as described in Section 10.6, Appendix 6, “ Reco mmended Laboratory  Testing for 
Hypersensi tivity Events”. Laboratory results are provided to the sponsor via the central 
laboratory . 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
71In case of skin lesio ns or rash consistent with vasculit is, efforts should be made to perform the 
following as soon as possible
derm atology consul tation
skin biopsy, and
photographs of lesio ns of interest, including skin biopsy site.
8.3.7. Infusion -related Reactions
As wi th other mAbs, infusio n-related reactions may  occur during or following IV administration . 
If an infusio n-related reacti on occurs, addi tional data describing e ach symptom  and sign should 
be provided to the sponsor in the CRF.  
This table describes the location of infusio n-related reacti on inform ation in this protocol.
Topic Location
Special treatment considerationsSection 6.1.1
Premedication for infusions Section 6.1.1.1
Management of infusion reactions Section 6.1.1.2
DAIDS table describing severity Section 6.1.1.2
Treatment guidelines for infusion -related reactions Section 6.1.1.2
Symptom s occurring during or after infusio n of study  intervent ionmay also be defined according 
toAE categories such as acute allergic reaction or cy tokine release syndrome ( refer to DAIDS ).
8.3.8. Injection Site Reactions
For subcutaneous inject ions, m anifestati ons of  a local ISR m ay include ery thema, indurat ion, 
pain, pruritus, and edema. If an ISR is reported by a participant or site staff, the ISR CRF will be 
used to capture addit ional informat ion about this r eaction,for example, inject ion-site pain, 
degree and area of ery thema, indurat ion, prurit is and edema.
8.3.9. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the identit y, qualit y, dur abilit y, reliabilit y, safety, effect iveness or performance o f a 
trial intervent ion.
Sponsor collects product complaints on study  intervent ionand drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor qu ality, and to 
facilitate process and product improvements.
Parti cipants will be instructed to contact the invest igator as soon as possible if theyhavea 
complaint or probl em wi th theintervent ionso that the si tuation can be assessed.
NOTE: AE s/SAE sthat are associated with a product complaint will also fo llow the processes 
outlined in Sect ion 8.3.3 and Appendix 10.3 of the protocol .
Time Period for Detecting Product Complaints
Product complaints that resul t in an adverse event will be detected, documented, and reported to 
the sponsor during all periods of the study in w hich the intervent ionis used.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
72If the inv estigator l earns of any product com plaint at any  time after a participant has been 
discharged from  the study , and such incident is considered reasonably related to a nintervent ion
provi ded for the study , the invest igator will pro mptly notify  the sponsor.
Prompt Reporting of Product Complaints to Sponsor
Product complaints will be reported to the sponsor within 24 hours after the invest igator beco mes 
aware of the complaint .
The Product Com plaint Form  will be sent to the sponsor by  a method desi gnated by  the sponsor.
Follow -up of Product Complaints
Follow-up applies to all participants, including those who discont inue study  intervent ion.
The invest igator is responsible for ensurin g that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the product complaint .
New or updated informat ion will be recorded on the originally co mpleted form wit h all changes 
signed and dated by the invest igator and submitted to the sponsor .
8.4. Treatment of Overdose
There i s no known ant idote for an overdose of LY3819253 or LY3819253 in combinat ion with 
LY3832479 . 
In the event of an overdose, the invest igator should
1.Contact the sponsor immediately.
2.Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities 
3.Provi de supportive care as necessary , and
4.Docum ent the quanti ty of the excess dose in the CRF.
Decisio ns regarding infusio ninterruptions or modificat ions will be made by the inve stigator ,in 
consultation wit hthe sponsor ,based on the clinical evaluat ion of the participant.
8.5. Pharmacokinetics
Venous blood samples will  be collected as specified in the SoA for determination of 
concentrations of LY3819253 and LY3832479 used to evaluate the PK for LY3819253 and 
LY3832479 .  
A maximum of 3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agreed upon between the invest igator and the sponsor.
Instructi ons for the collect ion and handling of biologi cal samples will be provided by Lilly . 
Site personnel will record
The date and time (24-hour clock time) of administrati on (start and end of infusio n), and
The date and time (24 -hour clock time) of each PK sample.
It is essent ial that the times are recorded accurately.   
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
738.5.1. Bioanalytical
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor.  Concentrations of LY3819253 and LY38324 79 will be assayed using 
a validated bioanaly tical method.   Analyses of samples collected from placebo -treated 
participants are not pl anned.
Sample retenti on is described in Appendix 1, Section 10.1.12.   Remaining samples used for PK 
may be used for exploratory  analyses as deemed appropriate.
8.6. Pharmacodynamics
The SARS -CoV -2 viral RNA level  and viral  clearance will be evaluated by nasopharyngeal 
swabs . See Section 10.2 Clinical Laboratory  Tests, and Secti on 1.3, the SoA for sample 
collect ion informat ion.  
Sample retenti on is described in Appendix 1, Section 10.1.12.   Remaining samples may be used 
for addi tional expl oratory  studies to better understand LY3819253 , LY3832479 and the di sease , 
which may  include sequencing and/or cul ture of the virus for future studies .
8.7. Genetics
A who le blood sample will be co llected in ad ult parti cipants for pharm acogenet ic analysis where 
local regulati ons all ow.  
See Secti on10.2,Clinical Laboratory Tests, and Section 1.3, the SoA for sample co llection 
inform ation.  
SeeSecti on10.5 for genetic research ,custody , and sam pleretenti on informat ion.
8.8. Biomarkers
Blood sam ples will be collected from all part icipants for analysis o f immune system -related 
markers. Serum, who le blood for cellular and/or epigenet ic analysis, and whole blood RNA 
samples for exploratory  biomarker research will be collected at the time specified in the SoA 
where local regulat ions allow.  
Samples will  be stored and analysis may  be performed on bio mark ersthought to pl ay a rol e in 
immune system related responses to viral infect ionincluding, but not limited to , immune 
pathways , cellular compos ition, serum  analy tes, or epi genet ic bio markers ,to eval uate thei r 
associ ation with observed clinical responses to LY3819253 , LY3832479 and the disease state .  
Samples may  be used for research to develop methods, assays, prognostics and/or companio n 
diagnosti cs rel ated to the intervention target (S protein), the COVID -19 di sease state, pathways 
associ ated wi th disease, and/or the mechanism of action of the study  intervent ion.
Sample retenti onis described in Section10.1.12 .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
748.9. Immunogenicity Assessments
Visits and times
At the visit s and t imes specified in the SoA, venous bl ood sam ples will  be collected to determine 
antibody  producti on against LY3819253 or LY3832479 .  The actual date and time (24 -hour 
clock time) of each sample collect ion will be recorded.
Sample collection, handling, and use
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.
Immunogenicit y may be assessed by a validated assay  designed to detect ADAs in the presence 
of LY3819253 or LY3832479 at a laboratory  approved by  the sponsor.  Antibodies may be 
further characterized for their abilit y to neutralize the act ivity of LY3819253 or LY3832479 .
Samples used for immunogenicit y may be used for exploratory  analyses as deemed appropriate.
Sample retention
Sample retenti onis described in Appendix 1, Section 10.1.12.
8.10. Health Economic s
This sect ion is not applicable for this study.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
759. Statistical Considerations
9.1. Statistical Hypotheses
For treatm ent arm  7, the hypoth esis is whether there is a difference in the proportion of 
participants who experience a COVID -related hospi talizat ion or death from any cause compared 
toconcurrently enrolled placebo data fro m treatm ent arm  8.
For treatm ent arm  9, the hypothesis is whether there is a differenc e in the proporti on of  
participants who experience a COVID -related hospi talizat ion or death from any cause compared 
to all placebo data from treatment arm 8.   
For treatm ent arm  14, the hypothes is iswhether there is a difference in the proporti on of  
participants wi th persistent ly high SARS -CoV
-2 viral  loadat Day  7 compared to treatment arm 
13.
For treatm ent arm  19, the hypothesis is non
-inferiorityin the proportion of participants with 
persistently high SARS -CoV -2 viral load at Day 7 com pared to treatm ent arm  18. 
9.2. Sample Size Determination
Sample Size
Treatment arms 1 -4 and 6
The initial planned sample size is approximately 500participants allocated across five treatm ent
arms(treatm ent arms 1 -
4and 6) .Additional placebo parti cipants m ay be enrolled to ensure up to 
50 concurrent placebo controls for treatm ent arm6.  
Up to 100 additional participants may be introduced foroptional treatment arm 5.See Section 9.5
for interim analysis details.
Treatment arms 7 -9
Parti cipants in treatm ent arm s 7-9 are adul ts and adol escents wi th at least 1 ri sk factor for 
developing severe COVID -19 illness. There i s no set sample size for the adolescent participants.
The pl anned sam ple size for the primary  com parison of treatment arm s 7and 8 isapproximately  
1000 participants equally randomized toplacebo orthe combinat ion of LY3819253 and
LY38 32479.   
The pl anned sam ple size for treatm ent arm  9 is approximately  500 participants. Since treatment 
arm 9 begins enrollment after treatment arm 7, addit ional part icipants will be enro lled in 
treatm ent arm  8 to ensure at l east a 33% increase in placebo participa nts and adequate placebo 
control  for the primary  com parison of treatm ent arms 8 and 9 .
Treatment arm s
13 and 14
Parti cipants in treatm ent arm s 13 and 14 are adults and adolescents with at least 1 risk factor for 
developing severe COVID -19 illness. There is no set sample size for the adolescent participants
or those with prior SARS -CoV -2 vaccine use.
The pl anned sam ple size for treatm ent arms 13and 14is approximately 400 participants 
rando mized 2:3, 
placebo :combinat ion of LY3819253 and LY3832479.  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
76Treatme nt arm 18
The pl anned sam ple size for treatm ent arm  18 is approximately  460 parti cipants. 
Treatment arm 19
The pl anned sam ple size for treatm ent arm  19 is approximately  460 parti cipants. 
Stratification
Participantswill be stratified by
durati on since symptom  onset category (≤8days versu s >8days)
ageat the time of screening (<18 y earsof age versus ≥18 yearsof age),and
and whether a participant received a SARS-CoV -2 vaccine or not prior to screening .
Treatment arms 1- 4 and 6
Simulations
A viral dynamic model was used to simulate viral loads over time for participants treated wi th 
LY3819253 and placebo . This simulated population andMonte Carlo m ethods were used to 
estimate statist ical power associ ated wi th the comparison of change fro m baseline to day o f 
interest in SARS -CoV-2 viral loadbetween LY3819253 and placebo .  
The m ean l og change from  baseline to Day  11 (± 4 day s) for LY3819253 and placebo in the 
simulated populat ion were approximately -4.38 and -3.48 (standard deviat ion 1.9), re spectively, 
represent ing an average of 87% viral load reduction. 
Given these assumpt ions, an assumed sample size of 100 participants per treatment arm provides 
approximately  91% power to test superiorit y of an investigat ional intervention vs placebo in 
effect on viral load, as measured by change fro m baseline to Day  11 (± 4 days), at the two -sided 
0.05 al pha level .
Periodic adj ustments to the allo cation rati o of partici pants will  be inform ed by  planned interim  
analyses. See Section 9.5for details.
Treatment arms 7-9
Sample size just ification is based on the endpoint of proporti on of  participa nts experiencing 
COVID -related hospi talizat ion or death from any cause . Asample size of approximately  500 
adult participants per treatment arm provides greater than 90% power to demonstrate that 
LY3819253 in combination wit h LY38 32479 is statistically significant lybetter than placebo, 
defined as odds ratio <1 in the proporti on of  parti cipants experiencing a COVID -related 
hospi talizati on or death from any cause . This sample size calculat ion assumes a placebo event 
rate of 8.7%and a relative reduct ion of 60% for LY3819253 in co mbinat ion with LY3832479, 
which were informed from available data o n hospitalizat ion or death events .
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 W -M C -P Y A B ( m )
7 7 Tre at me nt ar ms 1 3 - 1 4 
S a m ple size j ust ificati o n f or t hese ar ms is base d o n t he e n d p o i nt  of  pr o p orti o n of  p arti ci pa nts 
wi t h  persiste nt l y hi g h S A R S -C o V -2 vi r al  l oa d at Da y  7. A sa m ple size of a p pr o xi matel y 4 0 0 
parti ci pa nts pr o vi des greater t ha n 9 0 % p o wer t o de m o nstrate t hat L Y 3 8 1 9 2 5 3 i n c o m bi nat i o n 
wi t h  L Y 3 8 3 2 4 7 9 is stati st icall y si g nifica ntl y better t ha n place b o . T hi s s a m ple size calc ulat i o n 
ass u me d a place b o e ve nt rate of 3 0 % a n d a r el at i ve re d ucti o n of  6 0 % f or L Y 3 8 1 9 2 5 3 i n 
c o m bi nat i o n wi t h  L Y 3 8 3 2 4 7 9, w hic h were i nf or me d fr o m a vaila ble data o n rates of persiste nt l y 
hi g h S A R S -C o V -2 vi r al  l oa d. 
Tre at me nt ar ms 1 8- 1 9 
T he pri mar y  o bject i ve f o r t hese treat m e nt ar m sis t o de m o nstrate n o n -i nferi orit y( NI) of  
treat m e nt a r m  1 9c o m pare d t o t h e acti ve c o m parat or treat me nt a r m  1 8 . 
A n NI b o u n dar y  of  1. 9 6 will be use d, w hic h is s maller t ha n t h e i n verse of t he 9 7. 5t h perce nt ile of 
t h e p osteri or di stri b uti o n of  t he o d ds rati o ( O R) f or treat m e nt a r m  1 9t o treat m e nt a r m  1 8f o r t he 
D a y  7 persiste nt l y hi g h viral l oa d e n d p o i nt . T he p osteri or distri b ut i o n of t he O R was deri ve d 
usi n g a Ba yesia n hierarc hical meta -a nal ysis of  P Y A B data . 
T he NI mar gi n of 1. 9 6 e ns ures preser vat i o n of at least 5 0 % of treat m e nt a r m  1 9 efficac y ,
esti mate d usi n g t he o bser ve d o d ds rati o . A d di ti o nal  details re gar di n g t he j ust ificat i o n of t he NI 
b o u n dar y  of  1. 9 6 will be pr o vi de d i n t he statist ical a nal y si s pla n ( S A P). 
T he ra n d o mizat i o nof  a p pr o xi matel y 9 2 0 parti ci pa nts acr oss treat me nt ar ms 1 8 a n d 1 9 pr o vi des 
8 5 % p o wer t o esta blis h NI of tr e at m e nt a r m  1 9 c o m pare d t o treat m e nt a r m  1 8 . If D a y  7 
persiste ntl y hi g h viral l o a d stat us has a n o d ds rati o of 1 f o r t h e c o m paris o n of ar m 1 9, t he u p per 
b o u n d of t he 9 5 % CI of t he O R is ≤1. 9 6. 
9. 3. P o p ul ati o ns f or A n al yses 
This ta ble defi nes t he p o p ulati o ns f or a nal ysis. 
P o p ul ati o n Descri pti o n 
E ntere d All partici pa nts w h o si g n t he i nf or me d c o nse nt f or m 
Efficac y All ra n d o mize d partici pa nts w h o recei ve d st u d y i nter ve nti o n a n d pr o vi de d at 
least o ne p ost -baseli ne meas ure f or t he rele va nt e n d p oi nt. Partici pa nts will be 
a nal y ze d acc or di n g t o t he i nter ve nti o n t o w hic h t he y were ra n d o mize d. 
(I nte nti o n t o treat) .  
Safet y All partici pa nts ra n d o ml y assi g ne d a n d w h o recei ve d st u d y i nter ve nti o n. 
Partici pa nts will be a nal yze d acc or di n g t o t he i nter ve nti o n t he y act uall y 
recei ve d .  
P har mac o ki netic All ra n d o mize d partici pa nts w h o recei ve d st u d y i nter ve nti o n a n d ha ve 
e va l ua ble P K sa m ple. Partici pa nts will be a nal yze d acc or di n g t o t he 
i nter ve nti o n t he y recei ve d .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
789.4. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y ofthe sponsor or its desi gnee .
Unless otherwise specified, treatment effects using frequent ist approaches will be conducted 
using 2-sided tests at an alpha level of 0.05. When Bayesian methods areused for analyses ,and
posteri or mean, posteri or standard deviat ion, credible interval s
, and posteri or probabilit y of the 
effect of interest will be summarized. For the Bayesian analyses, the prior distribut ions and 
success definit ions will be fully described in the sta tistical analysis plan (SAP). No adjust ment 
for multiplicity will be perform ed in this study . Details of the handling o f dropouts or missing 
data will be fully described in the SAP. 
Analyses will be performed separately f ortreatm entarms 
1-4 and 6
7 and concurrent ly enro lled 8
8 and 9, 
13and 1 4, and
18and 19.
Note, for the key secondary  endpoint sof overall clinical status the analysis will u se data from  
multipletreatm ent arms.
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the SAP. Addi tional expl oratory  analyses of the data will be conducted as deemed appropriate.
The SAP will be finaliz ed pri or to the first final database lock (i.e., first unblinding o f the 
sponsor), and it will include a more technical and detailed descript ion of the statist ical analyses 
described in this sect ion. This sect ion is a summary o f the planned statist ical ana lyses of the most 
important endpoints including primary  and secondary  endpoints.
9.4.1. General Considerations
This table describes the general statist ical methods that m ay be used in this study .
Method Analysis 
Descriptive Statistics number of participants, mean, standard deviation, 
median, minimum, and maximum for continuous 
measures, and frequency counts and percentages for 
categorical measures
Kaplan -Meier curves and summary statistics Treatment comparisons oftime-to-event based 
endpoints
Logistic regression analysis Treatment comparisons of binary variables with 
treatment and randomization stratification variables in 
the model .
Nonparametric 
(for example, Mann -Whitney or van Elteren tests)Treatment comparison of ordinal, nominal and non -
normall y distributed continuous variables.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
79Addit ional statistical methodol ogy, sensi tivity analyses account ing for missing data ,and 
adjustm ents f or covariates , if any,will be described in the SAP. 
9.4.2. Primary Endpoints
Treatment Arms 1 -4 and 6
Primary endpo int for treatm ent arm s 1-4 and 6 is the change fro m baseline to Day  11 (± 4 day s) 
in SARS- CoV-2 viral load. Stati stical hypothesis testing for the primary  endpoint will be 
conducted using a mixed model repeated measure (MMRM) analysis method at the two -sided 
0.05 level.
Treatment Arms 7 -9
The primary endpo int is the overall participant clinical status ,measured by the proportion 
(percentage) of participants who experience COVID- 19 rel ated hospi talizat ion(defined as ≥24
hours of acute care) or death from any cause by Day  29.
The primary
 analysis method will bea logistic regressio n with a primary success criterion of  
one-sided alpha level 0.025 .
Treatment Arms 13-14
The primary  endpoint is the difference in the proporti on of  parti cipants wi th persistent ly high 
SARS -CoV -2 viral load at Day  7 between treatm ent arm  14 compared to treatm entarm 13.
The primary  analysis method will be a logist ic regressio n with a primary  success cri terion of  
one
-sided alpha level 0.02 5.
Treatment Arms 18-19
The primary  endpoint is noninferiorit y in the proportion of participants with persistent ly high 
SARS -CoV -
2 viral load at Day  7 between treatm ent arm  19compared to treatm ent arm  18.
The primary  analysis method will be a logistic regressio n with a primary  success cri terion of  the 
upper bound of the 95% CI ≤1.96.
Full details will be provided in the SAP.
9.4.3. S econdary Endpoints
9.4.3.1. Key Secondary Endpoints 
Treatment arms 7-9
Key secondary  endpoints for treatment arms 7 -9 incl ude
Reduction o f SARS -CoV -2 viral load m easured by change from baseline to Day  7 (±2 day s)
The p roporti on of  parti cipants wi th SARS -CoV -2 viral load greater than 5.27 on Day  7 
(+2days)
Proporti on (percentage) of participants who experience these events by  Day 29
oCOVID -19 related hospitalizat ion(defined as ≥ 24 hours of acute care), or
oa COVID -19 related emergency room visit, or 
odeath fro m any cause, and
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
80Time to sustained symptom  resol ution 
osymptoms are scored as absent. 
Treatment arms 13-14 and 18-19
Key secondary  endpoints include
Reduction o f SARS -CoV -2 viral load m easured by change from baseline to Day  7 (
±2 day s), 
and
Proporti on (percentage) of participants who experience COVID -19related hospitalization 
(defined as ≥24 hours of acute care) or death f rom any cause by Day  29
9.4.3.2. Safety
Safety analyses will be conducted using the safet y popul ation described above. 
All invest igational product and protocol procedure AEs will be listed, and if the frequency o f 
events allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of AEs for each treatment will be presented by  severi ty and by associ ation with 
intervent ionas perceived by the investigator. Adverse events reported prior to randomizat ion 
will be dist inguished from those rep orted as new or increased in severit y during the study  post -
rando mizat ion.
Safety param eters that will be assessed include, but are not limited to, safet y laboratory  
param eters, and vital signs. The parameters will be listed and summarized using standard 
descript ive statistics. Addit ional analysis will be performed if warranted upon review of the data.
For treatm ent arm s 13-14, 1 8-19 post-administration observat ionsand AEs will be evaluated.
For treatm ent arm  19, reported injection site react ions will be further characteriz ed. 
9.4.3.3. Additional Secondary Endpoints
Treatment Arms 1 -4 and 6
Addit ional secondary  
endpo ints for treatm ent arms 1 -4 and 6 include
Change from baseline to Day  11 (± 4 days) in SARS -CoV-2 viral lo adamong parti cipants 
enrolled with ≤8days of symptoms prior to randomizat ion
Time to symptom resolut ion 
osymptoms are scored as absent
Proporti on of  parti cipants dem onstrating symptom  improvement via the symptom 
questionnaire on Days 7, 11, 15 and 22
Proporti on of  parti cipants demonstrating symptom  resol ution via the symptom quest ionnaire 
on Day s 7, 11, 15 and 22
Time to symptom improvement
osymptoms scored as moderate or severe at baseline are scored as mild or absent ,AND 
osymptoms scored as mild or absent at baseline are score d as absent.
Change in symptom score (total of ratings) from baseline to Day s 7, 11, 15 and 22 
SARS -CoV -2 viral load and vi ral clearance including: 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
81oProporti on of  parti cipants that achi eve SARS -CoV -2 clearance (Days 7, 11, 15,and 
22)
oTime to SARS -CoV -2 clearance 
oSARS -CoV -2 viral load area under the concentration -time curve (AUC) assessed 
through Day 29
Proporti on (percentage) of participants who experience these events by Days 29, 60 and 85
oCOVID -19 related hospitalizat ion(defined as ≥ 24 hours of acute care)
oa COVID -19 related emergency room visit, or 
odeath.
Treatment Arms 7–9
Addit ional secondary  endpoints for treatment arms 7 -
9include
SARS -CoV -2 viral load reduct ion change from baseline to 
oDay 3 (+ 1 day) 
oDay 5 (± 2 day s)
SARS -CoV -2 viral load area under the response -time curve (AUC) assessed through Day 7
Time to SARS -CoV -2 clearance 
Time to symptom resolut ion 
Time to com plete symptom reso lution
Time to sustained co mplete symptom resolut ion  
Proporti on of  parti cipants demonstrating symptom resolut ion via the symptom quest ionnaire 
on Day s 2-11
Time to symptom improvement
osymptoms scored as moderate or severe at baseline are scored as mild or absent ,AND 
osymptoms scored as mild or absent at baseline are scored as absent , and
Proporti on of  parti cipants dem onstrating symptom  improvement via the symptom 
questionnaire on Days 2-11.
Treatment Arms 13–14, 1 8-19
Treatment arm 14 and treatm ent arm  
19will be compared to all high -risk pl acebo parti cipants in 
pooled treatm ent arm s 8 and 13
, for propo rtion (percentage) of participants who experience these 
events by Day
29
COVID -19 related hospitalizat ion (defined as ≥24 hours of acute care), or
a COVID -19 related emergency room visit, or 
death fro m any cause .
Addit ional secondary  endpoints will co mpar e
Treatment arm 13 to treatment arm 14, and
Treatment arm 19 to treatment arm 18 .  
The endpo ints are
otime to sustained symptom resolut ion
oSARS -CoV -2 viral load reducti on change from baseline to 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
82Day 3 (+ 1 day) 
Day 5 (± 2 day s)
oSARS -CoV -2 viral load area under the response -time curve (AUC) assessed through
Day 7
oTime to SARS -CoV -2 clearance
oTime to symptom resolut ion 
oTime to com plete symptom reso lution
oTime to sustained co mplete symptom resolut ion  
oPropor tion of  parti cipants dem onstrating symptom  resol ution via the symptom 
questionnaire on Days 2-11
oTime to symptom improvement
symptoms scored as moderate or severe at baseline are scored as mild or 
absent ,AND 
symptoms scored as mild or absent at baseline 
are scored as absent , and
oProporti on of  parti cipants dem onstrating symptom  improvement via the symptom 
questionnaire on Days 2-11.
Full details o f the analyses will be in the SAP.
9.4.3.4. Pharmacokinetic Analyses
Pharmacokinet ic analyses will be conducted on data from all participants who receive 
intervent ion and have evaluable PK. LY38 19253 and LY3832479 concentration data will be 
summarized descri ptively by sample collect iontime (e.g., Day  29)
.Addit ional p opulation
analysis approaches using non -linear mixed effects modeling may be used to evaluate exposure -
response of safety and efficacy .
Study  data m ay be pool ed wi th the resul ts of other studies for populat ion PK and PK/PD analysis 
purposes.
9.4.4. Exploratory Analyses
Full details o f the planned e xploratory  analyses will be described in the SAP.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate. Study  
resul ts may be pool ed wi th the resul ts of other studies for safet y, PD, or populat ion PK and 
PK/PD analysis purpose s.
9.4.5. Immunogenicity Analyses
If data fro m validated immunogenicit y assays are available, treatm ent-emergent anti -drug 
antibodies ( TE-ADAs) may be assessed. 
Treatment -emergent ADAs are defined as participants
with a 2-fold (1 dilution) increase in t iter than the minimum required dilut ion if no ADAs 
were detected at baseline (treatment -induced ADA) or 
with a 4-fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatment -boosted ADA).
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
83The frequency and percentage of participants with preexist ing ADA and who are TE -ADA 
positive (TE -ADA+) to LY3819253 or LY3832479 will be tabulated.   
The distribut ion of titers and frequency o f neutralizing ant ibodies (if assessed) for the TE -ADA+ 
participant smay also be tabulated.
The relationship between the presence of ant ibodies and PK parameters ,efficacy response or
safet y to LY3819253 or LY3832479 may also be assessed. Addit ional details may  be provi ded in 
the SAP.
9.4.6. Subgroup Analyses
This study  is not powered for subgroup analyses; therefore, all subgroup analyses will be treated 
as exploratory .
Subgroup analyses will be conducted for the primary  endpo int. Subgroups may  include 
time of symptom onset to studyrando mizat ion
baseline severit y of COVID -19
age 
sex 
race
ethnicit y
baseline wei ght
baseline body  mass index
concomitant medicat ion
high ri sk status for severe COVID -19 illness (treatment arms 1-4, 6), or
SARS -CoV -2 vaccine status (treatment arms 13 -14, 1 8-19).  
Treatment group differences will be evaluated wi thin each category  of the subgroup regardless of 
whether the interaction is statist ically significant. If any group within the subgroup is <10% of 
the total populat ion, only  summaries of the efficacy  data will be provi ded,that is, no inferent ia
l 
testing.
Definit ions for the l evels o f the subgroup variables, the analysis methodology , and any  addi tional 
subgroup analyses will be defined in the SAP. 
9.5. Interim Analyses 
Treatment Arms 1- 4 and 6
The ongoing study  may be m odified based on planned interim analyses . Based on the observed 
data at the time of the interim analyses, the study may 
suspend enrollment to any treatm ent arm  dem onstrating lack of efficacy, and/or
initiate/expand enrollment to an addit ional/exist ingtreatm ent arm  (or arm s).
The m odificat ions proposed are done so to ensure participants are being exposed to treatment 
with an acceptable risk-benefit profile during the ongo ing trial . Additionally, the potenti al 
modificati ons will provi de informat ionto more fully characterize the dose response pro file.  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
84Monitoring of unblinded safet y data (including AEs, SAEs, and selected laboratory
measurements) will occur throughout the study and will be conducted by  Assessment Committee 
(AC)members. Details of the unblinded safet y reviews, including the frequency and 
approximate timing, are specified in the AC charter .
The approximate timing, d ecisio n criteria,and statistical methods associ ated wi th each possible 
modificati on to the ongoing tri al will be f ully described in the SAP and AC Charter and finalized 
prior to the first study  unblinding. 
Periodic adj ustments to the allo cation rati o may be made toachieve an equal allocation across 
treatm ent arm s at the concl usion of enrollment. If additional placebo parti cipants are enrolled , 
thenthe allocat ion rati o maychange accordingly.
Prior to the primary  endpoint , only the ACis authorized to evaluate unblinded interim analyses
and safet y analyses . Study  sites will receive informat ion about interim res ults only  if they need to 
know for the safet y of their parti cipants. 
Treatment Arms 7 -9, 13 - 14 , 18-19
Unblinded assessment sof efficacy  will be done separately for treatment arms 7 and 8 , 8 and 9 , 
13and 1 4, and 18 and 19. 
Treatment Arms 7 and 8
Assessments will begin when all parti cipants for treatm ent arm  7 and concurrent ly enro lled 
treatm ent arm  
8 complete the Day 29 visit.Equal allocat ion to treatm ent arms 7 and 8 is planned.  
Treatment Arms 8 and 9
Assessments will begin w hen all addit ional participants from treatment arm 8 and participants 
from treatment arm  9 com plete the Day  29 visit. Additional parti cipants will be enrolled in 
treatm ent arm  8 to ensure at l east a 33% increase in placebo participants and adequate placebo
control  for the primary  com parison of treatm ent arms 8 and 9 .
Safety Reviews
Safety reviews will occur as specified in the DMC charter.
PK/PD 
A limited number of pre -identified individuals may gain access to unblinded data, as specified in 
the unblinding plan pri or to the primary lock, in order to init iate the popul ation PK/PD m odel 
development processes. Following the database lock, the sponsor will be unblinded to analyze 
and report the data.
Unblinding  
Unblinding details are specified in the unbl inding pl an sect ion of the SAP or in a separate 
unblinding plan document.   
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
859.6. Data Monitoring Committee (DMC)
Treatment Arms 1 -4 and 6
The sponsor will form  an ACto analyze the interim study  data. To minimize any bias introduced 
into the analysis o f the study  resul ts, analysis plans will be finalized and approved prior to the 
interim analys es.
The primary  goal  of the ACis to review the interim results regarding the continuing safet y of 
study  participants and the continuing validit y and scient ific merit o f the study .Inform ation that 
may unblind the study  during the analyses will not be reported to study  sites or the blinded study  
team  until the study  has been unblinded. 
Overall c ommittee structure information is in Sect ion 10.1.5. Details of the AC will be provided 
in the AC charter.
Treatment Arms 7 -
9
An external DMC willanalyze unblinded safet ydata as specified in a D MC charter .  
Inform ation that m ay unblind the study  during the analyses will not be reported to study  sites or 
the blinded study  team  until the study  has been unblinded. 
Overall committee structure information is in Sect ion 10.1.5. Details of the DMC will be 
provi ded in the DMC charter.
Treatment Arms 13 -14, 1 8
-19
An external DMC willanalyze safetydata as specified in a DMC charter .
Overall committee structure information is in Sect ion 10.1.5. Details of the DMC will be 
provi ded in the DMC charter.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
8610. Supporting Documentation and O perational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived fr om international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
Applicable Internat ional Council for Harmonizat ion (ICH) Good Clinical Practice (GCP)
Guidelines , and
Applicable laws and regulations .
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents 
(e.g., adverti sements) m ust be submitted to an IRB/IEC by  the investi gator and revi ewed and 
approved by  the IRB/IE C before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator w ill be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC
Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required by 
IRB/IEC procedures , and
Provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21 CFR, ICH gui delines, the IRB/IEC, European regulat ion 536/2014 for clinical 
studi es(if applicable), and all other applicable local regulat ions
.
Invest igator sites are compensated for participat ion in the study  as detailed in the Clinical Trial 
Agreement (CTA) .
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties.  Invest igators are 
responsible for providi ng informat ion on financial interests during the study  and f or 1 year after 
completion of the study .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
8710.1.3. Informed Consent Process
The investigator or theirrepresentative will explain the nature of the study , incl uding the ri sks 
and benefits, to the parti cipan t or theirlegally authori zed representative and answer all quest ions 
regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Participants or thei r legally 
authori zed representative will be required to sign a statement of informed consent and 
child /adolescent assent, as appropriate, that meets the requirements of 21 CFR 50, local 
regul ations, ICH guidelines, Health Insurance Portabilit y and Accountabilit y Act (HIPAA) 
requi rements, where applicable, and the IRB/IEC or study center.
Due to strict respiratory  isolation policies, limited access to COVID -19 patient rooms, and 
SARS -CoV -2 transmissibilit y via droplet -contaminated paper, verbal consent and alternat ive 
methods of obtaining consent (for example, by phone) will be all owed if  approved by  the IRB. 
If a signed paper copy  of the ICF or child/ado lescent assent is allowed by site/inst itution policy, 
then the process of how it will be obtained and stored will need to be determined.  
Any variation fro m the standard consent p rocess due to iso lation and infect ion control should be 
sent to the IRB for approval prior to enrollment.  The site will docum ent the process in their 
regul atory  files and demonstrate that the process has IRB concurrence or approval.
The m edical  record m ust include a statement that written informed consent or child/ado lescent 
assent was obtained before the participant was enter ed in the study  and the date the written 
consent or assent was obtained. The authorized person ob taining the informed consent or 
child/ado lescent assent, and, if applicable, the individual designated to witness a verbal consent,
must al so sign the ICF.   The m edical record should also describe how the invest igator 
determined that the person signing the ICF was the parti cipant’s legally  authori zed representative 
(parent/guardian).  
Parti cipants m ust be re -consented to the most current version of the ICF(s) during their 
participat ion in the study , per the reconsent ing guidelines as appropriate .Verbal recon senting 
and alternative methods of obtaining consent may be utilized if approved by the IRB .
Minor participants must be re -consented if they reach the age of majorit y during the course of 
study , in order to continue participating.
A copy  of the ICF(s) m ustbe provided to the participant or the participant’s legally authorized 
representative and is kept on file.
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets
or tissue samples that are trans ferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant identifiable will not be transferred.
The parti cipant must be informed that theirpersonal study -related data will  be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of disclosure m ust also be 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
88The parti cipant must be inform ed that theirmedical records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
The sponsor has processes in place to en sure data protection, informat ion securit y and data 
integrity.  These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.5. Committees Structure
The AC will consist of members internal and external to the sponsor .  The membership will 
include, at a minimum, a chair external  to Lilly , a statistician and two phy sicians.  The AC 
members will not have data entry /validat ion responsibilit ies or direct contact wi th the si te(s) or 
testing facil ities.  
The DMC will consist of members external to the sponsor (Lilly) .  The m embership will include, 
at a minimum, a chair (physician) , a stati stician and another physician.  The DMC members will 
not have data entry /validat ion responsibilit ies or direct con tact wi th the si te(s) or testing 
facilit ies.   
10.1.6. Dissemination of Clinical Study Data
A clinical study  report will be provided for this study  and a summary  of study information 
provi ded on publicly  available websi tes. 
10.1.7. Data Quality Assurance
Investigator responsibilities
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronica lly (e.g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or electroni cally 
signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct access to source data documents.
Data monitoring and management
The Monitoring Plan includes
monitoring details describing strategy , for example , risk-based init iatives in operations 
and qualit y such as Risk Management and Mit igation Strategies and Analyt ical Risk -
Based Monitoring 
methods 
responsibilit ies and requi rements 
handling of nonco mpliance issues and 
monitoring techniques.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
89The sponsor or designee is responsible for the data management of this study  including qualit y 
checking o f the data.   The sponsor assumes accountabilit y for acti ons del egated to other 
individuals (e .g., Contract Resear ch Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents.  They  will also ensure that the safet y and rights of  parti cipants are being protected ,
and that the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulatory  requi rements.
If on -site monitoring activit ies cann ot occur, al ternative measures will be used.  Examples of 
alternat ive measures are use of techno logy for off -site monitoring or providing pseudonymized 
copies of  source documents to the monitor electronically.  The remote source data verificat ion 
will be f ocused on cri tical efficacy  data and important safet y data.  
Records retention and audits
Records and documents, including signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for the time period outlined in the CTA unless local regulat ions or 
institutional policies requi re a l onger retenti on period. 
No records may be destroy ed during the retention period without the written approval of the 
sponsor. No records may  be transferred to another locat ion or party  without wr itten notificat ion 
to the sponsor.
The sponsor or its representatives will periodically check a sample of the 
participant data 
recorded against source documents at the study  site.  The study  may be audi ted by  the sponsor or 
its representatives, and by regulatory  agencies at any  time.  Invest igators will be given notice 
before an audit occurs.
Data Capture System
The invest igator i s responsible for ensuring the accuracy , com pleteness, l egibili ty, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a se parate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system.  
Only symptom  assessments might be direct ly recorded by the invest igator site personnel or a 
delegate into the EDC.  The direct ly entered data will se rve as source documentation .  The 
investigator will not maintain an original, separate, written or electronic record of these data.  A 
certified copy  of the respect ive data entry will be downloaded by the invest igator for retention.
The invest igator is res ponsible for the ident ificat ion of any  data to be considered source and for 
the confirmat ion that data reported are accurate and complete by  signing the CRF .
Data collected via the sponsor- provided data capture system swill be stored at third parties .  The
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.  Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
90Data m anaged by  a centr al vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention.  Data will subsequent ly be transferred fro m the central  vendor to the sponsor data 
warehouse.
Data from co mplaint forms submitted to sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate th e 
integrity of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF that are transcribed fro m source documents must be consistent with 
the source documents or the discrepancies must be explained. The invest igator may need to 
request previous medical records or transfer records, depending on the study . Current medical 
records m ust be available.
The definit ion of what constitutes source data can be found in Sect ion10.1.7 .
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered cl osed when a ll required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and enough notice is given in advance of the in tended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the s ponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  the investi gator , or
Discontinuati on of  further study  intervent ion developm ent.
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
Invest igators, the IECs/IRBs, the regulatory authorit ies, and any contract research 
organi zation(s) used in the study  of the reason for terminat ion or suspensio n, as specified by the 
applicable regulatory  requi rements. The Invest igator shall pro mptly inform t he participants and 
assure appropriate participant therapy  and/or fo llow-up.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
9110.1.10. Publication Policy
In accordance with the sponsor’s publication po licy, the results of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are d eemed to be of si gnificant m edical  
importance.
10.1.11. Investigator Information
Physicians with specialt ies, including, but not limit ed to infect ious di sease, acute or critical care, 
pulmo nary disease , immunol ogy, or other appropriate specialt iesmay participate as 
investigators.   
10.1.12. Long -Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of  the 
intervent ion or after  the intervent ion beco mes commercially  available.
This table describes the retention period for potential sample t ypes.
Sample Type CustodianRetention Period After Last Pa rticipa nt 
Visit
Pharmacodynamic Samples Sponsor or designee up to 7years
Pharmacogenetics sample Sponsor or designee up to 7years
Explo ratory  Biomarker Samples Sponsor or designee up to 7years
Immunogenicity (ADA) sample Sponsor or designee up to 7years
Pharmacokinetic (PK) sample Sponsor or designee up to 2 years
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
9210.2. Appendix 2: Clinical Laboratory Tests
Clinical laboratory  tests will  be perf ormed according to the SoA.  
Addit ional tests may be performed at any  time during the study  as determined necessary  by the 
investigator or required by  local regulati ons.
Central  and l ocal laboratori es will be used. The table below describes when the local or central 
laboratory  will be used .
Laboratory  resul ts that coul d unblind the study  will not be reported to invest igative sites or other 
blinded personnel.
Protocol -speci fic requi rements for inclusion or exclusio n of participants are detailed in Sect ion 5
of the protocol.
Pregnancy testing will be performed according to the SoA.
Invest igators must document their review of each laboratory  safety  report.
Refer to Section 10.6 for recommended laboratory  testing for hypersensit ivity events.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
93Clinical Laboratory Tests Comments  
Hematology Assay ed by Lilly -designated laboratory. 
Hemoglobin
Hematocrit
Erythrocy te count (RBCs -Red Blood Cells)
Mean cell volume 
Mean cell hemoglobin
Leukocytes (WBCs -White Blood Cells) 
Differential
   Neutrophils, segmented
   Lymphocy tes
   Monocytes
   Eosinophils
   Basophils
Platelets
Cell Morphology (RBC and WBC)
Clinical Chemistry Assay ed by Lilly -designated laboratory. 
Sodium
Potassium
Chloride
Bicarbonate
Total bilirubin
Direct bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine 
Creatine kinase (CK)
Uric acid
Total protein
Albumin
Calcium
Phospho rus
Glucose
Amylase
Lipase
Lactate dehydrogenase (LDH)
SARS-Co V-2 viral infection determination Local laboratory and/or Point-of-Care testing
SARS-Co V-2 Test Panel Assay ed by Lilly -designated laboratory.
C-reactive protein (CRP); high -sensitivity For adults only
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
94Clinical Laboratory Tests Comments  
Ferritin For adults only
D-dimer For adults only
Procalcitonin For adults only
Troponin For adults only
Hormones (female)
Urine Pregnancy Local laboratory
Serum Pregnancy Local laboratory
Pharmacokinetic Samples  Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
   LY381 9253
   LY3832479
Pharmacodynamic sample Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
   SARS -CoV-2 nasophary ngeal swab
Pharmacogenetics sample For adults only
Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Exploratory Biomarker Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Serum
   RNA (PAXGene)
Whole Blood (EDTA) For adults only
   Whole Blood (EDTA) Epigenetics For adults only
Immunogenicity Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
   Anti-LY3819253 antibodies 
   Anti-LY3832479 antibodies
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
9510.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: An AE can therefore be any unfavorable and uni ntended si gn (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemi stry, or uri nalysis) or 
other safet y assessments (e .g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the 
medical and scient ific judgment of the investigator (i .
e., not r elated to progression of 
underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.
“Lack of efficacy ”or “failure of expected pharmacol ogical act ion”per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae result ing fro m lack of efficacy 
will be reported as AE or SAE if they fulfil lthe definit ion of an AE or SAE.
Events NOT Meeting the AE D efinition
The fo llowing s tudy-specific clinical events related to COVID -19 are exempt fro m 
adverse event reporting unless the invest igator deems the event to be related to the 
administration of study  drug:
oHypoxemia due to COVID -19 requiring supplemental oxygen;
oHypoxemia due to COVID -19 requiring non -invasive vent ilation or hi gh flow 
oxygen devices;
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
96oRespiratory  failure due to COVID -19 requiring invasive mechanical vent ilation 
or ECMO
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying dise ase, unless j udged by  the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected f or the parti cipant’s 
condi tion.
Medical or surgical procedure (e .g., endoscopy , appendectomy): the condit ion that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a h ospital).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condi tions 
are met (e .g., hospitalizat ion for signs/symptoms of the disease under study , death due to 
progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal
for observat ion and/or treatment that would not have been appropriate in the 
physician’s office or ou tpatient setting. Com plicat ions that occur during hospitalization 
are AEs. If a complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, 
the event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE should be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen 
from baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
97This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, 
and accidental trauma (e .g., spra ined ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disrupt ion
.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent o ne of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsio ns that do not result in hospitalizat ion, or development of drug dependency or 
drug abuse .
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (e .g., hospital progress notes, laboratory  reports, and di agnosti cs 
reports) related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to Sponsor or designee in lieu of co mpletion of the AE/SAE CRF page.
There m ay be instances when copies of medical records for certain cases are requested 
by Sponsor or desi gnee . In thi s case, all part icipant identifiers, with the exception o f 
the participant number, will be redacted on the copies of the medical records before 
submissio n to Sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to one of the fo llowing categori es, which together with serious (i.e., 
SAE) criteria on the AE CRF (“results in death” and “life -threatening”), are aligned wit h the 
Divisio n of AIDS (D AIDS )Table fo r Grading the Severit y of Adult and Pediatric Adverse 
Events, version 2.1 (July  2017) .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
98Mild: Mild symptoms causing no or minimal interference with usual social and functional 
activit ies, with intervention not indicated .
Moderate: Moderate symptoms causing greater than minimal interference wit h usual 
social and f uncti onal activities, with intervention indicated .
Severe: Severe symptoms causing inabilit y to perform usual social and functional 
activit ies, with intervention or hospitalization indicated.
An even t is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship cannot be 
ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered a nd invest igated.
The invest igator will also consult the Invest igator’s Brochure (IB) and/or Product 
Inform ation, for marketed products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to Sponsor or designee . However, i t 
is very important that the investiga tor al ways make an assessment of causalit y for 
every event before the init ial transmissio n of the SAE data to Sponsor or designee .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by Sponsor or 
designee to elucidate the nature and/or causalit y of the AE or SAE as fully as possible . 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
99If a participant dies during participation in the study or during a recognized fo llow-up 
period,the inv estigator will provide Sponsor or designee with a copy  of any 
post-mortem findi ngs including histopathology . 
New or updated informat ion will be recorded in the originally co mpleted CRF.
The invest igator will submit any updated SAE data to Sponsor or desig neewithin 24 
hours of receipt of the informat ion.
10.3.4. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collect ion 
tool.
If the electronic system is unavailable, then the site will use the paper SAE data 
collect ion tool  (see next secti on) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken off -line to prevent the entry  of new data or changes to exist ing data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated 
data on a previ ously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this informatio n on a paper SAE form (see next 
section) or to the sponsor by telephone.
Contacts for SAE reporting can be found in site training documents .
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the sponsor .
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in site training documents .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
10010.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Women
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed be fore first dose of study  intervent ion, additional eval uation shoul d be considered.
Woman not of Childbearing Potential (WOCBP)
Women in the fo llowing categori es are not considered WOCBP
1.Prem enarchal
2.Prem enopausal  female wi th either
a.Docum ented hysterectomy
b.Docum ented bilateral  salpingectomy , or
c.Docum ented bilateral  oophorectomy .
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above, 
(e.g., mullerian agenesis, androgen insensit ivity), investigator discret ion shoul d be applied to 
determining study  entry .
Note: D etermina tion can com e from the si te personnel’s review of the participant’s medical 
records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female is defined as, women with:
d.12 m onths of amenorrhea for women >55, with no need for FSH
e.12 m onths of amenorrhea for women >40 y ears old wi th FSH ≥40 m IU/mL and 
no other m edical condit ion such as anorexia nervosa and not tak ing medicat ions 
during the amenorrhea (e.g. oral contraceptives, hormones, gonadotropin 
releasing hormone, ant i
-estrogens, select ive estrogen receptor modulators 
(SERMs), or chemotherapy  that induced amenorrhea)
Participation in the Study
Women of child-be aring potenti al and not of child- bearing potential may participate in this 
study .
Women of child- bearing potenti al who are not pregnant at the time of study  entry , and who are 
completely abstinent or in a same sex relat ionship ,as part of their preferred a nd usual  lifest yle,
must agree to either remain abst inent or stay in a same sex relat ionship without sexual 
relationships wit h males.
All other wom en of child- bearing potential who are not pregnant at the time o f study entry ,must 
agree to use two forms of effect ive contraception, where at least one form is highly effective 
(less than 1% failure rate), for the ent irety of the study . 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
101Abstinence or contraception must continue for 90 days after the l ast dose of intervent ion.
Acceptable Methods of Contraception
Highly effect ive method sof contracepti on (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives
implanted con tracepti ves,or 
intrauterine devices . 
Effect ivemethod sof contraception comprise but are n ot limited to diaphragms wit h spermicide 
or cervi cal sponges .  
Not Acceptable Methods of Contraception
Use of m ale and female condoms as a double barrier method is not considered acceptable due to 
the high failure rate when these barrier methods are combi ned.
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not a n effect ive or 
acceptable method of contracepti on. 
Periodic abst inence (e.g., calendar, ovulat ion, symptothermal, post -ovulation methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
Men
Men, regardl ess of their fertilit y status, m ust agree to ei ther remain abstinent (if this is their 
preferred and usual lifest yle) or use condoms as well as one additional highly effect ive method 
of contracepti on(less than 1% failure rate) or effective method of contraception with non-
pregnant women of child bearing potential partners for the duration of the study and until their 
plasma concentrations are below t he level that could result in a relevant potential exposure to a 
possible fetus, predicted to be 90 days after the l ast dose .
Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of est imated relevant potential exposure to the fetus , predi cted to be 90 days 
after the l ast dose.
Acceptable Methods of Contraception
Highly effect ive method sof contracepti on (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives
implanted con tracepti ves,or 
intrauterine devices . 
Effect ivemethod sof contraception comprise but are not limited to diaphra gms wi th spermicide 
or cervi cal sponges .  
Men and their partners may choose to use a double –barrier m ethod of contraception thatmust 
include use of a spermicide .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
102Other Guidance
Men should refrain fro m sperm  donat ion for the durati on of  the study  and unt il their plasma 
concentrations are below the level that could result  in a relevant potenti al exposure to a possible 
fetus , predi cted to be 90 days after the l ast dose. 
Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only to 
male participants who receive study  intervent ion.
After obtaining the necessary  signed informed consent and assent (if applicable) from the 
pregnant female partner direct ly, the investigator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the partner’ s 
pregnancy. 
The female partner will also be fo llowed to determine the outcome of the pregnancy . 
Inform ation on the status of the mother and child will be forwarded to the sponsor. Generally, 
this informat ion will include a follow-up of at least 5 half -lives after last exposure or birth .  Any 
termination o f the pregnancy  will be reported including fetal status (presence or absence of 
anomalies) andindication for the procedure. 
Female Participants who become pregnant or are pregnant at the time of study entry
The invest igator will co llect pregnancy information on any female participant who becomes 
pregnant while part icipating in this study or is pregnant at the time of study  entry . The init ial 
information will be recorded on the appropriate form an d submitted to the sponsor within 24 
hours of learning of a parti cipant's pregnancy . 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and th e inform ation will be 
forwarded to the sponsor. Generally, this informatio n will include a follow-up of at least 5 half -
lives after last exposure or birth.  Any terminat ion of pregnancy will be reported, including fetal 
status (presence or absence of anomalies) or indication for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <2 0 weeks gestational age) or still birth (occurring at >20
weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any post -study pregnancy related SAE considered reasonably related to the study intervention 
by the inves tigator will be reported to the sponsor as described in Sect ion8.3.4 . While the 
investigator is not obligated to actively seek this informat ion informer study  parti cipants, he or 
she m ay learn of an SAE through spontaneous reporting.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
10310.5. Appendix 5: Genetics
Sample collect ion informat ion is found in Appendix 2, Section 10.2 (Clinical Laboratory Tests).
Use/Analysis of DNA
Genet ic variat ion may impact a participant’s response to study  intervent ion, suscept ibilit y to, and 
severit y and progressi on of  disease. Varia ble response to study  intervent ion may be due to 
genet ic determinants that impact drug absorption, distribut ion, metabo lism, and excretion; 
mechanism o f action of  the drug; di sease et io
logy; and/or m olecular subt ype of the disease being 
treated. Therefore , where local regulations and IRB/IEC allow , a blood sample will be co llected 
for DNA analysis fro m consenting part icipants.
DNA samples m ay be used for research related to SARS -CoV -2and related diseases. They may 
also be used to develop tests/assays including diagnostic tests related to LY3819253 , 
LY3832479 or SARS -CoV -2.  Genetic research may consist of the analysis o f one or m ore 
candidate genes or the analysis of genet ic markers t hroughout the geno me as appropriate.
The samples may  be analyzed as part of a mult i
-study  assessment of genetic factors involved in 
the response to LY3819253 , LY3832479 or study  intervent ions of this class to understand study  
disease or related conditions.
The results of genet ic analyses may be reported in the clinical study  report (CSR) or in a separate 
study  summary .
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
The samples will be reta ined at a facilit y selected by the sponsor or its designee while research 
on SARS -CoV -2 continues but no l onger than 7years or other period as per local requirements. 
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
10410.6. Appendix 6: Recommended Laboratory Testing for Hypersensitivity 
Events.
Laboratory  assessments should be performed if the participant experiences generalized urticaria 
or if anaphylaxis is suspected .
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the 
event; however, samples may be obtained as late as 12hours after the event as analytes 
can remain altered for an extended period of time.  Record the time at which the sample 
was collected.
Obtain a fo llow-up sam ple at the next regularly scheduled visit or after approximately 4 
weeks , whichever is later .
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
105Clinical Lab Tests for Hypersensitivity Events
Hypersensitivity Tests Notes
Selected test may be obtained in the event of anaphylaxis or 
systemic allergic/hypersensitivity reactions.
LY3819253 and LY3832479 
anti-drug antibodies 
(immunogenicity/ADA)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
LY3819253 and LY3832479 
concentrations (PK)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Tryptase Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Urine N- methylhistamine testing is performed in addition to 
tryptase testing. Collect the first void urine following the event. 
Collect a follow -up urine sampleafter approximately 4 weeks .
Note: If a tryptase sample is obtained more than 2 hours after the 
event (that is, within 2 to 12 hours), or is not obtained because more 
than 12 hours have lapsed since the event, collect a urine sample for 
N-methylhistamine testing. 
N-methylhistamine Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Drug -specific IgE Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Basophil activation test Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
NOTE: The basophil activation test is an in vitro cell based assay 
that only requires a serum sample. It is a surrogate assay for drug 
specific IgE but is not specific for IgE.
Complement (C3, C3a and 
C5a)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Cytokine panel Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Abbreviations: ADA = anti -drug antibody; IgE = immunoglobulin E; PK = pharmacokinetic.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
10610.7. Appendix 7: Liver Safety: Suggested Actions and Follow -up 
Assessments
Close Hepatic Monitoring
This table describes when close hepat ic monitoring shoul d occur.
If a participant with baseline results 
of ... develops the following elevations …
ALT or AST < 1.5x ULN ALT or AST ≥3x ULN
ALP <1.5x ULN ALP ≥2x ULN
TBL <1.5x ULNTBL ≥2x ULN (except for pa rticipa nts with Gilbert’s 
syndrome)
ALT or AST ≥1.5x ULN ALT or AST ≥2x baseline
ALP ≥1.5x ULN ALP ≥2x baseline
TBL ≥1.5x ULNTBL ≥2xbaseline (except for pa rticipa nts with Gilbert’s 
syndrome)
The l aboratory  tests listed in Appendix 2, including ALT, AST, ALP, TBL, direct bilirubin , 
gamma
-glutamyl  transferase, and creatine kinase, should be repeated within 48 to 72 hours to 
confirm the abnorm ality and to determine whether it is increasing or decreasing.
If the abnormalit y persists or worsens, clinical and laboratory  monitoring ,and evaluat ion for the 
possible causes of the abnormal liver tests should be init iated by  the investi gator in consultation 
with the sponsor.
At a minimum, this evaluat ion should include a physical examinat ion and a thorough medical 
history , including symptoms, recent illnesses (for example, heart failure, systemic infect ion, 
hypotension, seizures) recent travel , history  of concomi tant m edicat ions (including over -the-
counter), herbal and dietary  supplements, history  of alcoho l use, and other substance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 ti mes weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemical tests.  
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks if the 
participant’s clinical condit ion and l aboratory results stabilize.  Monitor ing of ALT, AST, ALP ,
and TBL should continue unt il levels norm alize or return to approximate baseline levels.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
107Compr ehensive Hepatic Evaluation  
A comprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m oreof these condit ions occur:
If a participant with baseline 
results of... develops the following elevations …
ALT or AST <1.5x ULN ALT or AST ≥3x ULN with hepatic signs/symptoms*, or
ALT or AST ≥5x ULN
ALP <1.5x ULN ALP ≥3x ULN
TBL <1.5x ULN TBL ≥2x ULN (except for pa rticipa nts with Gilbert’s syndrome)
ALT or AST ≥1.5x ULN ALT or AST ≥2x baseline with hepatic signs/symptoms*, or
ALT or AST ≥3x baseline
ALP ≥1.5x ULN ALP ≥2x baseline
TBL ≥1.5x ULN TBL ≥1.5x baseline (except for pa rticipa nts with Gilbert’s syndrome) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or 
eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for PT -INR; tests for viral hepat itis A, B, C, or E; tests 
for autoimmune hepatit is; and an abdominal imaging study  (for example, ultrasound or CT scan). 
Based on the pa rticipa nt’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus 
(HDV), cy tomegalovirus (CMV), Eps tein-Barr vi rus (EBV), acetaminophen levels, 
acetaminophen protein adducts, urine toxico logy screen, W ilson’s disease, blood alcoho l levels, 
urinary  ethyl  glucuronide, and serum phosphat idylethano l. 
Based on the circumstances and the invest igator ’s assess ment of the participant ’s clinical 
condi tion, the invest igator should consider referring the participant for a hepatologist or 
gastroenterologist consultation, magnet ic resonance cho langiopancreatography  (MRCP), 
endoscopi c retrograde cholangiopancreatograp hy (ERCP), cardiac echocardiogram, or a liver 
biopsy .  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
108Additional Hepatic Data Collection ( Hepatic Safety CRF) 
Additional hepatic safety data collection in hepatic safety case report forms (CRF) should be performed in 
study participants who either have a hepatic event considered to be an SAE or meet 1 or more of the se
conditions:
If a participant with baseline... has the following elevations …
ALT <1.5 ×ULN ALT ≥5 × ULN on 2 o r more consecutive blood tests
ALP <1.5 ×ULN ALP ≥2 × ULN on 2 or more consecutive blood tests
TBL <1.5 ×ULN TBL ≥2 ×ULN , except for cases of known Gilbert’s syndrome
ALT ≥1.5 ×ULN ALT ≥3 ×baseline on 2 or more consecutive blood tests
ALP ≥1.5 ×ULN ALP ≥2 ×baseline on 2 or more consecutive blood tests
TBL ≥1.5 ×ULN TBL ≥2 × baseline
Abbreviations:  ALP =alkaline phosphatase; ALT =alanine aminotransferase; AST = aspartate
aminotransferase; TBL =total bilirubin; ULN =upper limit of normal .
Note:  The interval between the 2 consecutive blood tests should be at least 2 days.
Hepatic Evaluation Testing
The Lilly -designated central laboratory  must com plete the analysis of all selected testing except 
for microbi ology testing.
Local  testing m ay be performed in addition to central  testing when necessary for immediate 
participant m anagement.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
    Neutrophils, segmented Gamma -glutamyl transferase (GGT)
    Lymphocytes Creatine kinase (CK)
    Monocytes Other Chemistry
    Basophils Acetaminophen
    Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
Coagulation Copper
Ethyl alcohol (EtOH)
Prothrombin time, INR (PT -INR) Haptoglobin
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
109Serology Immunoglobulin IgA (quantitative)
Hepatitis A virus (HAV) testing: Immunoglobulin IgG (quantitative)
    HAV total antibody Immunoglobulin IgM (quantitative)
    HAV IgM antibody Phosphatidylethanol (PEth)
Hepatis B virus (HBV) testing: Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug screen
    Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (anti -HBc) Other Serology
    Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
    Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
    HBV DNA b Anti- actin antibody c
Hepatis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
    HCV antibody     EBV antibody
    HCV RNA b     EBV DNA b
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
    HDV antibody     CMV antibody
Hepatitis E virus (HEV) testing:     CMV DNA b
    HEV IgG antibody Herpes simplex virus (HSV) testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody 
    HEV RNA b     HSV (Type 1 and 2) DNA b
Microbiology d Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
    Blood
    Urine
aNot required if anti -actin antibody is tested.
bReflex/confirmation dependent on regulatory requirements, testing availability, or both.
cNot required if anti -smooth muscle antibody (ASMA) is tested.
dAssay ed ONLY by investigator -designated local laboratory; no central testing available.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
11010.8. Appendix 8: Abbreviations
Term Definition
AC assessment committee
ADA anti-drug antibody
ADE antibody -dependent enhancement
adolescent Participant 12 to 17 years of age
assent Agreement from a child or other individual who is not legally capable of providing 
consent, but who can understand the circumstances and potential risks involved in 
participating in a study.
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or v ice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and theparticipant are not.
A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treat ment or clinical evaluation of the 
participan ts are aware of the treatment received.
CIOMS Council forInternational Organizations ofMedical Sciences
Complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a n intervention .
Compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRP clinical r esearch physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CTA Clinical trial agreement
DMC data monitoring committee
ECG electrocardiogram
FiO2 fraction of inspired oxygen in the air
Enroll The act of assigning a participant to a treatment.  Participants who are enrolled in the 
study are those who have been assigned to a treatment.
Enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
GCP good clinical practice
IB Investigator’s Brochure
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
111ICF informed consent form
ICH International Council for Harmonisation
IMP Investigational Medicinal Product
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are releva nt to the participant’s decision to participate.  Informed consent is 
documented by means of a written, signed and dated informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
Intervention A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IWRS interactive web -response sy stem
Legal representative An individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective participant , to the irparticipation in the clinical study .
NP Nasophary ngeal
Participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PK/PD pharmacokinetics/pharmacodynamics
SAE serious adverse event
SAP statistical analysis plan
Screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SpO2 saturatio n of peripheral oxygen
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
11210.9. Appendix 9: Protocol Amendment History
The Protocol Amendme nt Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment l : 03 February 2021
Overall Rationale for the Amendment:
This amendment addresses changes in response to emerging data.  As a result, participants will no 
longer receive placebo, the sample size for treatment arms 13 and 14 is reduced, open -label 
treatm ent arm s 16- 19 are added and object ives and endpo ints changed.  
Treatment arms 16 and 17 will evaluate faster infusion t imes using sent inel dosing.  
Treatment arm 18 will act as the active comparator for treatment arms 14, 16 -17 and 19.  
Treatment arm 19 will evaluate the efficacy and safet y of subcutaneous dosing.
Treatment arms 16 -19 will not be blinded because of the change in primary  endpoint to a m ore 
objective evaluat ion of change in viral load.  This also removes the need for a double -dummy 
design requiring every  parti cipant to receive an infusion and subcutaneous injec tions.
Section # and Name Description of Change Brief Rationale
Throughout the protocol Rem oved treatment arms 13 -14 
from most headers and sub -
headings w here it was grouped 
with treatment arms 7-9.Treatment arm 13-14 was added to new 
sections with new t reatment arms 16 -19.
1.1 Synopsis New Objectives/Endpoints table 
for treatment arms 13-14, 16-19Change in primary endpoint to viral load for 
treatment arms 14, 16-18.
Addition of new treatment arms and 
comparison analysis
1.1 Synopsis Updated Treatment and 
Assessment PeriodAddition of new treatment arms
1.1 Synopsis Updated Disclosure Statement Addition of new open -label treatment arms.
1.1 Synopsis Updated Number of Participants Addition of new treatment arms and new 
objectives and endpoints
1.1 Sy nopsis Updated Intervention Groups and 
Duration table.  Added text for 
new treatment arms.Addition of new treatment arms
1.1 Synopsis Updated Data Monitoring 
Committee treatment armsAddition of new treatment arms
1.2 Schema Updated the study schema Added new treatment arms and associated 
note
1.3.2 Schedule of Activities Added treatment arms 16 -19 to 
this SoATreatment arms 16- 19 will follow this SoA
1.3.2 Schedule of Activities Vital Sign –updated text to 
include SQ dosing.Addition of treatment arm 19
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
113Section # and Name Description of Change Brief Rationale
1.3.2 Schedule of Activities Pharmacokinetic (PK) sample –
clarified sample collection timing 
after the end of IV infusionSite feedback that this needed clarification.
1.3.2 Schedule of Activities Pharmacokinetic (PK) sample -
added Day 3 sample and sample 
times for SQ dose.Needed to complete the PK profile for SQ 
dose.
Addition of SQ dose.
1.3.2 Schedule of Activities Immunogenicity sample –
clarified that no sample is needed 
to match the Day 3 PK sample 
for SQ dose. Day 3 sample not needed to match the Day 
3 PK sample
2.3 Benefit/Risk Assessment Added the risk of injection site 
reactions (ISRs).Addition of SQ dose
3.3 Objectives and Endpoints Added new objectives and 
endpoints table for treatment 
arms 13-14, 16 -19Change in primary endpoint to viral load for 
treatment arms 14, 16 and 17 compared to 
treatment arm 18.
Addition of new treatment arms and 
comparison analysis
4.1.1 Design Outline Updated Figure 2 participant 
flow diagramIncluded injections for SQ dosing
4.1.1 Design Outline Treatment and Assessment 
Period –updated last bullet from 
post-infusion to post -doseAddition of SQ dosing
4.1.1 Design Outline Updated Treatment arm table Addition of new treatment arms
4.1.1 Design Outline Added treatment arms 16 -19 will 
be open -label .  
Added text and a new table to 
describe the sentinel dosing for 
treatment arms 16 and 17.New treatment arms and primary endpoint.
Treatment arms 16 and 17 will evaluate 
shorter infusion times using sentinel dosing 
to ensure safety is acceptable.
4.1.1 Design Outline Added text to describe that 
treatment arm 18 will be an 
active comparator, and for the 
safety review for treatment arm 
19Participants will no longer receive placebo.
A safety review will occur for participants 
in treatment arm 19 receiving SQ dose
4.1.1 Design Outline Added new treatment arms for 
visit ty pesAddition of new treatment arms
4.2 Scientific Rationale for 
Study DesignAdded text for participants no 
longer receiving placebo and 
description of open -label 
treatment arms. Added te xt for 
the multiple safety reviews for 
treatment arms 16-19Emerging data.
Safety reviews to minimize the risk of any 
unanticipated safety concerns before fully 
enrolling the treatment arms.
4.3 Justification for Dose Added treatment arm 18 to the 
justifi cation of the 700/1400 
dose.  Added treatment arms 16 
and 17 for the 350/700 dose.  
Added treatment arm 19 for SQ 
dose.Addition of new treatment arms.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
114Section # and Name Description of Change Brief Rationale
5.1 Inclusion Criteria Added new treatment arms for 
Criteria #27 and #28.Addition of new treatment arms
5.1 Inclusion Criteria Added “are pregnant” to criteria 
#27 and #28Emerging data indicate that being pregnant 
is a risk factor for COVID -19 illness
6.1 Study Intervention(s) 
AdministeredUpdated first sentence to broaden 
scopeIntroduction of SQ dosing in addition to IV 
infusion
6.1 Study Intervention(s) 
AdministeredUpdated the Study Intervention 
table with new dose levelsAddition of new treatment arms
6.1 Study Intervention(s) 
AdministeredAdded text for subcutaneous 
dosingAddition of treatm ent arm 19
6.1.2 Temporary Stopping 
CriteriaAdded stopping criteria for 
treatment arms 16- 17 and 19.These treatment arms will evaluate faster 
infusion times and SQ dosing.
6.2 Preparation/Handling/
Storage/AccountabilityUpdated text to accommodate 
new open -label treatment armsAddition of new treatment arms.
6.3 Measures to Minimize 
Bias: Randomization and 
BlindingUpdated Blinding sub -section to 
accommodate new open -label 
treatment armsAddition of new treatment arms
8.2.2 Vital Signs Updated text f or data collection 
on the CRF for new treatment 
armsAddition of new treatment arms
8.3.8 Injection Site Reactions New section for SQ dose Addition of SQ dosing
8.3.9 Product Complaints Renumbered section to 8.3.9 
with addition of new Section 
8.3.8 Injection Stie Reactions
9.1 Statistical Hypotheses Updated and added text for 
treatment arms 14, 16-18.Addition of new treatment arms and new 
primary  objective
9.2 Sample Size 
DeterminationUpdated sample size for 
treatment arms 13 and 14New strategy for objectives and endpoints 
and analyses
9.2 Sample Size 
DeterminationAdded sample size for new 
treatment arms 16-19Addition of new treatment arms
9.2 Sample Size 
DeterminationRem oved simulation information 
for previous treatment arms 13 
and 14, and added simulation 
information for treatment arms 
14, 16-19Addition of new treatment arms
9.3 Populations for Analyses Rem oved the row for Modified 
Efficacy populationNo longer needed
9.4 Statistical Analyses Updated treatment arms for 
analy sesAddition of new treatment arms
9.4.2 Primary Endpoint Updated endpoint for treatment 
arms 14, 16 -18Treatment arm 13 is no longer needed for 
the primary endpoint.  
The addition of treatment arms.
9.4.3.1 Key Secondary 
EndpointsUpdated for new treatment arms New endpoints per emerging data
9.4.3.2 Safety Added text for new treatment 
armsPost-administratio n observations and AEs 
will be evaluated for the new treatment 
arms.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
115Section # and Name Description of Change Brief Rationale
Injection site reactions will be 
characterized.
9.4.3.3 Additional Secondary 
EndpointsAdded separate section for new 
treatment arms for clarity as 
some endpoints are different for 
the new treatment arms.New treatment arms and endpoints
9.4.6 Subgroup Analyses Added SARS -CoV -2 vaccine 
statusParticipants who received a vaccine are 
allowed in the study
9.5 Interim Analyses Updated for new treatment arms Addition of new treatment arms
9.6 Data Monitoring 
CommitteeUpdated for new treatment arms Addition of new treatment arms
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described
Amendment k:20 January 2021
Overall Rationale for the Amendment:
This amendment allows participants in the study who have received the SARS -CoV -2 vaccine.  
SARS -CoV -2 vaccines are now available to the public and those who received a vaccine or have 
participated in a SARS -CoV -2 vaccine study are allowed in the study.
Section # and Name Description of Change Brief Rationale
Section 1.3.2 Schedule of 
Activities for Treatment Arms 
7-9,13 -14Updated Prior treatments of 
special interest to allow the 
SARS - CoV -2 vaccineThe SARS -CoV -2 vaccine is now allowed
2.3 Benefit/Risk Assessment Updated risk information for 
LY3819253Emerging data
4.2 Scientific Rationale for 
Study DesignAdded a sub -section for 
participants who have received 
the SARS -CoV -2 vaccineVaccines are now available to the public 
and those who received a vaccine are 
allowed in the study
5.2 Exclusion Criteria Criterio n #21 is removed SARS -CoV -2 vaccines are now available to 
the public and those who received a vaccine 
or have participated in a SARS -CoV -2 
vaccine study are allowed in the study
6.5 Concomitant Therapy Added vaccines to prior 
treatment list that should be 
recorded.
Added “non -SARS -CoV -2” to 
clarify  what vaccines are 
recorded for adolescents.  Need a record of those who received a 
SARS -Cov -2 vaccine.
Need a record of non -SARS -CoV -2 
vaccines that adolescents received 90 days 
prior to signing informed consent.
9.2 Sample Size Added clarification that there is 
no set sample size for 
participants wi th prio r vaccine 
use.Those who received a SARS -CoV -2 
vaccine are allowed in the study.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
116Section # and Name Description of Change Brief Rationale
Added stratification factor for 
whether a participant received a 
vaccine or not prior to screening
9.3 Populations for Analyses Added the Modified Efficacy 
populatio n to tableTo distinguish a population for analysis that 
will not include those that received a 
SARS -CoV -2 vaccine.
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
117Amendment j: 07 January 2021
Overall Ratio nale for the Amendment:
This amendment addresses changes in response to emerging data, discussions with the FDA and the 
addition of treatment arms 13 and 14.  Treatment arms 10 -12 were skipped due to internal 
programming capabilities.  
Section # and Name Description of Change Brief Rationale
Throughout protocol Added treatment arms 13 -14 
identifiers where applicableAddition of treatment arms 13 and 14
1.1 Synopsis Updated treatment arms 7 -9 
Objectives and Endpoint table. 
This table is now also applicable 
for treatment arms 13-14.Alignment with FDA feedback and 
emerging data.  Identified key secondary 
objectives, updated other secondary 
endpoints.
1.1 Synopsis Updated Disclosure Statement to 
accommodate all treatment armsStatement applies to a ll treatment arms
1.1 Synopsis Updated Number of Participants 
for treatment arms 7-9 and 13 -14Correction of sample size for 7 -9 and 
addition of treatment arms 13 and 14
1.1 Synopsis Updated Intervention Groups and 
Duration table with new 
treatment arms.
Added information about placebo 
control for treatment arms 13 and 
14.Addition of treatment arms 13 and 14.
1.1 Synopsis Updated Data Monitoring 
Committee to include treatment 
arms 13 and 14Addition of treatment arms 13 and 14.
1.2 Schema Updated Schema and Figure title Addition of treatment arms 13 and 14.
1.3.2 Schedule of Activities 
(SoA) for 7 -9Will use this SoA for treatment 
arms 7-9, 13 -14Addition of treatment arms 13 and 14.
1.3.2 Schedule of Activities 
(SoA) for 7 -9, 13 -14Clarified col lection of prio r 
“non -COVID” vaccine 
treatments for adolescentsclarificatio n
1.3.2 Schedule of Activities 
(SoA) for 7 -9, 13 -14Updated vital signs and Oxygen 
Support timing for Day 1 for an 
infusion that is <15 minutesAddition of treatment arms 13 and 1 4.
1.3.2 Schedule of Activities 
(SoA) for 7 -9, 13 -14Added clarification that 
pregnancy testing is not 
applicable for females pregnant 
at screeningPregnant females are eligible in this study.
2.3 Benefit/Risk Assessment Updated the risk associated with 
administration of LY3819253 From emerging clinical data
2.3 Benefit/Risk Assessment Added benefit/risk information 
for the pregnant populationPregnant females are eligible in this study.
3.2 Objectives and Endpoints 
forTreatment arms 7-9, 13 -14Added treatment arms 13 -14.  
Identified key secondary 
objectives, updated other 
secondary and exploratory 
endpoints.Addition of treatment arms 13 and 14.  
Alignment with FDA feedback and 
emerging data.  
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
118Section # and Name Description of Change Brief Rationale
4.1.1 Design Outline Updated treatment arm table with 
new treatment arms.
Added information about placebo 
control for treatment arms 13 and 
14.Addition of treatment arms 13 and 14.
4.2 Scientific Rationale for 
Study DesignAdded information for pregnant 
participantsPregnant females are eligible in this study
4.3 Justification for Dose Added information for new 
treatment armsAddition of treatment arms 13 and 14.
5.1 Inclusion Criteria Updated Criterion #5 to include 
pregnant femalesPregnant females are eligible in this stu dy
5.1 Inclusion Criteria Added “requires daily 
medication for control” to 
Criterio n #28Per the Emergency Use Authorization 
(EUA) for adolescents
5.2 Exclusion Criteria Added “or have received a 
SARS -CoV -2 vaccine” to 
Criterio n #21Clarification of crit erion because of the 
availability  of the vaccine.
5.2 Exclusion Criteria Rem oved “pregnant or” from 
Criterio n #24Pregnant females are eligible in this study
6.1 Study Intervention(s) 
AdministeredAdded new dose levels to Study 
Intervention tableAddition of treatment arm 14.
6.1 Study Intervention(s) 
AdministeredReplaced “pharmacy preparation 
instructio ns” for “pharmacy 
manual”Correction.  Infusion information may be 
found in the pharmacy preparation 
instructio ns.
6.1.1.2. Management of 
Infusi on ReactionsRem oved duplicate text about 
premedication for infusionsThis information is located in Section 
6.1.1.1. and was inadvertently repeated in 
Section 6.1.1.2.
7.2 Participant 
Discontinuation/Withdrawal 
from StudyRem oved “if the participant 
becomes pregnant during the 
study” from the bulleted listPregnant females are eligible in this study
8.2.2 Vital Signs Updated Treatment arms 7 -9, 13-
14 table for Day 1 data collection 
for an infusion that is <15 
minutesAddition of treatment arms 13 and 14.
8.2.3 Clinical Laboratory 
AssessmentsRem oved text from Pregnancy 
testing sub -section “Participants 
who are pregnant will be 
discontinued from the studyPregnant females are eligible in this study
8.3.5 Pregnancy Rem oved text from section so 
that it is aligned with Section 
10.4, Appendix 4.Correction
8.3.6 Hy persensitivity 
ReactionsRem oved text about the risk of 
systemic hy persensitivity  
reactionsThe risks are outlined in Section 2.3. 
Benefit/Risk Assessment
9.1 Statistical Hypotheses Updated text according to 
changes to primary endpoint and 
added text for new treatment 
armsAlignment with FDA feedback and 
emerging data.
Addition of treatment arms 13 and 14.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
119Section # and Name Description of Change Brief Rationale
9.2 Sample Size 
DeterminationAdded sub -headers for clarity.  
Updated sample size for 
treatment arms 7-9.
Added sample size and 
randomization for treatment arms 
13-14.Statistician decision and addition of 
treatment arms 13 and 14.
9.4 Statistical Analyses Added treatment arms 13 and 14 Addition of treatment arms 13 and 14.
9.4.2 Primary Endpoints Updated text according to 
changes to primary endpoint and 
for new treatment armsAlignment with FDA feedback and 
emerging data.
Addition of treatment arms 13 and 14.
9.4.3.1 Key Secondary 
EndpointsNew Section Alignment with FDA feedback and 
emerging data.
9.4.3.2 Safety This section is renumbered Section moved down due to new Key 
Secondary Endpoints section
9.4.3.3 Additional Secondary 
EndpointsThis section is renumbered.  
Updated endpoints for treatment 
arms 7-9 and added arms 13 and 
14Renumbered due to new Key Secondary 
Endpoints section.
Alignment with FDA feedback and 
emerging data.
9.4.3.4 Pharmacokinetic 
Analy sesThis section is renumbered.  Renumbered due to new Key Secondary 
Endpoints section.
9.4.6 Subgroup Analyses Rem oved i ncorrect text Correction
9.5 Interim Analyses Added sub -headers and updated 
text for treatment arms 7 -9. 
Added text for new treatment 
armsUpdates made for clarification and addition 
of treatment arms 13 and 14.
9.6 Data Monitoring 
CommitteeAdded treatment arms 13 -14 to 
Treatment Arms 7 -9 sub -header 
and updated first sentence under 
this headerRem oved text that was not applicable to 
these treatment arms.
10.4 Appendix 4 
Contraceptive Guidance and 
Collection of Pregnancy 
InformationUpdated text fo r the inclusio n of 
pregnant females Pregnant females are eligible in this study
11 References Added Chen et.al.2020 reference Source for information in Section 2.3
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
120Amendment i:30 November 2020
Overall Rationale for the Amendment:
This amendment addresses changes in response to discussions with the FDA to enable independent 
confirmation of the safety and efficacy of LY3819253 in co mbinat ion with LY38324 79 for the 
treatm ent of COVID-19.  The decision was made to remove treatment arms 10 and 11, and change 
the primary objective, statistical methods and sample size for treatment arms 7 -9.  
Section # and Name Description of Change Brief Rationale
Title Page Updated Phase 2 to Phase 2/3 Per FDA feedback to more accurately 
describe study
1.1 Synopsis Updated protocol title to Phase 
2/3Per FDA feedback to more accurately 
describe study
1.1 Synopsis Updated Objectives and 
Endpoints table for treatment 
arms 7-9 to reflect changes in 
Section 3.Rem oved treatment arm 10, updated the 
primary  objective for treatment arms 7-9, 
moved reduction in viral load from primary 
to first secondary endpoint, and added Day 
29 to symptom resolution and symptom 
improvement endpoints.
1.1 Synopsis Rem oved treatment arm 11 
objectives and endpoints tableTreatment arm 11 is removed from this 
study 
1.1 Synopsis Updated Overall Design to say 
Phase 2/3Per FDA feedback to more accurately 
describe study 
1.1 Synopsis Updated v isit ty pe table Treatment arms 10 and 11 are removed 
from this study
1.1 Synopsis Updated Disclosure Statement Treatment arms 10 and 11 are removed 
from this study
1.1 Synopsis Updated Number of Participants Treatment arms 10 and 11 are removed 
from this study and the sample size 
increased for treatment arms 7 -9 
1.1 Synopsis Rem oved treatment arms 10 and 
11 and updated placebo control 
information in Intervention 
Groups and Duration Treatment arms 10 and 11 are removed 
from this study
1.1 Synopsis Rem oved treatment arms 10 and 
11 from Data Monitoring 
CommitteeTreatment arms 10 and 11 are removed 
from this study
1.2 Schema Updated existing figure for 
treatment arms 1-9 and removed 
treatment arm 11 figureTreatment arms 10 and 11 are removed 
from this study
1.3.2. Schedule of Activities Rem oved reference to treatment 
arms 10 and 11Treatment arms 10 and 11 are removed 
from this study
1.3.2. Schedule of Activities Changed visit window for Study 
Day 11 to -2/+3 from ±3In order to avoid overlapping visits with 
study day 7 and more flexibility with study 
day 11 visit
2.3 Benefit/Risk Assessment Rem oved text for Risks and 
Benefits Associated with Faster 
Rates of Infusion and removed 
text related to treatment arm 11Rem oved treatment arm 11
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
121Section # and Name Description of Change Brief Rationale
3.2 Objectives and Endpoints Updated table for treatment arms 
7-9. Rem oved treatment arm 10, updated the 
primary  objective for treatment arms 7 -9, 
moved reduction in viral load from primary 
to first secondary endpoint, and added Day 
29 to symptom resolution and symptom 
improvement endpoints.
3 Objectives and Endpoints Rem oved treatment arm 11 
objectives and endpoints tableTreatment arm 11 is removed from this 
study 
4.1 Overall Design Updated Overall Design to say 
Phase 2/3Per FDA feedback to more accurately 
describe study 
4.1.1 Design Outline Rem oved treatment arms 10 and 
11 from Treatment Arm table 
and textTreatment arms 10 and 11 are removed 
from this study
4.1.1 Design Outline Updated text to describe that 
treatment arm 8 will be the 
corresponding placebo control 
for treatment arms 7 and 9Will increase the sample size for 8 and 
enroll with both treatment arms 7 and 9.
4.1.1 Design Outline Rem oved information for 
treatment arms 10 and 11 for 
visit ty pesTreatment arms 10 and 11 are removed 
from this study
4.2 Scientific Rationale for 
Study DesignRem oved rationale for treatment 
arm 11 and updated text to 
remove reference to treatment 
arms 10 and 11Treatment arms 10 and 11 are removed 
from this study
4.3 Justification for Dose Rem oved references to treatment 
arms 10 and 11Treatment arms 10 and 11 are removed 
from this study
5.1 Inclusion Criteria Rem oved reference to treatment 
arms 10 and 11 for inclusion 
criteria #27 and #28Treatment arms 10 and 11 are removed 
from this study
5.1 Inclusion Criteria Added “have chronic kidney 
disease” to criterion #28Medical decision
6.1.1.2 Management of 
Infusion ReactionsAdded footnote and source back 
to table describing the severity of 
reactions according to Divis ion 
of Allergy  and Infectious 
Diseases ( DAIDS )This information was inadvertently 
removed in a previous version of the 
protocol
6.1.2 Temporary Stopping 
CriteriaRem oved reference to treatment 
arms 10 and 11 and removed 
specific stopping criteria for 
treatment arm 11Treatment arms 10 and 11 are removed 
from this study
6.3 Measures to Minimize 
Bias: Randomization and 
BlindingRem oved reference to treatment 
arms 10 and 11Treatment arms 10 and 11 are removed 
from this study
8.2.2 Vital Signs Rem oved reference to treatment 
arms 10 and 11 for vital signs 
data collection tableTreatment arms 10 and 11 are removed 
from this study
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
122Section # and Name Description of Change Brief Rationale
9.1 Statistical Hypotheses Rem oved reference to treatment 
arms 10 and 11 and updated 
hypothesis for treatment arm 9Treatment arms 10 and 11 are removed 
from this study, and updates reflect changes 
for the primary objective and endpoint.
9.2 Sample Size 
DeterminationRem oved reference to treatment 
arms 10 and 11 and updated 
sample size information for 
treatment arms 7 - 9Change in strategy per discussions with 
FDA 
9.4 Statistical Analyses Rem oved reference to treatment 
arms 10 and 11 and updated 
information for treatment arms 7 
- 9Treatment arms 10 and 11 are removed 
from this study, and updates reflect changes 
in analyses
9.4.2 Primary Endpoints Rem oved reference to treatment 
arms 10 and 11 and updated 
information for treatment arms 7 
- 9Treatment arms 10 and 11 are removed 
from this study, and updates reflect changes 
in analyses
9.4.3.2 Additional Secondary 
EndpointsRem oved reference to treatment 
arms 10 and 11 and updated 
information for treatment arms 7 
- 9Treatment arms 10 and 11 are removed 
from this study, and updates reflect the 
move of viral load from primary to 
secondary endpoint, and the addition of Day 
29 to s ymptom improvement and symptom 
resolution endpoints
9.4.6 Subgroup Analyses Rem oved reference to treatment 
arms 10 and 11Treatment arms 10 and 11 are removed 
from this study
9.5 Interim Analyses Rem oved reference to treatment 
arms 10 and 11 and updated 
information for treatment arms 7 
- 9Treatment arms 10 and 11 are removed 
from this study, and updates reflect changes 
in analyses
9.6 Data Monitoring 
Committee (DMC)Rem oved reference to treatment 
arms 10 and 11Treatment arms 10 and 11 are removed 
from this study
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described
Amendment g :17 November 2020
Overall Rationale for the Amendment:
This amendment addresses the addition of treatment arms 9 -11.  Treatment arm 9 wi ll explore a 
lower dose level of the combination of LY3819253 and LY3832479.  Treatment arm 10 will provide 
a bridge to the existing placebo arms.  Treatment arm 11 is an open -label sub -study comprised of two 
cohorts to evaluate a faster IV infusion rate o f the combination of LY3819253 and LY3832479.   
Section # and Name Description of Change Brief Rationale
1.1 Synopsis Added Objectives and Endpoints 
tables for treatment arms 9 -11Addition of new treatments
1.1 Synopsis Updated sub -headings under 
Design Outline to remove 
“double -blind”Addition of the open -label treatment arm 11
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
123Section # and Name Description of Change Brief Rationale
1.1 Synopsis Updated Disclosure Statement 
for treatment arms 7-11Addition of new treatments
1.1 Synopsis Added Number of Participants 
for treatment arms 9-11Addition of new treatments
1.1 Synopsis Added information for treatment 
arms 9-11 to Intervention Groups 
and DurationAddition of new treatments
1.1 Synopsis Updated text under Data 
Monitoring CommitteeAddition of new treatments
1.2 Schema Updated existing figure and
added figure for treatment arm 
11Addition of new treatments
1.3.2. Schedule of Activities Updated to include the new 
treatmentsNew treatments will use the same SoA as 
treatment arms 7-8
2.3 Benefit/Risk Added sub -headings for 
clarificatio n of information.  
Added the potential benefit/risks 
associated with an increased rate 
of infusionTreatment arm 11 will use a faster infusion 
rate than the other treatment arms
3 Objectives and Endpoints Added new sub -headings for the 
separate tables for the different 
treatment armsEasier document navigation
3 Objectives and Endpoints The table for treatment arms 7 -8 
is now applicable for treatment 
arms 7-10.  
Added clarifying text for 
secondary objectives in this table 
to describe differences between 
treatment arms 7-8 versus 9 -10Treatment arms 9-10 will have basically the 
same objectives and endpoints, but will 
need more flexibility for the secondary 
objectives.
3 Objectives and Endpoints Added a new table for treatment 
arm 11Addition of new treatment
4.1.1 Design Outline Added sub -headings for 
clarificatio nAddition of new treatments
4.1.1 Design Outline Updated sub -headings to remove 
“double -blind”Addition of the open -label treatment arm 11
4.1.1 Design Outline Added information for treatment 
arms 9-11 in treatment arm table 
and textAddition of new treatments
4.1.1 Design Outline Added information for treatment 
arms 9-11 for visit typesAddition of new treatments
4.2 Scientific Rationale for 
Study DesignAdded rationale for the addition 
of trea tment arm 11This treatment arm is an open -label sub -
study to evaluate a faster infusion rate.
4.2 Scientific Rationale for 
Study DesignUpdated participant 
characteristics to add new 
treatment armsAddition of new treatments
4.3 Justification for Dose Section was updated to include 
the new treatment informationAddition of new treatments
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
124Section # and Name Description of Change Brief Rationale
5.1 Inclusion Criteria Added sub -headings for criteria 
#27 and #28Addition of new treatments
6.1 Study Intervention(s) 
AdministeredAdded new dose level for 
LY383247 9Addition of new treatments
6.1.2 Temporary Stopping 
CriteriaAdded sub -headings for 
treatment arms 1-10 and criteria 
for treatment arm 11Addition of new treatments and the 2 
cohorts in treatment arm 11
6.3 Measures to Minimize 
Bias: Randomization and 
BlindingAdded sub -headings for 
treatment arms 1-11 and indicate 
that treatment arm 11 is open 
labelAddition of new treatment
8.2.2 Vital Signs Added new treatment arms to 
table outlining Day 1 vital signs 
data collection and added the 90 
and 120 minute collection to the 
treatment arms 7-11 tableAddition of new treatments
9.1 Statistical Hypotheses Added information for treatment 
arms 9-10Addition of new treatments
9.2 Sample Size 
DeterminationAdded sample size for new 
treatment arms
Added text to c larify  
stratification is not applicable for 
treatment arm 11.Addition of new treatments
9.2 Sample Size 
DeterminationAdded information for treatment 
arm 11 under stratificationStratification is not applicable to treatment 
arm 11.
9.4 Statistical Analyses Added information for treatment 
arms 9-11Addition of new treatments
9.4.2 Primary Endpoints Added information for new 
treatment armsAddition of new treatments
9.4.3.2 Additional Secondary 
EndpointsUpdates made to include 
treatment arms 9-10 a nd added 
text for treatment arm 11Addition of new treatments
9.4.3.3 Pharmacokinetic 
Analy sesRem oved reference to 
noncompartmental analysis and 
replaced with descriptive 
summary.  Number of study participants with 
evaluable PK concentration data has 
increased.
9.4.6 Subgroup Analyses Updates made to include 
treatment arms 9-10 and added 
text for treatment arm 11Addition of new treatments
9.5 Interim Analyses Updates made to include 
treatment arms 9-10, added text 
to explain that unblinded 
assessmen ts will be done 
separately for treatment arms 7 
and 8, and 9 and 10, and added 
text for treatment arm 11Addition of new treatments
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
125Section # and Name Description of Change Brief Rationale
9.6 Data Monitoring 
Committee (DMC)Updates made to include 
treatment arms 9-10 and added 
text for treatment arm 11Addition of new treatments
11 References Added FDA EUA fact sheet for 
bamlanivimabAddition of reference.
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described
Amendment f: 20 October 2020
Overall Rationale for the Amendment:
This amendment addresses changes requested by the Food and Drug Administration (FDA) for 
treatment arms 7 and 8.  Treatment arms 7 and 8 will now include adolescent participants at higher 
risk for severe disease and hospitalization, and the prim ary and secondary endpoints will be updated.  
Section # and Name Description of Change Brief Rationale
1.1 Synopsis Updated treatment arms 7 and 8 
objectives and endpointsPer FDA request to capture primary and 
secondary clinical endpoints until Day 29
1.1 Synopsis Added child/adolescent assent to 
the screening procedureAddition of adolescent participants
1.1 Synopsis Added text in Number of 
Participants to say that adult and 
adolescent participants with at 
least 1 risk factor are in treatment 
arms 7 and 8Addition of adolescent participants
1.3.2 Schedule of Activities 
for Treatment Arms 7 and 8Added a row for informed assent For adolescent participants
1.3.2 Schedule of Activities 
for Treatment Arms 7 and 8Added a row to collect 
information on va ccines at 
screeningFor adolescent participants
1.3.2 Schedule of Activities 
for Treatment Arms 7 and 8Updated comments for the 
SARS -CoV -2 Test Panel This panel is for adults only to reduce 
invasive procedures and blood volume 
collection in adolescent p articipants
1.3.2 Schedule of Activities 
for Treatment Arms 7 and 8Updated comments for 
pharmacokinetics Day 1 predose 
samplePredose sample is for adults only to reduce 
invasive procedures and blood volume 
collection in adolescent participants
1.3.2 Schedule of Activities 
for Treatment Arms 7 and 8Updated comments for 
pharmacogenetics sampleThis sample is for adults only to reduce 
invasive procedures and blood volume 
collection in adolescent participants
2.3 Benefit/Risk Assessment Added text for a dolescents Addition of adolescent participants
3 Objectives and Endpoints Updated endpoints for Treatment 
Arms 7 and 8Per FDA feedback
4.1.1 Design Outline Added child/adolescent assent to 
the screening procedureAddition of adolescent participants
4.2Scientific Rationale for 
Study DesignAdded rationale for including 
adolescent participantsAddition of adolescent participants
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
126Section # and Name Description of Change Brief Rationale
4.3 Justification for Dose Added justification for 
adolescentsAddition of adolescent participants
5.1 Inclusion Criteria Rem oved note about new 
criterion #27Not applicable any longer 
5.1 Inclusion Criteria Updated Criterion #1 to include 
participants ≥12 years of ageAddition of adolescent participants
5.1 Inclusion Criteria Updated Criterion #5 
nomenclature for particip ant sex 
from “men” and “women” to 
“male” and “female”More appropriate terms for adolescent 
participants
5.1 Inclusion Criteria Updated Criterion #8 to include 
assentAddition of adolescent participants
5.1 Inclusion Criteria Updated criterion #27 to indicate 
that it is for participants 18 years 
of age or olderTo distinguish this criterion from the new 
#28 criterion for adolescents
5.1 Inclusion Criteria Updated criterion #27 to 
state”type 1 or type 2” diabetesClarification of diabetes description
5.1 Inclusion Criteria Added criterion #28 Addition of adolescent participants
5.2 Exclusion Criteria Added criterion #29 Addition of adolescent participants
6.1 Study Intervention(s) 
AdministeredAdded that the site must have 
“age-approriate” resuscitation 
equipmentFor the adolescent participants
6.3 Measures to Minimize 
Bias: RandomizationAdded stratification by age Addition of adolescent participants
6.5 Concomitant Therapy Updated Prior Treatment to add 
recording vaccines for 
adolescentsAddition of adolescent participants
8.7 Genetics Added clarification that sample 
collection will be collected in 
adults onlyThis sample is for adults only to reduce 
invasive procedures and blood volume 
collection in adolescent participants
9.1 Statistical Hypotheses Minor change from “and” to “or”
9.2 Sample Size 
DeterminationAdded stratification by age Addition of adolescent participants
9.2 Sample Size 
DeterminationUpdated justification for 
Treatment arms 7 and 8Further clarifications for the sample size 
justification
9.4.2 Primary Endpoints Updated according to objectives 
and endpoints tablePer FDA feedback
9.4.3.2 Additional Secondary 
EndpointsUpdated according to objectives 
and endpoints tablePer FDA feedback
9.5 Interim Analys es Unblinded assessments of 
efficacy will not be conducted 
until participants complete Day 
29 visit, not Day 22.correction
10.1.3. Informed Consent 
ProcessUpdated for adolescent 
populatio nAddition of adolescent participants
10.2 Appendix 2 Clinical 
Laborato ry TestsAdded comments where sample 
collection is for adults onlyAddition of adolescent participants
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
127Section # and Name Description of Change Brief Rationale
10.4 Appendix 4 
Contraceptive Guidance and 
Collection of Pregnancy 
InformationAdded women not of child -
bearing potential to those 
participating in the study.Correction and addition of adolescent 
participants
10.4 Appendix 4 
Contraceptive Guidance and 
Collection of Pregnancy 
InformationAdded assent to section about 
male participants with partners 
who become pregnantAddition of adolescent parti cipants
10.8 Abbreviations Added “assent” and “legal 
representative”Addition of adolescent participants
11 References Added references used in new 
textAdditional references used in body of 
protocol.
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described
Amendment e: 13 October 2020
Overall Rationale for the Amendment:
This amendment addresses changes for treatment arms 7 and 8 .  Thi s popul ation is at higher risk 
for more severe disease and hospitalizatio n.  The sample size is increased, and the objectives and 
endpoints are updated to support potential marketing applications.  The changes for treatment arms 
7 and 8 affect sections throughout the protocol. 
Section # and Name Description of Change Brief Rationale
1.1 Synopsis Updated text to match the body 
of the protocol for the Objectives 
and EndpointsSee rationale for Section 3.
1.1 Synopsis Updated information to match 
the body of the protocol for the 
Design Outline  Updated visit type table and a dded another 
specifically for treatment arms 7 and 8
1.1 Synopsis Updated text to match the body 
of the protocol for the Number of 
participants.Increase in sample size for treatment arms 7 
and 8.  See rationale for Section 9.2.
1.1 Synopsis Updated Data Monitoring 
Committee (DMC) information 
to match the body of the protocolSee rationale for Section 9.6
1.3 Schedule of Activities 
(SoA)Rem oved information pertaining 
to treatment arms 7 and 8 in the 
existing SoA Participants enrolling into treatment ar ms 7 
and 8 will have a different visit and sample 
schedule than treatment arms 1 -4 and 6.
1.3 Schedule of Activities 
(SoA)Created a separate SoA for 
treatment arms 7 and 8Participants enrolling into treatment arms 7 
and 8 will have a different visit and sample 
schedule.
2.2 Background Rem oved information specific to 
a previous amendmentNo longer applicable
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
128Section # and Name Description of Change Brief Rationale
3 Objectives and Endpoints Updated the table for treatment 
arms 7 and 8Changed the primary endpoints and updated 
the secondary endpoints based on emerging 
data
3 Objectives and Endpoints Added pharmacokinetic endpoint 
for treatment arms 7 and 8Will analyze the pharmacokinetics
4.1.1 Design Outline Rem oved treatment arms 7 and 8 
information from the visit type 
information tableTreatment arms 7 an d 8 will have a 
different visit structure
4.1.1 Design Outline Created a separate visit type 
information table for treatment 
arms 7 and 8To match the new SoA specific to treatment 
arms 7 and 8 
4.2 Scientific Rationale for 
Study DesignAdded text for tr eatments 7 and 8 
participant characteristicsAdditional rationale for studying the 
populatio n
5.1 Inclusion Criteria Updated criterion #27 to include 
other chronic respiratory diseasesTo broaden the population with high risk 
factors
6.1 Study Intervention(s) 
AdministeredChanged monitoring from 2 
hours after completion of the 
infusion to 1 hourBased on available safety data
6.1.2 Temporary Stopping 
CriteriaAdded information for DMC’s 
roleAn external DMC will review safety for 
treatment arms 7 and 8
6.3 Measures to Minimize 
Bias: Randomization and 
BlindingUpdated the Unblinding (IWRS) 
table to remove ‘case report 
form’A case report form is not used to record 
unblinding.
8.1 Efficacy Assessments Rem oved specific endpoint dates Endpoints are not the same across all 
treatment arms.  Removed text to make 
more general.  The information is also 
located in other sections of the protocol.
8.2.2 Vital Signs Added clarifications for 
treatment arms 1-4 and 6 versus 
7 and 8.  Added a table for 
treatment arms 7 and 8.Treatment arms 7 and 8 have different 
collection times for Day 1
8.5.1 Bioanalytical Generalized text for remaining 
sample usageTo optimize the amount of information 
from sample collection, samples may be 
used for exploratory analyses beyond just 
metabolism or bioanalytical experiments
8.9 Immunogenicity Generalized text for remaining 
sample usageTo optimize the amount of information 
from sample collection, samples may be 
used for exploratory analyses
9.1 Statistical Hypotheses Adde d statistical hypothesis for 
treatment arms 7 and 8New information to match the updated 
primary  endpoints
9.2 Sample Size 
DeterminationUpdated sample size for 
treatment arms 7 and 8Increase in sample size to provide statistical 
power for updated primary endpoints
9.2 Sample Size 
DeterminationUpdated section, moved text 
within section and added 
clarificatio ns for treatment arms 
1-4 and 6 versus 7 and 8.  Updated sample size rationale for 
treatments 7 and 8 sample size
9.4 Statistical Analyses Updated section with new 
analy sesAligned analysis plan with updated primary 
endpoints
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
129Section # and Name Description of Change Brief Rationale
9.4.2 Primary Endpoints Updated treatment arms 7 and 8 
primary  endpointsNew endpoints based on emerging data
9.4.3.2 Additional Secondary 
EndpointsUpdated treatment arms 7 and 8 
secondary endpointsChanges made to the primary endpoints 
dictated a change in secondary endpoints.
Day 15 endpoints were removed per the 
new SoA.
9.4.6 Subgroup Analyses Added clarifying text Last bullet only applicable to treatment 
arms 1-4 and 6
9.5 Interim Analyses Added clarifying text for 
treatment arms 7 and 8 Interim analyses will be different compared 
to treatment arms 1 -4 and 6
9.6 Data Monitoring 
Committee (DMC)Added clarifying text for 
treatment arms 7 and 8The sponsor will for m an external DMC to 
analy ze safety  data
10.1.3 Informed Consent 
ProcessAdded text to re -consenting 
informationClarification
10.1.5 Committees Structure Added clarifying text for 
treatment arms 7 and 8The sponsor will form an external DMC to 
analy ze safety  data
Appendix 4: Contraceptive 
Guidance and Collection of 
Pregnancy InformationUpdated text for collection of 
information on infants after a 
woman gives birthPer FDA feedback on pediatric 
development of LY3819253
Throughout the protocol Minor ed itorial and formatting 
changesMinor, therefore not described
Amendment d:18 September 2020
Overall Rationale for the Amendment:
This amendment broadens the definit ion of pat ients with COVID -19 who are at a high risk of 
hospi talizati on.
Section # and Name Description of Change Brief Rationale
5.1 Inclusion Criteria Updated inclusion criterion 27. Broadened definition of patients with 
COVID -19 at high risk for hospitalization.  
Amendment c: 31 August 2020
Overall Rationale for the Amendment:
The sponsor is activat ing the optional treatment arm 7 wit h the combinat ion of LY3819253 and 
LY3832479.  Treatment arm 7 will consist of a populat ion with risk factors for severe COVID -
19 illness.  Treatment arm 8 is added to the study  as the corresponding placebo control .  The 
primary  and key  secondary  endpoints for treatm ent arms 7 and 8 are different than treatments 1-4 
and 6.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
130Section # and Name Description of Change Brief Rationale
1.1 Synopsis Updated text to match the body 
of the protocol for the Num ber of 
participants.Updates were made to Section 9.2 to more 
accurately describe the sample sizes for the 
different treatment arms.
1.1 Synopsis Updated text to match the body 
of the protocol for the
Intervention Groups and 
Duration.Activation of treatment arm 7 and addition 
of treatment arm 8.
1.1 Synopsis Updated text to match the body 
of the protocol for the Objectives 
and EndpointsSee rationale for Section 3 below.
1.1 Synopsis Updated text to match the body 
of the protocol for the Study Day
and Visit Type tableSeveral study days had different visit types 
for treatment arms 1-4 and 6 versus 
treatment arms 7 and 8
1.1 Synopsis Added text to clarify the 
corresponding placebo control 
treatment armTreatment arm 1 is the corresponding 
placebo c ontrol for treatment arms 2-4 and 
6.  Treatment arm 8 is the corresponding 
placebo control for treatment arm 7.
1.2 Schema Updated treatment arm 7 
information and added treatment 
arm 8.Activation of treatment arm 7 and addition 
of treatment arm 8.
1.3 Schedule of Activities Added a sentence to beginning 
paragraph to refer to the study 
day and visit ty pe table in 
Section 4.1.1.The referenced table provides additional 
clarificatio ns.
1.3 Schedule of Activities Days 4 -6 were separated to 
accommodate proc edures 
specific to treatment arms 7 and 
8Activation of treatment arm 7 and addition 
of treatment arm 8.
1.3 Schedule of Activities Added footnotes in the Study 
Day row to indicate when 
telepho ne visits are allowed for 
the different treatment armsClarifi cation
1.3 Schedule of Activities Days 18 and 25 are telephone 
visits for treatment arms 7 and 8 
onlyNasophary ngeal swabs and vital signs not 
collected on these days for treatment arms 7 
and 8
1.3 Schedule of Activities Day 5 is still a telephone visit for 
treatment arms 1-4 and 6Clarification 
1.3 Schedule of Activities Updated visit windows for Days 
5 and 7To avoid overlap
1.3 Schedule of Activities Added Day 5 vital sign collection 
only for treatment arms 7 and 8Collection for participants with r isk factors 
for severe disease
1.3 Schedule of Activities Vital signs not collected on Days 
18 and 25 for treatment arms 7 
and 8To accommodate a telephone visit.
1.3 Schedule of Activities Added a nasopharyngeal (NP) 
swab on Day  5 only  for treatment 
arms 7 and 8Collect additional data to inform future 
clinical development
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
131Section # and Name Description of Change Brief Rationale
1.3 Schedule of Activities NP swabs not collected on Days 
18 and 25 for treatment arms 7 
and 8Based on emerging blinded data
1.3 Schedule of Activities Added an exploratory biomarker 
sample on Day 5 for treatment 
arms 7 and 8To help understand the correlation of 
emerging immune response to other 
parameters
3 Objectives and Endpoints Created separate table for 
treatment arms 7 and 8These treatment groups have different 
endp oints based on emerging data 
4.1.1 Design outline Updated treatment arm 7 
information and added treatment 
arm 8.Activation of treatment arm 7 and addition 
of treatment arm 8.
4.1.1 Design outline Updated the Study Day and Visit 
Type tableSeveral study days had different visit types 
for treatment arms 1-4 and 6 versus 
treatment arms 7 and 8
4.1.1 Design outline Added text to clarify the 
corresponding placebo control 
treatment armTreatment arm 1 is the corresponding 
placebo control for treatment arms 2-4 and 
6.  Treatment arm 8 is the corresponding 
placebo control for treatment arm 7.
4.2 Scientific Rationale for 
Study DesignAdded participant characteristics 
for treatment arms 7 and 8Activation of treatment arm 7 and addition 
of treatment arm 8.
5.1Inclusion Criteria Added criterion #27 specifically 
for treatment arms 7 and 8.To focus on participants with risk factors 
for severe COVID -19 illness.  
5.2 Exclusion Criteria Criterio n #20, changed “a history 
of” to “received”Clarification
6.1 Study Intervention(s) 
AdministeredRem oved information that 
described the optional treatment 
arm 7.Treatment arm is now activated and dose 
levels are described in Section 4.1.1.
6.2 
Preparation/Handling/Storage/
AccountabilityIn first sentence, replaced 
‘temperature’ with ‘storage’.
In 5thparagraph, replaced text to 
say “The investigator or 
designee…”Clarifications 
7.1 Discontinuation of Study 
InterventionClarified the days and 
assessments in SoA if 
discontinuedClarification 
7.2 Participant 
Discontinuation/Withdrawal
from the StudyClarifications at the time of 
discontinuationClarification
8.2.5 Procedures of Special 
InterestLimitations on activities due to 
COVID -19 are measured with a 
patient global assessment for 
daily  activities of phys ical 
function Clarification
9.2 Sample Size 
DeterminationUpdates to more accurately 
describe the sample sizes for the 
different treatment arms.
Added text titles to improve 
readability. Addition of treatment arms 7 and 8 and 
clarificatio n for other treatment arms.
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
132Section # and Name Description of Change Brief Rationale
9.4 Statistical Analyses Added text for treatment arms 7 
and 8.Clarification
9.4.2 Primary Endpoints Added endpoint for treatment 
arms 7 and 8.Based on preliminary blinded data.
9.4.3.2 Additional Secondary 
EndpointsAdded a sub -sectio n for 
treatment arms 7 and 8. Secondary endpoints for treatments 7 and 8 
are based on changes to the study 
populatio n to include participants with risk 
factors for severe illness and emerging 
blinded data.
9.4.6. Subgroup Analyses Added text for treatment arms 7 
and 8.Clarification
9.5 Interim Analyses Updated first bullet in first 
paragraphNot only applicable for LY3819253-only 
treatment arms
9.5 Interim Analyses Clarification of timing for when 
the Assessment Committee is 
autho rized to eval uate unblinded 
interim analyses and safety 
analy ses.Clarification
11 References Rem oved irrelevant reference Correction
Throughout the protocol Minor editorial and formatting 
changesMinor, therefore not described
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
133Amendment b:31 July 2020
Overall Rationale for Amendment b:
A new treatment is added to this study  with the combinat ion of LY3819253 and LY3832479.
Section # and Name Description of Change Brief Rationale
Title Page Change in study title Updated text for the addition of LY3832479
1.1 Synopsis Updated text to match the body of 
the protocol.  
Rationale
Objectives and endpoints 
table
Design Outline
Number of participants
Intervention Groups and 
Duration -moved 
treatment group table here 
and updated content.Updated text for the addition of LY3832479 and 
new combination treatment arm.  
Moved information to more appropriate section.  
1.2 Schema Updated Schema and removed 
footnote that was no longer correct Addition of new combination treatment arm 
1.3 Schedule of 
ActivitiesVisit 3 v isit window changed to +1 To avoid the possibility of too many blood 
draws for the participant
1.3 Schedule of 
ActivitiesAdded assessment on Day 85 for 
participant questionnaire and 
instructio ns for Day 1Needed to meet clinical status endpoint
2.0 Introduction Updated text For the addition of LY3832479
2.1 Study Rationale Updated text For the addition of LY3832479
2.2 Background Updated text For the addition of LY3832479
2.3 Benefit/Risk 
AssessmentUpdated text For the addition of LY3832479and availability 
of new data
3 Objectives and 
EndpointsObjectives were restructured to add 
text for the combination with 
LY3832479For the addition of LY3832479
3 Objectives and 
EndpointsChanged SARS -CoV -2 viral load 
area under the concentration -time 
curve to area under the response -
time curveCorrection 
3 Objectives and 
EndpointsUpdated PK objective and 
endpointsFor the addition of LY3832479
4.1.1 Design outline Updated text, moved text around 
and updated the treatment tableMoved text for better flo w of information.  
Updated text and table for the addition of the 
new combination treatment.
4.2 Scientific Rationale 
for Study DesignUpdated text Addition of new combination treatment
4.3 Justification for 
DoseText was rearranged and added for 
LY3819253.
New text added for LY3832479. Addition of new combination treatment and 
availability  of new data for LY3819253
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
134Section # and Name Description of Change Brief Rationale
6.1 Study 
Intervention(s) 
AdministeredText was rearranged for 
LY3819253.
New text added for LY3832479.For the addition of LY383247 9
6.3 Measures to 
Minimize Bias: 
Randomization and 
BlindingAdded new text for additional 
placebo participantsAddition of new combination treatment and 
optional treatment arms
6.6 Dose Modification New text added for LY3832479 For the addition of LY3832479
8.1 Efficacy 
AssessmentsUpdated text Addition of new combination treatment arm
8.1 Efficacy 
AssessmentsAdded Day 11 Per objective endpoints
8.2.2 Vital Signs Added clarifying text before table 
and text in table Clarify ing the collection tim epoints because the 
infusion times may vary
8.3.6 Hy persensitivity 
ReactionsRem oved LY3 819253-specific text For the addition of LY3832479
8.3.7 Infusion -related 
ReactionsRem oved LY38 19253 -specific text For the addition of LY3832479
8.4 Treatment of 
OverdoseUpdated text For the addition of LY3832479
8.5 Pharmacokinetics Updated text For the addition of LY3832479
8.5.1 Bioanalytical Updated text For the addition of LY3832479
8.6 Pharmacodynamics Updated text For the addition of LY3832479
8.8 Biomarkers Updated text For the addition of LY3832479
8.9 Immunogenicity 
AssessmentsUpdated text For the addition of LY3832479
9.2 Sample Size 
DeterminationUpdated text Addition of new treatment arms
9.4.3.3 
Pharmacokinetic 
Analy sesUpdated text Detai ls of the analyses added.
9.4.4 Exploratory 
Analy sesUpdated text Clarifications provided
9.4.5 Immunogenicity 
Analy sesUpdated text For the addition of LY3832479
9.5 Interim Analyses Updated text For the addition of the new treatment arms
10.1.7. Data Quality 
Assurance, Data 
Capture SystemAdded text for symptom 
assessment direct entry into EDCTo provide flexibility for data entry into the 
EDC
10.2 Appendix 2 
Clinical Laboratory 
TestsRem oved eGFR calculation Not needed.
10.2 Appendix 2 
Clinical Lab oratory  
TestsUpdated pharmacokinetic and 
immunogenicity samplesFor the addition of LY3832479
10.5 Appendix 5 
GeneticsUpdated text For the addition of LY3832479
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
135Section # and Name Description of Change Brief Rationale
10.6 Appendix 6 
Recommended 
Laborato ry Testing for 
Hypersensitivity EventsUpdated table For the addition of LY3832479
Throughout the 
protocolMinor editorial and formatting 
changesMinor, therefore not described
Amendment a:19 June 2020
Overall Rationale for the Amendment:
This amendment addresses the United States Food and Drug Administrati on (FDA) feedback and 
provi des m ore cl arity for clinical  sites.
Section # and 
NameDescription of Change Brief Rationale
1.1 Synopsis Updated objectives and endpoints to 
match changes in Section 3.Per FDA feedback
1.3 Schedule of 
ActivitiesPreexisting conditions and medical 
history  –added information for risk 
factors and comorbidities associated 
with severe COVID -19 illnessClarification of information collected
1.3 Schedule of 
ActivitiesVital Signs –added an ‘X’ at 
screening for clarifi catio n that it 
would be done for inclusion/exclusion 
criteria, but the data will not be 
collected on the Case Report Form.
Updated Day 1 vital sign collection 
times.Per FDA feedback
1.3 Schedule of 
ActivitiesParticipant questionnaire –added Day 
1Quest ionnaire should be completed for Days 1 –
29.
3 Objectives and 
EndpointsAdded Day 11 to proportion of 
participants that achieve SARS -CoV -2 
clearance endpointAnaly sis will include Day 11.
3 Objectives and 
EndpointsAdded Days 60 and 85 to secondary 
endp oint for clinical status.Per FDA feedback
3 Objectives and 
EndpointsExplo ratory  endpoint for viral 
resistance –updated description Clarification that assessment will be from 
baseline to the last evaluable timepoint up to 
Day 29
3 Objectives and 
EndpointsClarified for all applicable endpoints 
that AUC is assessed through Day 29Clarification that AUC calculations are not for a 
specific day, but through Day 29
3 Objectives and 
EndpointsAdded an exploratory endpoint for 
overall improvement using the NIAID 
ordinal scaleFor consistency across protocols
5.1 Inclusion 
CriteriaAdded website URL for the FDA 
resource pagePer FDA
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
136Section # and 
NameDescription of Change Brief Rationale
8.2.2 Vital Signs Added a table to explain what data 
will be collected on the CRF on Day 1Clarity  for sites
9.4.3.2. Additional 
Secondary 
EndpointsUpdated according to changes in 
Section 3Consistency across sections.
9.4.6. Subgroup 
Analy sesUpdated the subgroup analyses New information available
10.1.11 Investigator 
InformationUpdated description Per feedback
Section 10.2. 
Clinical Laboratory 
TestsRem oved antibody neutralization Assay  is not available at this time
Throughout the 
protocolMinor editorial and formatting 
changesMinor, therefore not described
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
13711. References
Aoki FY, Macleod MD, Paggiaro P, Carewicz A, El Sawy A, Wat C, Griffiths M, Waalberg E, 
Ward P on behalf of the IMPACT Study  Group. Early  administrati on of  oral oseltamivir 
increases the benefit s of influenza treatment. J. Antimicrob Chemother. January 2003:123-129.
https://doi .org/10.1093/j ac/dkg007.
CDC resource page. 
Coronavirus Disease 2019 (COVID- 19) People Who Are at Increased Risk 
for Severe Illness .Centers for Disease Control and Prevent ionweb si te. Available at: 
https://www.cdc.gov/coronavirus/2019 -ncov/need -extra -precauti ons/peopl e-at-increased -
risk.ht ml?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019 -
ncov%2Fneed -extra -precautions%2Fpeople -at-higher -risk.ht ml. Accessed: 28 August 2020.
CDC growth charts .  National Center for Health Statist ics, Clinical Growth Charts .  Centers for 
Disease Control  and Prevent ion web site.  Available at: https://
www.cdc.gov/growthcharts/clinical_charts.htm . Accessed: 19 October 2020.
Chen P, Ni rula A, Heller B, Gottlieb RL, et. al. SARS -CoV -2 Neutralizing ant ibody  LY-CoV555 
in Outpatients with Covid -19. NEJM. Published 28 October 2020. DOI: 
10.1056/NEJMoa2029849.
Divisio n of AIDS ( DAIDS )Table for Grading the Severit y of Adult and Pediatric Adverse 
Events . Nati onal Inst itute of Allergy and Infect ious Di seases. Nati onal Insti tutes of Heal th.US 
Departm ent of Healt h and Human Services. Corrected version 2.1 .July 2017 . Available at: 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf . Accessed: 14 April 
2020.
FDA EUA fact sheet .  Fact sheet for health care providers, Eme rgency  Use Authori zation (EUA) 
of bamlanivimab . Available at: https://www.fda.gov/media/143603/download . Accessed : 16 
November 2020.
FDA resource page. COVID -19: Developing Drugs and Bio logical  Products for Treatm ent or 
Prevent ion Guidance for Industry . Food and Drug Administration web site. May 2020. 
Available at: https://www.fda.gov/regulatory -informat ion/search -fda-guidance -
docum ents/covid -19-developing -drugs -and-biological -products -treatm ent-or-prevent ion. 
Accessed :19 October 2020 .
FDA resource page. Development of Ant i
-Infect iveDrug products for the Pediatric Populat ion. 
Draft Guidance for Industry . Food and Drug Administration web site. June 2020. Available at: 
https://www.fda.gov/media/139586/download . Accessed: 19 October 2020.
Hoang A, Chorath K, Morei ra A, Evans M ,et.al. COVID -19 in 7780 pediatric patients: A 
system atic review. EClinicalMedicine 2020. 24: e100433. DOI: 
https://doi .org/10.1016/j .eclinm .2020.100433 . 
Hoffmann M, Kleine -Weber H, Schroeder S, Krüger N, Herrier T, Erichsen S, Schierge ns TS, 
Herrler G, Wu NH, Nitsche A, Müller M, Drosten C, Pöhlmann, S. SARS -CoV-2 Cell Entry 
Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. 
Cell. 2020;181:1-10. DOI: 10.1016/j.cell.2020.02.052 .
Kim L, Whitaker M, O’Halloran A , Kambhampati  A, et.al . Hospi talizat ion Rates and 
Characteristics of Children Aged <18 Years Hospitalized wit h Laboratory -Confi rmed COVID -
CONFIDENTIAL Protocol  number J2W -MC-PYAB (m)
13819 – COVID -NET, 14 States, March 1- July25,2020. US Department of Health and Human 
Services/Centers for Dis ease Control  and Prevent ionMorbidit y and Mortalit y Weekly Report. 
2020;69(32): 1081 -1088 .
Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, Yu L. Clinical features and progression of acute 
respi ratory  distress syndrome in coronavirus disease 2019. medRxiv . Pos ted 27February 2020. 
preprint DOI : https://doi.org/10.1101/2020.02.17.20024166 . 
Shekerdemian L, Mahmood NR, Wo lfe KK, Riggs BJ , et al.International COVID -19 PICU 
Collaborative. Characterist ics and outcomes of children with coronavirus disease 2019 
(COVID -19) infection admitted to US and Canadian pediatric intensive care units. JAMA 
Pediatr . 2020. 174( 9):1-6.DOI: https://doi.org/10.1001/jamapediatrics.2020.1948 .
Leo Document ID = 92915380-49a4-4e5f-9cd9-ad0612eb6ee6
Approver: 
Approval Date & Time: 02-Mar-2021 04:13:23 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 02-Mar-2021 04:15:23 GMT
Signature meaning: Approved
PPD
PPD